Washington University in St. Louis

Washington University Open Scholarship
All Theses and Dissertations (ETDs)
5-24-2012

Isoform-Specific Roles of Extracellular Signal-Regulated Kinases
in Pain
Benedict Alter
Washington University in St. Louis

Follow this and additional works at: https://openscholarship.wustl.edu/etd

Recommended Citation
Alter, Benedict, "Isoform-Specific Roles of Extracellular Signal-Regulated Kinases in Pain" (2012). All
Theses and Dissertations (ETDs). 680.
https://openscholarship.wustl.edu/etd/680

This Dissertation is brought to you for free and open access by Washington University Open Scholarship. It has
been accepted for inclusion in All Theses and Dissertations (ETDs) by an authorized administrator of Washington
University Open Scholarship. For more information, please contact digital@wumail.wustl.edu.

WASHINGTON UNIVERSITY IN ST. LOUIS
Division of Biology and Biomedical Sciences
Neurosciences

Dissertation Examination Committee:
Robert Gereau, Chair
Yu-Qing Cao
Zhou-Feng Chen
Steven Mennerick
Karen O’Malley
Narendrakumar Ramanan

Isoform-Specific Roles of Extracellular Signal-Regulated Kinases in Pain
by
Benedict Joseph Alter

A dissertation presented to the
Graduate School of Arts and Sciences
of Washington University in
partial fulfillment of the
requirements for the degree
of Doctor of Philosophy

May 2012
Saint Louis, Missouri

Copyright by
Benedict Joseph Alter
2012

ABSTRACT OF THE DISSERTATION
Isoform-specific roles of Extracellular Signal-Regulated Kinases in pain
by
Benedict Joseph Alter
Doctor of Philosophy in Biology and Biomedical Sciences
Neurosciences
Washington University in St. Louis, 2012
Professor Robert Gereau, Chairperson

The extracellular signal-regulated kinase (ERK) isoforms, ERK1 and ERK2, are believed to be
key signaling molecules in nociception and nociceptive sensitization. Studies utilizing inhibitors
targeting the shared ERK1/2 upstream activator, mitogen-activated protein kinase kinase (MEK),
and transgenic mice expressing a dominant negative form of MEK have established the
importance of ERK1/2 signaling. However, these techniques do not discriminate between ERK1
and ERK2. To dissect the function of each isoform in pain, mice with a targeted genetic deletion
of ERK1 (ERK1-/-) and mice with a conditional deletion of ERK2 in nociceptors (ERK2f/f;NaV1.8Cre) were used. Although both isoforms are activated (phosphorylated) following inflammation,
deletion of ERK1 had no effect in several models of chemical nociception, inflammatory pain, and
neuropathic pain. In contrast, conditional deletion of ERK2 in nociceptors attenuates nociceptive
spontaneous behavior in the second phase of the formalin test, reduces inflammatory mechanical
hypersensitivity, and eliminates heat hypersensitivity due to the inflammatory mediator, nerve
growth factor (NGF). Nociceptive sensitization was not reduced in all models tested, since
ERK2f/f;NaV1.8-Cre mice developed robust heat hypersensitivity to other inflammatory and
chemical insults. Biochemical analysis of both lines revealed that eliminating one ERK isoform led
to elevated phosphorylation of the remaining isoform at baseline, which could explain the lack of
a phenotype in ERK1-/- mice. However, this is probably not the case since the elevation in spinal
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cord ERK2 phosphorylation above baseline following noxious stimulation is not affected by the
deletion of ERK1. It is also possible that other intracellular signaling cascades may compensate
for the loss of ERK1. This seems less probable since systemic MEK inhibition attenuates
formalin-induced spontaneous nociceptive behaviors similarly in ERK1-/- and WT littermate
controls. These experiments demonstrate an isoform-specific role for ERK2 on the behavioral
level. On the cellular level, ERK2 is also partially required for innervation of the epidermis by
peptidergic nociceptive afferents that express the NGF receptor, TrkA. The partial reduction in
epidermal innervation is not accompanied by cell loss, suggesting a defect in axon growth or
maintenance. Fiber loss is unlikely to account for all behavioral phenotypes observed in
ERK2f/f;NaV1.8-Cre mice since remaining epidermal fibers have previously been shown to play
important roles on the behavioral level. Additionally, ERK1-/- mice have exaggerated NGFinduced heat hypersensitivity but do not have altered epidermal innervation. Overall, these data
highlight the complicated interplay between ERK1 and ERK2 in vivo and suggest that ERK2 is the
critical isoform for nociceptor sensitization.
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Chapter 1: Introduction
The advantages of nociception
The detection of noxious, potentially damaging stimuli is an important function of the
sensory nervous system. This process, termed nociception (Loeser and Treede, 2008), and its
modulation represent the culmination of evolutionary adaptation. The ability to sense and avoid
potentially lethal threats provides an obvious advantage for survival (Scholz and Woolf, 2002).
Equally important is the ability to recover from injury. In mammals, tissue damage is associated
with an immune response, inflammation, and eventual wound repair. Although physiologic wound
healing is relatively robust, the process would be severely hampered by repeated injury. In this
light, enhanced nociception seems to provide some benefit. If the injured tissues become more
sensitive to noxious stimuli, the organism may guard against reinjury. A similar phenomenon
occurs with innocuous stimuli, which become exquisitely noxious following an injury. Enhanced
nociception may not always be adaptive, however. In life-threatening situations, it may be more
advantageous to silence nociceptive information in order to escape or resist a threat. This function
of the nociceptive system has been observed in many organisms and can be appreciated in our own
personal accounts of sports injuries or heroic actions in extreme situations. Thus, the nociceptive
system not only faithfully detects noxious stimuli but can also enhance or repress nociception
in a context-appropriate fashion. The overall benefit of the nociceptive system is highlighted by
patients with severe inherited deficits in the nociceptive sensory system due to loss-of-function of
NaV1.7 or TrkA (Nagasako et al., 2003; Drenth and Waxman, 2007). With congenital insensitivity to
pain, patients acquire self-inflicted facial and oral injuries, burn injuries, undetected fractures and
subsequent orthopedic complications. In many ways, the nociceptive system is largely beneficial.
Chronic pain
Pain is distinct from nociception (Loeser and Treede, 2008). The International Association
for the Study of Pain defines pain as “an unpleasant sensory and emotional experience associated
with actual or potential tissue damage, or described in terms of such damage.” Nociception is
a sensory process that may or may not be associated with the percept of pain. For example,
modulation of nociception may prevent the percept of pain during stress. Chronic pain can be defined
as persistent or intractable pain that may or may not be associated with injury. One broad class of
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chronic pain is pain due to injury of the nervous system, or neuropathic pain (Costigan et al., 2009).
Common examples of neuropathic pain include painful peripheral neuropathies, such as carpal
tunnel syndrome or postherpetic neuralgia, pain resulting from central nervous system damage,
such as spinal cord injury or stroke, and pain associated with limb amputation, such as phantom
limb pain. In neuropathic pain, the damaged nervous system signals as if noxious stimuli were
occurring, even when they are not. Moreover, plastic changes in the undamaged nervous system
amplify these inappropriate nociceptive inputs and contribute to the perception of pain. This dual
effect results in persistent pain that is unrelated to external stimuli. In contrast, inflammatory pain
arises from a normally functioning nociceptive system. As mentioned above, inflammatory pain can
be thought of as beneficial in order to allow wound healing. Although biological phenomena often
make sense in the light of evolutionary adaptation, this teleological argument does little for patients
suffering from pain following traumatic injury or surgery. Another example of inflammatory pain
includes rheumatoid arthritis, in which inflammatory mediators persist within joints and enhance
nociception. Injury and arthritis are often referred to as nociceptive pain, since the nociceptive
system is not damaged.
Inflammatory and neuropathic pain share important features. Both can persist for long
periods of time, compromising patients’ daily activities and reducing their quality of life. Both forms
of chronic pain involve enhanced or sensitized nociception. In inflammatory pain, nociceptive
afferents respond more vigorously to noxious stimuli and become sensitive to previously innocuous
stimuli. This results from a process known as peripheral sensitization, in which inflammatory
mediators enhance nociceptor excitability, reduce sensory thresholds, and initiate transcriptional
changes thought to underlie long-term sensitization (Woolf and Ma, 2007). Certain types of
peripheral sensitization also occur due to nerve injury. Although nerve injury may lead to areas
of denervation and insensitivity, intact axons that comingle with injured axons can acquire new
properties which contribute to enhanced sensitivity to noxious and innocuous stimuli (Costigan et
al., 2009). Inflammatory and neuropathic pain both involve central sensitization (Costigan et al.,
2009; Sandkuhler, 2009). Second order neurons found in the superficial dorsal horn of the spinal
cord receive input from nociceptors, transmitting this information to higher brain centers. After injury
or inflammation, the incoming nociceptive information is amplified (Ikeda et al., 2006; Sandkuhler,
2009). For example, the same nociceptive input that produced low frequency firing in dorsal

2

horn neurons will evoke increased firing frequencies as a result of central sensitization. Similar
plasticity can occur in other higher order structures in the context of inflammatory or neuropathic
pain. Although the pathophysiological mechanisms of inflammatory and neuropathic pain are quite
different, they share basic themes including plasticity at the level of the nociceptor and at the level
of the spinal cord, termed peripheral and central sensitization respectively.
Despite significant progress in our understanding of chronic pain, treatments for chronic
pain conditions are limited. The mainstays of pain control are non-steroidal anti-inflammatory drugs
(NSAIDs) and opiates. These drugs are analgesic in nociceptive pain, but are often not completely
effective in inflammatory pain and have almost no efficacy in many neuropathic conditions (Kissin,
2010). Moreover, these analgesics are limited by their side-effect profiles. NSAIDs are associated
with gastric and renal toxicity, and opiate dosage is restricted by sedating effects and constipation.
In a concerted effort to find novel pain medications, researchers have uncovered several promising
pharmacological targets. In the 1990’s, TRPV1 was identified as a molecular sensor of noxious heat
and protons, and it has enjoyed great interest by pharmaceutical companies since then (Szallasi et
al., 2007). Even with a body of evidence suggesting that its expression is restricted to nociceptive
sensory neurons, functional evidence has suggested that TRPV1 modulates synaptic plasticity
in hippocampus and plays an important role in thermoregulation (Szallasi et al., 2007; Alter and
Gereau, 2008; Gibson et al., 2008; Khairatkar-Joshi and Szallasi, 2009). Both functions represent
potential side-effect pitfalls when considering TRPV1 antagonists for the treatment of pain. Instead
of targeting sensory transduction machinery like TRPV1, it may be more fruitful to target molecules
that sensitize sensory transduction. The detection of noxious stimuli is not the main clinical problem
in chronic pain. Sensitization processes, occurring in the central and peripheral nervous systems,
should be the main focus for developing new chronic pain therapies. One promising area of
investigation involves indentifying intracellular signaling molecules that play an important role in
nociceptive sensitization.
The ERK1/2 toolbox
Extracellular signal-regulated kinases (ERK) 1 and 2 are mitogen-activated protein kinases
(MAPK) that have become a focus of pain research. ERK1/2 are part of a three-tiered intracellular
signaling module of serially arranged protein kinases. Activated Raf phosphorylates and activates
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the MAP kinase kinase MEK1/2, which goes onto phosphorylate and activate ERK1/2 (Fig. 1,
English et al., 1999; Pearson et al., 2001). Much information about the function of this signaling
cascade has been gleaned using protein kinase inhibitors and phospho-specific antibodies. Since
many protein kinases share a high degree of homology, selective inhibitors are rare (Davies et al.,
2000). Fortunately, several relatively selective inhibitors of MEK1/2 have been discovered, perhaps
as a result of their mode of action. PD98059 (Dudley et al., 1995) and U0126 (Favata et al., 1998)
do not bind at MEK1/2 active site, but instead inhibit MEK1/2 activity through a non-competitive
mechanism probably involving allosteric modulation of MEK (Fischmann et al., 2009). Since the
only known substrate of MEK1/2 is ERK1/2, inhibition of MEK1/2 is a way to selectively block
ERK1/2 activity. It is important to point out that at each level of this three-tiered intracellular signaling
system, there are several different isoforms with relatively high sequence homology. PD98059 and
U0126 have similar potency at both MEK isoforms, MEK1 and MEK2 (Servant et al., 1996; Favata
et al., 1998). Since in vitro assays have shown that both MEK1 and MEK2 can phosphorylate both
ERK1 and ERK2 (Pearson et al., 2001) and since MEK1/2 inhibitors decrease the phosphorylation
status of both ERK1 and ERK2 in cells or in vivo (see Chapters 2 and 3, Servant et al., 1996; Karim
Figure 1: MAP Kinase Module Raf, MEK1/2, and

activators

ERK1/2 are serially arranged protein kinases that
integrate signals from cell surface receptors and

Raf

second messenger systems (activators). Upon dual
phosphorylation of ERK1/2 at threonine and tyrosine

MEK1/2

residues within the phosphorylation loop, ERK1/2
kinase activity increases dramatically, acting as a
molecular switch. Activated ERK1/2 phosphorylates

MEK inhibitors

ERK1/2

factors. To study this pathway, MEK inhibitors can
be used to block ERK1/2 activation. Phosphospecific antibodies specifically recognize dually
phosphorylated ERK1/2, allowing for the detection
of ERK1/2 activation.
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P

Y

P

Phospho-specific Ab

many downstream effector molecules, such as ion
channels, cytoskeletal proteins, or transcription

T

effectors

et al., 2001; Carrasquillo and Gereau, 2007), MEK1/2 inhibitors are likely to prevent signaling
between every combination of MEK and ERK isoform. Therefore, MEK1/2 inhibitors provide
no information about which specific MEK1/2 or ERK1/2 isoform is important. Phospho-specific
antibodies to ERK1/2 allow for the measurement of ERK1/2 activation (phosphorylation). Since
the ERK domain phosphorylated by MEK, known as the phosphorylation loop, is highly conserved
between ERK1 and ERK2 (Fig. 2), phospho-specific antibodies bind both phosphorylated ERK1
(pERK1) and pERK2. Therefore, immunostaining experiments cannot be used to distinguish
isoform specific activity. Western blotting does allow for this sort of analysis since ERK1 and ERK2
are different sizes. However, this method is limited since tissue homogenates used in Western
blotting represent a heterogeneous mixture of cells. Nevertheless, using these tools has produced
a wealth of information about the role of ERK1/2 in nociception and nociceptive sensitization.
ERK1/2 and nociception
Studies using rodent models have demonstrated that ERK1/2 activation occurs rapidly in
nociceptive afferents following noxious stimulation. In anesthetized rats, pERK1/2 immunostaining
can be observed in cell bodies of afferents, found in dorsal root ganglia (DRG), by stimulating the
paw for 2 minutes using a heated water bath (Dai et al., 2002). At 42°C, a small but significant
increase in the number of pERK1/2-positive DRG neurons is detected when compared with untreated
control rats. Increasing the temperature of the stimulus to noxious temperatures (46°C-60°C)
linearly increases pERK1/2-positive cell bodies. Heat-induced ERK1/2 activation is associated
with the noxious heat sensor, TRPV1. Roughly 80% of pERK1/2-positive cell profiles colocalize
with TRPV1, and TRPV1 antagonists reduce pERK1/2 immunoreactivity. Activation of TRPV1 by
hindpaw injection of capsaicin, the pungent component of chili peppers, also induces pERK1/2
immunoreactivity in the cell bodies of DRG neurons. Overall these data suggest that acute noxious
heat leads to ERK1/2 activation via TRPV1 within minutes. However, the cell body of nociceptive
afferents is quite distant from the initial site of sensory transduction, raising the question of how heat
stimuli could lead to somatic ERK1/2 phosphorylation so quickly. In a critical experiment, Dai et al.
applied topical lidocaine to the sciatic nerve, which contains the axons of nociceptors innervating
the hindpaw. Following this nerve conduction block, capsaicin-induced pERK1/2 immunoreactivity
was completely abrogated, indicating that electrical activity was necessary for somatic ERK1/2
activation. Voltage-gated calcium channels likely connect membrane depolarization with ERK1/2
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Figure 2: Comparison of ERK1 and ERK2 structure A. Diagram of ERK1 and ERK2 structure
annotated with putative cellular functions and important domains. Information compiled from Cobb
and Goldsmith, 2000, English et al., 1999, Pearson et al., 2001, Kinoshita et al., 2008, and Marchi
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et al., 2008. Isoforms share approximately 90% sequence homology; however differences (denoted
by green arrows or hatched boxes) occur throughout the proteins, especially at the termini. B.
Primary amino acid sequence comparison of ERK1 and ERK2 (Boulton et al., 1991). Amino acid
numbering is based on ERK1 sequence. ERK2 sequence appears below ERK1 sequence with
shared amino acids denoted by periods (.) and nonhomologous sequence listed.
activation via calcium sensitive kinases such as CaMK or certain PKC isoforms (Fields et al.,
1997). Somatic ERK1/2 phosphorylation is poised to initiate changes in transcription by nuclear
translocation and phosphorylation of transcription factors such as CREB. It is unclear whether
noxious stimulation as described above would initiate these processes, which are better understood
in persistent inflammatory pain models (see discussion below). Nevertheless, it is clear that ERK1/2
becomes phosphorylated in the soma of DRG following noxious heat.
Although the nociceptor soma represents the physical site of transcriptional modulation, posttranslational modifications can also affect the function of sensory neurons. Functionally significant
post-translation modifications can occur throughout the subcellular extent of the nociceptor. This
has been most studied in the terminals of nociceptors that innervate target tissues, such as the skin,
and contain sensory transduction machinery. One potential mechanism for modulating nociceptor
sensitivity is to modulate sensitivity of this transduction machinery. For example, the phosphorylation
of TRPV1 by PKC, PKA, and Src enhance TRPV1 function by increasing channel open probability,
reversing desensitization of the channel, and increasing exocytosis of the channel, respectively
(Huang et al., 2006). It is therefore quite interesting that subcutaneous injection of capsaicin into the
plantar surface of the hindpaw (intraplantar) results in rapid increases in pERK1/2 immunoreactivity
in epidermal free nerve endings (Dai et al., 2002). Moreover, this activation of ERK1/2 is behaviorally
relevant. The injection of capsaicin in humans causes a burning pain that rapidly resolves within 15
minutes but is accompanied by hypersensitivity to heat and mechanical stimuli lasting about one
hour (Torebjork et al., 1992). This is recapitulated in rodents, producing hypersensitivity to heat
with a similar timecourse (Dai et al., 2002). Interestingly, intraplantar injection of a MEK inhibitor
immediately before capsaicin reduces heat hypersensitivity and concomitantly attenuates pERK1/2
immunoreactivity in fine nerve endings of the skin. Future experiments should directly test whether
noxious heat stimulation induces ERK1/2 activation in peripheral terminals, as one might expect.
However, based on the above results, it appears that ERK1/2 is activated following noxious heat
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and that ERK1/2 activation in afferent fibers is required for behavioral sensitization.
ERK1/2 phosphorylation in nociceptive afferents has been observed after other types of
noxious stimuli. These include noxious cold (Mizushima et al., 2006). At temperatures between
28°C and 20°C, pERK1/2-positive cells are rare, ~1% of the total number of DRG neurons, and
similar to the frequency observed in naïve animals. Exposure of the paw to a 16°C water bath
for 2 min (10 s in bath, 10 s out of bath, repeated 6 times) yields significantly more pERK1/2positive cells, and their frequency progressively increases with colder temperatures down to 4°C,
at which ~10% of all neurons label for pERK1/2. As an interesting parallel to the discussion above,
cold-induced pERK1/2 immunostaining co-occurs with in situ hybridization signal for sensory
transduction channels that are activated by cold, TRPM8 and TRPA1. Approximately 80% of the
pERK1/2-positive cell profiles colocalize with TRPM8 mRNA, while ~10% of pERK1/2-positive cells
also express TRPA1 mRNA. In addition to noxious heat and noxious cold, noxious mechanical
stimulation increases pERK1/2 staining in the soma of DRG (Dai et al., 2002). A similar stimulation
paradigm (10 s of pinch followed by 10 s without pinch, repeated 6 times) yields significant increases
pERK1/2-positive DRG neurons. Additionally, electrical stimulation of the sciatic nerve that evokes
Aδ- and C-fiber compound action potentials is sufficient to induce pERK1/2 immunostaining in
DRG neurons (Dai et al., 2002). Clearly, noxious stimulation in several modalities (heat, cold,
mechanical) leads to ERK1/2 activation in DRG neurons.
Given these observations, there are several important considerations regarding the
function of ERK1/2 phosphorylation in DRG neurons. It appears that innocuous stimuli do not lead
to ERK1/2 activation. Paw stimulation with temperatures between 20°C and 38°C have no effect
on pERK1/2 immunostaining above the background levels observed in naïve rats (Dai et al., 2002;
Mizushima et al., 2006). Additionally, electrical stimulation at current amplitudes that evoke Aβ
compound action potentials is not sufficient to increase pERK1/2 in DRG neurons. Since changes
in pERK1/2 above baseline values are not affected by innocuous stimulation, it seems plausible
that ERK1/2 activation is related to nociception and may be involved in nociceptive sensitization.
Another related consideration is the effect of MEK inhibitors in naïve animals. Inhibition of ERK1/2
in unstimulated rats by intraplantar injection of MEK1/2 inhibitors has no effect on their sensitivity to
short applications of heat or mechanical stimuli (Hao et al., 2008). These experiments suggest that
low levels of basal ERK1/2 phosphorylation do not modulate the sensation of acute noxious stimuli.
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Therefore, it seems that innocuous stimuli do not increase pERK1/2, and basal levels of pERK1/2
do not actively modulate acute nociception.
In the preceding discussion, a tacit distinction has been made about acute nociception and
noxious stimulation. This is a helpful distinction, but in regards to ERK1/2 signaling, its boundaries
are only roughly known. Noxious stimulation with heat, cold, pinch, or pulses of electrical current
all increase pERK1/2. All paradigms used involve repeated or prolonged stimulation – 2 minutes
of continuous exposure to heat, for example. This is a dramatically different stimulus than briefly
applied heat stimuli used to assess acute nociception. In a well characterized behavioral assay
measuring acute heat sensation known as the Hargreaves test (Hargreaves et al., 1988; Mogil et
al., 2001), the mouse or rat is placed on a glass platform within a small enclosure, and a radiant
heat source is then applied to the plantar surface of the paw. The amount of time between the
onset of the heat source and withdrawal of the paw is measured. Heat intensity is calibrated to yield
paw withdrawal latencies of ~10 seconds, and a cutoff time is also used, typically 20 seconds. It is
unlikely that these short heat applications are sufficient to induce pERK1/2 in nociceptors, although
this has not been directly tested. Additionally, as part of the test, the interval between applications of
radiant heat is between 10 and 15 minutes. With this protocol, sensitization to repeated application
of these brief stimuli has not been observed (Hargreaves et al., 1988). Therefore, on the behavioral
level, acute nociception and noxious stimulation are very different.
Given these results, it is interesting to speculate that the magnitude and/or duration of
ERK1/2 activation may determine whether behavioral sensitization occurs. Evidence directly
addressing this question is limited. For instance, the behavioral relevance of ERK1/2 activation
following two-minute heat stimulation has not been addressed, since the experiments were carried
out in anesthetized animals and MEK inhibitors were not used. However, in a burn injury model,
a first-degree burn with associated behavioral hypersensitivity occurs after exposing the paw to
a 52°C metal surface for 45 seconds (Sorkin et al., 2009). ERK1/2 phosphorylation occurs at
temperatures below 52°C, but at lower levels than those observed after capsaicin injection (Dai
et al., 2002). Interestingly, pERK1/2 immunostaining occurs in more cells at temperatures higher
than 52°C. Therefore, there may be a threshold of ERK1/2 activation which if crossed initiates
peripheral and behavioral sensitization to heat. A greater magnitude of ERK1/2 activity above this
threshold may produce more exaggerated or longer lasting hypersensitivity. Although the amount
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of ERK1/2 activity is likely important, the duration of ERK1/2 phosphorylation may also be relevant.
In other cell types, the timecourse of ERK1/2 activation determines whether cells continue to divide
or begin to differentiate (Murphy et al., 2002; Murphy and Blenis, 2006). It will be interesting to
determine the timecourse of ERK1/2 after noxious stimulation. Comparison with the timecourse of
capsaicin-evoked pERK1/2 (Dai et al., 2002) will allow a better understanding of the relationship
between ERK1/2 activation and behavioral sensitization.
Given that noxious stimulation and capsaicin injection result in robust activation of ERK1/2
in primary afferents, it is not too surprising that similar stimuli result in phosphorylation of ERK1/2
in spinal cord dorsal horn neurons. Noxious heat, noxious cold, noxious mechanical stimuli, and
C-fiber level electrical stimulation, applied for several minutes with protocols similar to those
described above, all lead to increases in pERK1/2 immunoreactivity in the dorsal horn (Ji et al.,
1999; Kominato et al., 2003; Polgar et al., 2007; Honda et al., 2008). ERK1/2 activation appears to
occur primarily in the superficial lamina of the dorsal horn (lamina I and II), which receive inputs from
nociceptive afferents (Ji et al., 1999). The staining pattern includes cell profiles which colocalize
with the neuronal marker NeuN (Fukui et al., 2007). A subset of pERK1/2-positive cells also stains
for the neurokinin 1 (NK1) receptor, which labels spinal cord neurons with axons that project to
higher brain centers (Polgar et al., 2007). Besides staining within clearly defined cell bodies, images
also reveal staining in the neuropil, which may include staining from primary afferent terminals
projecting from the DRG and staining from the dendritic arbor of dorsal horn neurons (Ji et al.,
1999). As with pERK1/2 staining in the DRG, innocuous stimuli do not activate ERK1/2. Light touch
stimulation of the hindpaw for 2 min does not induced ERK1/2 phosphorylation in the spinal cord
dorsal horn (Ji et al., 1999). Additionally, in a slice preparation consisting of spinal cord sections
with attached dorsal nerve roots, stimulation of Aβ fibers which generally transmit innocuous light
touch is not sufficient to induce pERK1/2 immunostaining. In accordance with in vivo data, C-fiber
strength electrical stimulation and bath application of capsaicin both produce robust pERK1/2
immunostaining. Therefore, as with ERK1/2 activation in primary sensory neurons, it appears that
only noxious stimulation results in pERK1/2 immunoreactivity. Although specific for nociceptive
activity, the behavioral relevance of pERK1/2 immunoreactivity following noxious stimulation is
unclear, since application of MEK inhibitors to the spinal cord by intrathecal injection has no effect
on baseline responses to acute nociception (Ji et al., 1999; Ji et al., 2002; Obata et al., 2003; Hu
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et al., 2006; Karim et al., 2006) (see discussion above regarding the distinction between noxious
stimulation and acute nociception). To better understand the functional importance of pERK1/2
activation in nociceptors and spinal cord for behavioral sensitization, other models have been used.
ERK1/2 in chemical nociception and sensitization
The injection of noxious chemicals into the hindpaw, such as capsaicin or formalin,
produces robust behavioral sensitization (Tjolsen et al., 1992; Torebjork et al., 1992). As mentioned
above, capsaicin injection not only evokes minutes of burning pain it also triggers subsequent
hypersensitivity to heat and mechanical stimuli. To determine the behavioral relevance of
capsaicin-induced ERK1/2 activation in nociceptors, MEK inhibitors were injected into the paw
before capsaicin injection. MEK inhibition attenuates heat hypersensitivity but has no effect
on mechanical hypersensitivity (Dai et al., 2002), suggesting that afferent ERK1/2 activation is
necessary for capsaicin-induced heat hypersensitivity. Capsaicin injection also increases pERK1/2
immunostaining in the spinal cord dorsal horn with a peak in the number of pERK1/2 cell bodies at
2 min which is sustained for 30 minutes – a similar timecourse to that observed in DRG (Ji et al.,
1999; Kawasaki et al., 2004). The staining pattern of capsaicin-evoked pERK1/2 immunoreactivity
is similar to that observed after noxious stimulation, occurring robustly in neuronal cell bodies
(Kawasaki et al., 2006). The presence of pERK1/2 immunostaining is not too surprising, given
that noxious heat stimulation and C-fiber stimulation both induced pERK1/2 (Ji et al., 1999). In
this case, however, capsaicin injection allowed for a critical test of the behavioral relevance of
ERK1/2 activation in the spinal cord. Indeed, intrathecal pretreatment of a MEK inhibitor attenuated
capsaicin-induced mechanical hypersensitivity (Kawasaki et al., 2004). These data indicate that
capsaicin induces ERK1/2 activation at the level of the DRG and spinal cord dorsal horn and that
ERK1/2 activation is necessary for behavioral sensitization that accompanies capsaicin injection.
In experimental animals, it is difficult to assess spontaneous pain, and many pain models
rely on hypersensitivity to stimuli (Mogil et al., 2001). However, there are often stereotyped
spontaneous responses expressed by animals that occur after injection of noxious chemicals, and
these behaviors may more closely parallel spontaneous pain in humans than evoked withdrawal
reflexes. Immediately following intraplantar capsaicin injection, mice lick the injected paw (Sakurada
et al., 1992). However, this only occurs for 5 minutes and has completely subsided by 10 minutes,
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potentially limiting its experimental utility. The effect of MEK inhibition on capsaicin-induced
spontaneous behavior has not yet been reported. Another model of spontaneous chemical pain
is the formalin test. Formalin is a dilute solution of paraformaldehyde, the injection of which elicits
robust spontaneous behaviors including licking, lifting and flinching of the injected paw which can
last for 1 hour (Tjolsen et al., 1992). Formalin injection results in two distinct phases of spontaneous
behaviors. Immediately following injection, the time spent performing spontaneous behaviors is
quite high. By 5-10 minutes after injection, spontaneous behaviors subside but then resume over
the following 30-40 minutes, forming a second peak. This biphasic behavioral response correlates
with distinct mechanisms. The first phase is attributed to direct stimulation of nociceptive afferents,
while the second phase is thought to result from continued nociceptor activity and peripheral
sensitization as well as central sensitization within the spinal cord dorsal horn. Evidence supporting
a role for nociceptive afferents comes from in vivo electrophysiological recordings indicating activity
among Aβ-, Aδ-, and C-fibers following injection (Tjolsen et al., 1992; Puig and Sorkin, 1996).
Although Aβ activity subsides with 5-10 minutes, firing frequencies of Aδ- and C-fibers persist well
into the 2nd phase. Systemic administration of NSAIDs decreases the 2nd phase of the formalin test
(Shibata et al., 1989; Tjolsen et al., 1992). Inhibition of a variety of inflammatory mediators impacts
only the 2nd phase as well, suggesting that peripheral, inflammatory processes are important in
the 2nd phase. Active processes in the spinal cord dorsal horn also appear to be important (Tjolsen
et al., 1992). After 1st phase activity, local anesthesia of the injected paw with lidocaine reduces
but does not eliminate spontaneous behaviors (Coderre et al., 1990), indicating that peripheral
activity is not sufficient for the full expression of formalin-induced behaviors. More recent studies
have indentified activity-dependent synaptic strengthening in the spinal cord dorsal horn following
formalin injection, which is likely to contribute to the behavioral response (Ikeda et al., 2006;
Sandkuhler, 2009). Therefore, the formalin test provides an interesting model to assess both acute
chemical nociception as well as sensitization in both nociceptors and spinal cord dorsal horn.
Formalin injection induces ERK1/2 activation, and this activation is required for spontaneous
behaviors observed in the formalin test (Ji et al., 2009). The original study investigating a potential
role for ERK1/2 in pain revealed that formalin injection rapidly increased pERK1/2-positive cell
profiles in rat spinal cord dorsal horn (Ji et al., 1999). Shortly thereafter, a similar observation was
made in mice (Karim et al., 2001). The timecourse of ERK1/2 activation is fairly rapid, peaking at
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3 minutes after injection and persisting for at least 30 minutes (Ji et al., 1999; Karim et al., 2001).
Quantitative Western blot analysis also shows a significant increase in ERK1/2 activation (Karim et
al., 2001). Since ERK1 and ERK2 are slightly different sizes (44 and 42 kDa, respectively), Western
blotting provides a direct assessment of ERK1 and ERK2 activity. Although pERK1 and pERK2 both
increased after formalin, the amount of change was greater for pERK2. Additionally, the pERK2
band was consistently darker than the pERK1 band. Although enticing, these observations do not
directly address the relative roles of ERK1 and ERK2, since antibody binding affinity may be different
between isoforms and since phosphorylation does not necessarily imply functional relevance. To
address functional relevance without specifically interrogating each isoform, MEK inhibitors were
applied to spinal cord by intrathecal injection (Ji et al., 1999; Karim et al., 2001; Tsuda et al., 2007).
Intrathecal pretreatment with PD98059 dose-dependently reduced the 2nd phase of the formalin test,
without affecting the 1st phase (Ji et al., 1999; Karim et al., 2001). Moreover, this was accompanied
by a significant decrease in pERK1/2 immunostaining (Karim et al., 2001). Additionally, intrathecal
PD98059 after the 1st phase was also sufficient to reduce 2nd phase behaviors (Ji et al., 1999),
suggesting that ERK1/2 actively contributes to central sensitization downstream of afferent activity
in the 1st phase. Less evidence exists about the role of afferent ERK1/2 following formalin injection.
One study has reported that pERK1/2 immunoreactivity occurs in the soma of DRG neurons
following formalin injection (Tsuda et al., 2007). Although Tsuda et al. reported an attenuated
2nd phase following intrathecal MEK inhibition with U0126, they did not investigate the effects of
U0126 on formalin-induced DRG pERK1/2, leaving the question of the behavioral relevance of
DRG ERK1/2 activity unanswered. Additionally, intrathecal MEK inhibition would affect both DRG
and spinal cord ERK1/2 activity (see discussion below), making it difficult to conclude about the
relative importance of ERK1/2 in either location. In addition to pharmacological studies, transgenic
expression of a dominant negative MEK1 construct in all neurons also decreases formalin-induced
spontaneous behaviors (Karim et al., 2006). Experiments with pharmacologic and genetic targeting
of MEK1/2-ERK1/2 signaling all indicate that ERK1/2 activation is necessary for formalin-induced
spontaneous behaviors.
ERK1/2 in models of inflammatory pain
Formalin- and capsaicin-induced spontaneous behaviors are ultimately short-lived
compared to the pain complaints of patients suffering from chronic pain. Much work in the pain field
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has involved the development of additional rodent models that more closely recapitulate human
disease. Inflammatory pain states, such as rheumatoid arthritis, have been modeled by injecting
complete Freund’s adjuvant (CFA), which is a suspension of heat-killed Mycobacterium tuberculosis
(Neugebauer et al., 2007). Subcutaneous injection of CFA into the plantar surface of the hindpaw
produces local inflammation as well as robust hypersensitivity to heat and mechanical stimuli which
persists for at least one week (Bennett, 2001). CFA injection into the hindpaw induces pERK1/2
immunostaining in DRG (Obata et al., 2003; Tamura et al., 2005). The number of pERK1/2-positive
cell profiles increases as early as 6 hours, peaks 1 day after injection, and subsides 3 days after the
injection. pERK1/2 immunoreactivity occurs primarily in small-diameter neurons, which are mostly
unmyelinated C-fiber afferents (Lawson and Waddell, 1991). The effect of MEK inhibitors applied
to the hindpaw has not yet been reported. However, in a related inflammatory model involving CFA
injection into the knee joint, passive joint movement induced pERK1/2 activation in fibers innervating
the synovial lining of the joint (Seino et al., 2006). More importantly, injection of U0126 before
passive movement dose-dependently reduced already established behavioral hypersensitivity.
This indicates that long-term inflammation due to CFA induces ERK1/2 phosphorylation in
peripheral terminals, which contributes to behavioral sensitization. Another study applied MEK
inhibitors intrathecally and claimed that diminished sensitization following hindpaw injection of CFA
was due to inhibition of ERK1/2 in DRG neurons (Obata et al., 2003). Although DRG pERK1/2
immunostaining also decreased following MEK inhibition, intrathecal drug delivery almost certainly
also affects processes in the spinal cord (see below). Therefore, it is unclear whether ERK1/2
activation in the DRG soma is behaviorally relevant. Finally, it is interesting to note that Western
blot analysis indicated that both ERK1 and ERK2 phosphorylation increased 1 d after CFA injection.
CFA-induced inflammation of the paw also leads to ERK1/2 activation in the spinal cord.
In both rats and mice, CFA injection induces a significant increase in pERK1/2 immunoreactivity
in superficial lamina of the spinal cord dorsal horn (Ji et al., 2002; Adwanikar et al., 2004). The
number of pERK1/2-positive cell profiles peaks at the earliest time point reported, 10 min, and then
slowly diminishes over the course of several days (Ji et al., 2002). By Western blot, significantly
elevated ERK1/2 activation was observed at 7 days (Adwanikar et al., 2004). Western blot analysis
also indicated that both ERK1 and ERK2 phosphorylation was robustly elevated 30 min and 7
days following CFA injection (Ji et al., 2002; Adwanikar et al., 2004). Clearly, CFA-induced paw
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inflammation produces dramatic and sustained increases in ERK1/2 activity in the spinal cord dorsal
horn. Unlike other shorter term models discussed above, ERK1/2 protein expression may also be
affected by long-term inflammation. Three days after CFA injection, ERK1 and ERK2 expression is
slightly but significantly increased in superficial dorsal horn (Xu et al., 2008). A similar phenomenon
was observed at extended time points (12 h) after formalin injection (Li et al., 2004), although this
would have no bearing on the initial spontaneous behaviors and may or may not be behaviorally
relevant. Given these changes in expression, it is tempting to speculate that ERK1/2 may be part
of a positive feedback loop which would amplify signal transduction within dorsal horn neurons. It is
unlikely that increased expression accounts for the observed increases in ERK1/2 phosphorylation
since, in most studies, phospho-specific bands are normalized to total protein bands.
To address the behavioral importance of ERK1/2 activation in the spinal cord, researchers
have applied the MEK inhibitor, U0126, intrathecally and measured hypersensitivity to mechanical
and heat stimulation following CFA injection (Ji et al., 2002). Using osmotic pumps, U0126 was
delivered before CFA injection and then throughout behavioral testing. Animals treated with U0126
had significantly less CFA-induced mechanical and heat hypersensitivity, although hypersensitivity
was not completely abolished. Additionally, post-treatment with U0126 after behavioral sensitization
had been established also significantly attenuated mechanical and heat hypersensitivity. This
indicates that continued ERK1/2 activity is important to maintain CFA-induced hypersensitivity. A
different group reported similar results using intrathecal delivery of U0126 and found attenuation
of CFA-induced hypersensitivity (Obata et al., 2003). However, they also reported a significant
decrease in CFA-induced ERK1/2 activity within DRG as a result of intrathecal MEK inhibition.
Taken together, these studies demonstrate that intrathecal drug delivery can exert effects in both
spinal cord and DRG, complicating the interpretation of the above results. Despite this uncertainty,
it can still be concluded that ERK1/2 activation is important for sensitization. Future experiments
to determine the anatomic locus of ERK1/2 activity may aid in drug design. If peripheral ERK1/2
is required for sensitization, then peripherally restricted antagonists may be therapeutic but avoid
CNS-related side effects.
The CFA model described above in detail is just one example among many others
demonstrating an involvement for ERK1/2 in inflammatory pain. ERK1/2 activity has also been
implicated in several other models that utilize different inflammatory agents (carrageenan, bee
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venom; Galan et al., 2002; Yu and Chen, 2005; Hu et al., 2006; Hao et al., 2008) injected into
different peripheral tissues (temperomandibular joint, knee joint; Seino et al., 2006; Suzuki et al.,
2007). Inflammatory mediators which are required for CFA-induced hypersensitivity also feed
into ERK1/2 signaling. Analyzing the effects of each mediator on ERK1/2 activity provides more
detailed mechanistic information about signaling pathways upstream of ERK1/2. For example,
nerve growth factor (NGF) is required for CFA-induced hypersensitivity since function neutralizing
antibodies attenuate CFA-induced hypersensitivity (Woolf et al., 1994; Pezet and McMahon,
2006). Exogenous NGF alone is also sufficient to induce heat and mechanical hypersensitivity
(Pezet and McMahon, 2006). In relation to ERK1/2, intraplantar injection of NGF induces ERK1/2
phosphorylation in the soma of DRG neurons (Averill et al., 2001). Pretreatment with intraplantar
MEK inhibitors attenuates NGF-induced heat and mechanical hypersensitivity (Zhuang et al., 2004;
Malik-Hall et al., 2005). This indicates that ERK1/2 activation is required for NGF-induced thermal
hypersensitivity. Other chemical messengers implicated in inflammation have also been shown to
induce ERK1/2 activation in sensory afferents, including bradykinin (Rashid et al., 2004; Korkmaz
et al., 2008), nitric oxide (Freeman et al., 2008), and epinephrine (Aley et al., 2001). Together,
these data suggest that ERK1/2 in nociceptive afferents may integrate signals from several distinct
inflammatory mediators. When acting in concert, as is the case after CFA injection, ERK1/2 is
required for behavioral sensitization.
ERK1/2 in models of neuropathic pain
Neuropathic pain is a general term that applies to chronic pain conditions which involve
damage to the nervous system (Costigan et al., 2009). It can involve damage to the central nervous
system or peripheral nervous system, termed central and peripheral neuropathic pain respectively,
and can be caused by multiple different insults. Although in most cases of peripheral nerve damage
sensory function is actually lost, in some cases pain does develop (Bennett, 2001; Costigan et
al., 2009). In this light, neuropathic pain represents a gain of positive neurological symptoms
including spontaneous pain in the absence of injury, hypersensitivity to light touch or heat, and
parasthesias (Costigan et al., 2009). To study the active processes that underlie neuropathic pain,
several animals models have been developed (Bennett, 2001). Peripheral neuropathic pain models
involve transection or partial transection of peripheral nerves, nerve entrapment accompanied with
inflammation within the nerve sheath, transection of nerve roots which contribute to large peripheral
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nerves, as well as other variations.
ERK1/2 phosphorylation has been observed in both the spinal cord and dorsal root ganglion
in several of these models. In dorsal root ganglion, transection of the sciatic nerve induces pERK1/2
immunoreactivity in medium- to large-diameter myelinated neurons expressing NF200 as well as
glial satellite cells that surround neuronal soma within the DRG (Obata et al., 2003). Additionally,
pERK1/2 immunostaining colocalizes with ATF3, which labels axotomized DRG neurons (Tsujino et
al., 2000). ERK1/2 activation within axotomized DRG neurons was confirmed with a different model
involving transection of the L5 nerve root. The sciatic nerve is composed of afferents from L3-L5,
so the L5-spinal nerve ligation (L5-SNL) model allows for the neat segregation of injured (L5)
and uninjured (L3-L4) afferents. Virtually all L5 DRG neurons express ATF3, indicating axotomy.
Within the injured L5 ganglion, pERK1/2 immunoreactivity occurs primarily in medium- to largediameter DRG neurons, although small diameter neurons expressing pERK1/2 were also observed
(Obata et al., 2004b). Interestingly, pERK1/2 immunostaining was not significantly elevated in the
uninjured L4 DRG. In a third model in which the sciatic nerve is loosely ligated with chromic gut
sutures and inflammation of perineural tissues leads to constriction (chronic constriction injury,
CCI; Bennett, 2001), a similar observation is made in which pERK1/2 activation occurs primarily in
larger diameter, injured neurons (Obata et al., 2004a). Taken together, nerve injury induces ERK1/2
activation only in axotomized afferents, most of which are medium to large diameter neurons. This
is in contrast with the cellular distribution of pERK1/2 immunostaining following inflammation, in
which ERK1/2 activation is primarily observed in small-diameter DRG neurons.
This also suggests that ERK1/2 may play distinct roles behaviorally and mechanistically in
inflammatory and neuropathic pain. To test this, researchers have again used the pharmacological
approach. Intrathecal MEK inhibitors delivered before sciatic nerve transection and then continuously
throughout testing reduce autotomy behavior, which is the self-induced damage of the denervated
hindpaw (Obata et al., 2003). Additionally, intrathecal MEK inhibition attenuates hypersensitivity
to mechanical stimuli following CCI or L5-SNL, with little or no effect on thermal hypersensitivity
(Obata et al., 2004a; Obata et al., 2004b). However, as mentioned above, intrathecal application
of inhibitors affects spinal cord processing as well, making conclusions about the specific role of
peripheral ERK1/2 activity in neuropathic pain somewhat tenuous.
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This is especially true given that ERK1/2 activation has been observed in spinal cord dorsal
horn following nerve injury. L5-SNL induces ERK1/2 phosphorylation in spinal cord dorsal horn with
an interesting timecourse and cellular localization (Zhuang et al., 2005). Immediately following spinal
nerve transection, pERK1/2 immunoreactivity increases in the superficial dorsal horn. In neurons,
this increase occurs rapidly (within 10 min) and appears to subside over 6 hours. However, Western
blot analysis indicates a sustained increase in both pERK1 and pERK2 from 1 day to 21 days after
the injury. Apparently, this is due to increases in ERK1/2 phosphorylation in non-neuronal cells.
At 2 days post-injury, OX42-positive microglia account for most of the pERK1/2 immunostaining,
while at 21 days post-injury most of the pERK1/2 immunostaining occurs within GFAP-positive
astrocytes. In the CCI model, persistent pERK1/2 increases were also observed, although the
specific cell type was not addressed (Song et al., 2005). To test whether spinal ERK1/2 activation
was necessary for behavioral sensitization in these models, researchers used intrathecal delivery
of MEK inhibitors. In the studies mentioned above focusing on DRG ERK1/2 activation, continuous
intrathecal administration of MEK inhibitors reduced mechanical hypersensitivity without significant
effect on thermal hypersensitivity (Obata et al., 2004a; Obata et al., 2004b). Similar results were
obtained in the CCI model with nonselective antisense oligonucleotides to both ERK1 and ERK2
(Song et al., 2005). However, in this study CCI-induced heat hypersensitivity was also affected.
This may be due to differences in administration, i.e. multiple intrathecal injections versus osmotic
pump delivery or subtle differences in the CCI surgery. Regardless, it seems that ERK1/2 activity
is important for the behavioral effects of CCI. In the L5-SNL model, MEK inhibition also decreases
behavioral hypersensitivity (Zhuang et al., 2005). Interestingly, both the amplitude and duration of
analgesia following intrathecal MEK inhibition increased at later time points after L5-SNL, perhaps
suggesting that persistent ERK1/2 activity in microglia or astrocytes is necessary for the long-term
maintenance of hypersensitivity. Of course, this would also imply that neuronal ERK1/2 activity is
not as important for the maintenance of nerve-injury induced sensitization. Overall, it is clear that
sciatic nerve injury initiates ERK1/2 activity in DRG and spinal cord. Intrathecal administration of
MEK inhibitors or ERK1/2 antisense attenuates behavioral sensitization following injury, indicating
that ERK1/2 activity is required for injury-induced hypersensitivity in models of neuropathic pain.
ERK1/2 in the nociceptive brain
Thus far, the discussion has focused on the activation and behavioral importance of
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ERK1/2 in primary afferents and spinal cord. However, recent studies are revealing critical roles
of higher brain structures in chronic pain (Tracey, 2005). Certainly, the percept of pain involves
the brain, with the somatosensory cortex being involved in sensory-discriminative aspects of the
sensation of pain, such as the location, quality, and duration of a noxious stimulus. However, other
structures are playing previously unappreciated roles in the affective component of pain, such as
attaching negative emotional valence to the noxious stimulation. Moreover, recent data suggests
that ERK1/2 activation in these structures may contribute to rodent correlates of affective pain.
Noxious stimulation results in ERK1/2 phosphorylation in limbic structures including the anterior
cingulate cortex (Wei and Zhuo, 2008; Cao et al., 2009) and the amygdala (Carrasquillo and
Gereau, 2007). In the anterior cingulate cortex, ERK1/2 is activated following formalin injection
to the paw (Cao et al., 2009). MEK inhibition in the ACC has no effect on formalin-induced
spontaneous behaviors or CCI-induced mechanical or thermal hypersensitivity. However, MEK
inhibition prevents the association between formalin injection and contextual cues in a conditioned
place aversion task (formalin-conditioned place aversion, F-CPA). Interestingly, if rats underwent
F-CPA, re-exposure to the formalin-associated context actually resulted in increases ERK1/2
phosphorylation, mimicking ERK1/2 activation seen immediately following formalin injection. This
molecular correlate of memory retrieval is functionally relevant because MEK inhibitors delivered
after F-CPA erase aversion for the formalin-associated context. Importantly, MEK inhibition in the
ACC has no effect on spatial learning and no effect on conditioned place aversion to shock, which
unlike formalin does not sensitize nociceptive spinal dorsal horn neurons. Cao et al. also observed
increases in the phosphorylation of ERK1 and ERK2 in the ACC using Western blot, indicating that
both isoforms are activated. Overall, this study demonstrated that ERK1/2 activity may be involved
in memories associated with painful stimuli, which may relate to the affective component of pain in
humans.
ERK1/2 activity is also important in other areas of the brain that are involved in chronic pain.
Formalin induces ERK1/2 activation in the amygdala (Carrasquillo and Gereau, 2007). As opposed
to the ACC, ERK1/2 activity in the amygdala contributes to stimulus-evoked hypersensitivity.
Formalin-induced mechanical hypersensitivity, which lasts hours after the injection of formalin,
is diminished by infusion of MEK inhibitors into the amygdala (Carrasquillo and Gereau, 2007).
Interestingly, activation of ERK1/2 using agonists or activators of upstream pathways is sufficient
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to induce hypersensitivity to mechanical stimuli without any injury or noxious stimulus (Carrasquillo
and Gereau, 2007; Kolber et al., 2010). These studies indicate that ERK1/2 activity in the amygdala
is both necessary and sufficient for mechanical hypersensitivity. Other areas of the brain involved
in nociception have also been examined. ERK1/2 activation has been observed in the brainstem
(Imbe et al., 2005; Imbe et al., 2009), which is the site of several important nuclei that are part
of descending modulatory circuits that participate in the processing of nociceptive input in the
spinal cord. CFA induces pERK1/2 in the nucleus raphe magnus (NFM), and application of MEK
inhibitors to the rostral ventromedial medulla attenuates CFA-induced heat hypersensitivity (Imbe
et al., 2005; Imbe et al., 2008). Since cells within the NRM can either facilitate or inhibit nociception
(Mason, 2005), the MEK inhibitor study suggests that the net effect of ERK1/2 activation in the
NRM is facilitatory and thereby increases heat hypersensitivity. ERK1/2 activation has also been
reported in the locus coeruleus (Imbe et al., 2009), but it is unclear what behavioral effect this might
have since inhibitor studies have not yet been reported.
ERK1/2 – Upstream Activators and Downstream Targets
Although sustained noxious stimulation, inflammatory pain, and neuropathic pain are
distinct in many ways, they share some common mechanisms (Costigan et al., 2009). Similar
sensitization processes occurring peripherally and centrally seem to be present in many different
models of pain. An excellent example of this is the importance of ERK1/2 signaling at the level
of the primary afferent and the spinal cord in multiple models of inflammatory and neuropathic
pain. Although expression and behavioral experiments have been outlined in detail above, the
precise activators and downstream targets have not yet been discussed. Much recent work has
demonstrated that similar mechanisms of sensitization involving ERK1/2 can be found in the
context of many different pain models, suggesting that ERK1/2 may be an attractive target for the
treatment of pain.
ERK1/2 has been implicated in peripheral sensitization and is thought to integrate signals
from a variety of channels and receptors. Activation of sensory transduction channels, such as
TRPV1, lead to ERK1/2 activation (Dai et al., 2002; Zhuang et al., 2004). The observation that
capsaicin induces ERK1/2 phosphorylation in vitro (Zhuang et al., 2004) argues for cell autonomous
activation of ERK1/2, which could result from TRPV1-mediated Ca2+ influx and activation of Ca2+-
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sensitive kinases such as PKC or CaMK (Rosen et al., 1994; Agell et al., 2002). It is tempting to
speculate that Ca2+ influx from other TRP channels, such as TRPA1, may activate ERK1/2 through
a similar mechanism, which would explain the observed increase of pERK1/2 in vivo following
noxious cold (Mizushima et al., 2006). Besides sensory transduction channels, receptor tyrosine
kinases and G-protein coupled receptors feed into ERK1/2 activation in DRG neurons. The best
example of receptor tyrosine kinase coupling to ERK1/2 is the receptor for NGF, TrkA (Averill et
al., 2001; Zhuang et al., 2004; Malik-Hall et al., 2005). In vivo and in vitro evidence suggests that
ERK1/2 phosphorylation occurs directly downstream of TrkA, since pERK1/2 occurs within TrkApositive neurons and short applications (10 minutes) of NGF activate ERK1/2 in cultured cells
(Averill et al., 2001; Zhuang et al., 2004). TrkA is likely to signal through adaptor proteins (Shc/
Grb2/SoS) in order to recruit Ras and ultimately activate the Raf-MEK1/2-ERK1/2 cascade (MalikHall et al., 2005). Parallel signaling cascades downstream of TrkA include the PLC-PKC and PI3KAkt cascades. Although these three cascades can be distinct and functionally isolated in other cell
types, it appears that there is some cross-talk in DRG neurons. In vivo and in vitro studies have
indicated that PI3K inhibitors attenuate NGF-induced ERK1/2 activation (Zhuang et al., 2004; MalikHall et al., 2005). PI3K-Ras interaction has been observed before in DRG neurons (Jones et al.,
2003), supporting the idea that NGF-TrkA intracellular signaling likely involves the intersection of
PI3K and ERK1/2. Several G-protein coupled receptors also activate ERK1/2 in primary afferents.
Epinephrine activates ERK1/2 in DRG neurons via β2-adrenergic receptors (Aley et al., 2001).
Interestingly, this is independent of PKC and PKA signaling but instead involves Gi/o and Ras.
Bradykinin has also been shown to activate ERK1/2 in vivo and in vitro (Rashid et al., 2004; Tang
et al., 2006), probably through B2 receptors. These are just a few examples of important signaling
molecules that activate ERK1/2 cell autonomously.
After integrating signaling from a variety of upstream receptors and channels, ERK1/2
phosphorylates downstream effector proteins which go on to sensitize nociceptors. Conceptually,
this could occur rapidly via direct phosphorylation of effector proteins, such as sensory transduction
channels or voltage-gated ion channels, or via phosphorylation of intermediate kinases and
transcription factors which would lead to transcriptional changes. Recent studies have identified
both mechanisms at play in the context of peripheral sensitization. In nociceptors, ERK1/2 activity
has been linked to sensitization of TRPV1 (Zhuang et al., 2004). Specifically, TrkA binding to NGF

21

leads to activation of PI3K and then ERK1/2 in cultured DRG neurons. Patch clamp recordings
of capsaicin-evoked currents were then used to assess NGF-induced sensitization, which was
found to depend on both PI3K and ERK1/2 activity. Several other protein kinases regulate TRPV1
function, including but not limited to PKA, PKC, Src and CDK5 (Bhave and Gereau, 2004; Huang et
al., 2006; Stucky et al., 2009). One plausible mechanism for ERK1/2-dependent TRPV1 modulation
could involve the placement of ERK1/2 upstream of one of the above kinases. Indeed, interplay
among these pathways has been reported previously in other systems (Della Rocca et al., 1997;
English et al., 1999; Parekh et al., 1999; Maudsley et al., 2000; Kalia et al., 2004; Utreras et
al., 2009). It is also possible that ERK1/2 may directly phosphorylate TRPV1, since predicted
ERK1/2 phosphorylation sites do occur in cytoplasmic TRPV1 domains (NetPhos 2.0 search,
unpublished). One putative ERK1/2 site can be phosphorylated by CDK5, which has also been
implicated in heat hypersensitivity in vivo (Pareek et al., 2007). This supports a model in which
direct phosphorylation of TRPV1 by ERK1/2 may enhance TRPV1 function and, additionally, posits
interaction between ERK1/2 and CDK5 at this phosphorylation site. Of course, this must be tested
directly by mutagenesis studies. The use of MEK inhibitors has established a role for ERK1/2 in
sensitizing TRPV1 and elucidating the precise molecular machinery involved will be an interesting
area of investigation.
In addition to ERK1/2 modulation of TRPV1, ERK1/2 may sensitize nociceptors by
modulating their excitability, i.e. the likelihood that local depolarizations from sensory transduction
channels like TRPV1 will lead to an action potential. There are many examples of ERK1/2
modulating excitability in other neurons (see below, Adams and Sweatt, 2002; Sweatt, 2004; Hu et
al., 2006; Hu et al., 2007). In nociceptors, ERK1/2 activation downstream of the protease-activated
receptor 2 (PAR2) is associated with membrane depolarization, a decrease in rheobase, and an
increase in input resistance (Kayssi et al., 2007). All of these ERK1/2-dependent effects increase
nociceptor excitability. PAR2 activation was also accompanied by inhibition of sustained voltagegated K+ currents, which may be related to the observations of ERK1/2 dependent modulation of
excitability. There is also evidence that ERK1/2 may modulate voltage-gated Na+ currents by direct
phosphorylation of NaV1.7 (Stamboulian et al., 2010). In this study, inhibition of basal ERK1/2 activity
in cultured DRG neurons decreased action potential number in response to current stimulation,
consistent with an effect on Na+ currents. However, this was accompanied by a depolarizing shift in
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the resting membrane potential. Although this is consistent with activation of ERK1/2 depolarizing
the cell (Kayssi et al., 2007), it is unclear whether the effect of ERK1/2 inhibition in current clamp
recordings is related to modulation of Na+ or K+ currents. To further complicate the picture, ERK1/2
has also been shown to regulate Ca2+ currents in DRG neurons, perhaps by direct phosphorylation
in the case of the N-type Ca2+ channel, CaV2.2 (Fitzgerald, 2000; Martin et al., 2006; Woodall et
al., 2008). Although the importance of specific phosphorylation sites cannot be determined without
functional characterization of mutations at those sites in the context of the native cellular system,
MEK inhibitor studies clearly show an effect of ERK1/2 activity on the excitability of nociceptors.
Altogether, these data suggest that ERK1/2 activation by upstream signals can result in dramatic
sensitization of nociceptors within minutes by modulation of sensory transduction as well as the
transmission of nociceptive information.
In addition to rapid effects of ERK1/2 on cellular physiology, recent studies have identified
links between ERK1/2 activity and transcriptional regulation within nociceptors. Inflammation and
inflammatory mediators induce dramatic transcriptional changes within nociceptors that are likely
to be important for long-term behavioral hypersensitivity (Woolf and Ma, 2007). Inflammation
of tissues innervated by nociceptors increases the expression of substance P, CGRP, sodium
channels, TRPV1, and BDNF in the soma of neurons. ERK1/2 is likely to participate in the signaling
events that underlie this remodeling, since a number of inflammatory mediators feed into ERK1/2
signaling and have also been implicated in transcriptional regulation. For example, NGF regulates
the expression of all of the molecules listed above (Pezet and McMahon, 2006). MEK inhibitors have
been used in some cases, specifically implicating ERK1/2 in transcriptional regulation. CFA injection
leads to ERK1/2 phosphorylation and BDNF expression within the same DRG neurons, and MEK
inhibition prevents BDNF upregulation (Obata et al., 2003). This is likely related to NGF signaling
since pERK1/2-positive neurons colocalized with TrkA and since intrathecal application of NGF in
a separate set of experiments induced pERK1/2 and BDNF within the same neurons. ERK1/2 is
also required for NGF-induced upregulation of TRPV1 expression in cultured DRG neurons (Bron
et al., 2003). Another inflammatory mediator, IL-1β, has also been observed to exert transcription
changes via ERK1/2, since upregulation of COX2 mRNA by IL-1β is prevented with MEK inhibitors
(Amaya et al., 2009). Neuropathic pain also involves dramatic transcriptional changes, and ERK1/2
may be involved in these as well (Obata et al., 2003; Obata et al., 2004a). The exact downstream
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molecules accounting for ERK1/2-dependent transcription in DRG neurons are not well understood.
It is possible that ERK1/2 exerts its effects on transcription via CREB phosphorylation, which occurs
in DRG soma after inflammation (Tamura et al., 2005) and is downstream of ERK1/2 activation in
other neuronal systems (Adams et al., 2000; Mao et al., 2008). Other transcription factors may also
be involved, Elk and SRF, although their role in sensory neurons during chronic pain is unstudied
(Wickramasinghe et al., 2008; Kerr et al., 2010). Therefore, the pro-nociceptive effects of ERK1/2
activation in sensory afferents can occur rapidly by post-translational modifications of channels and
can also occur by transcriptional regulation of genes that govern nociceptor function.
In spinal cord dorsal horn neurons as in nociceptors, ERK1/2 activation has both rapid
post-translational effects on neuronal function and delayed but perhaps longer-lasting effects on
transcription. ERK1/2 is activated by GPCRs, including mGluR5 and NK1R, receptor tyrosine
kinases, such as TrkB, and NMDA and AMPA glutamate receptors (Ji et al., 1999; Karim et al.,
2001; Kawasaki et al., 2004; Zhao et al., 2006; Hu et al., 2007; Ji et al., 2009). Several signaling
cascades initiated by these cell surface receptors converge upon ERK1/2 in dorsal horn neurons,
including cAMP/PKA, PLC/PKC, Src, PI3K, Ca2+ influx and Ca2+-sensitive enzymes such as adenylyl
cyclase 1 (AC1) and AC8, and probably others (Hu and Gereau, 2003; Hu et al., 2003; Kawasaki et
al., 2004; Wei et al., 2006; Pezet et al., 2008; Ji et al., 2009). Several molecules acting downstream
of ERK1/2 have been identified. One excellent example of ERK1/2 post-translational modulation
involves the rapidly inactivating K+ current, IA. ERK1/2 activation with phorbol esters to activate
PKC, AC activators to stimulate cAMP production and activate PKA, and group I mGluR agonists
all rapidly decrease IA (Hu et al., 2003; Hu et al., 2007). The use of MEK1/2 inhibitors confirms
that these effects occur via ERK1/2 activation. Moreover, ERK1/2 modulation of IA occurs through
the specific modulation of KV4.2, since KV4.2 deletion or point mutations of candidate ERK1/2
phosphorylation sites prevents ERK1/2-mediated inhibition of IA (Hu et al., 2006). Associated with
these effects on K+ currents, ERK1/2 modulates the intrinsic excitability of spinal cord neurons,
and this modulation requires KV4.2 (Hu and Gereau, 2003; Hu et al., 2006). Additionally, these
electrophysiological effects are behaviorally relevant since KV4.2-/- mice exhibit reduced behavioral
sensitivity in the formalin test and in inflammation-induced mechanical hypersensitivity (Hu et al.,
2006). This series of studies strongly suggests that the rapid post-translational modulation of KV4.2
has functional implications on the cellular and behavioral level. Besides, modulation of KV4.2,
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ERK1/2 may exert rapid post-translational effects by increasing NMDA and AMPA currents perhaps
by direct phosphorylation of the channels (Slack et al., 2004; Kohno et al., 2008; Ji et al., 2009).
ERK1/2 may also be able to modulate the activity and function of spinal cord dorsal horn
neurons by transcriptional regulation. One identified pathway involves activation of the transcription
factor CREB (Ji et al., 2009). Sciatic nerve injury, injection of formalin or capsaicin to the paw,
and C-fiber stimulation all induce CREB phosphorylation in the spinal cord dorsal horn, and in
each case CREB phosphorylation is reduced with MEK1/2 inhibition (Ji and Rupp, 1997; Kawasaki
et al., 2004; Song et al., 2005). Several immediate early genes regulated by CREB have also
been observed in spinal cord dorsal horn following noxious stimulation. For example, CFAinduced inflammation is associated with an increase in prodynorphin and NK1 expression, which is
prevented with intrathecally-delivered MEK inhibitors (Ji et al., 2002). Other CREB-regulated genes
are upregulated in models of pain, such as c-fos (Coggeshall, 2005; Ji et al., 2009), suggesting that
ERK1/2 may coordinate transcriptional reprogramming of spinal cord dorsal horn neurons in pain
states. However, direct evaluation of each putatively regulated gene target must be done. Perhaps
a more fundamental question involves the functional importance of ERK1/2-mediated CREB
activation. This might be addressed by testing whether ERK1/2 is required for the maintenance of
hypersensitivity. If transcriptional changes dominated at later time points, MEK inhibition at these
time points would either not reduce hypersensitivity at all or not decrease it immediately. In the
CFA model, MEK inhibition long after established hypersensitivity is still able to reduce behavioral
sensitization (Ji et al., 2002). However, the effects of MEK inhibition take 6-24 hours to evolve. This
suggests that sustained ERK1/2 activation contributes to hypersensitivity but that this may involve
processes with longer decay kinetics, such as those on the transcriptional level. Although this is
suggestive, direct testing of the importance of ERK1/2-mediated transcription changes should be
done to better understand the relative importance of post-translational and transcriptional effector
mechanisms in spinal cord dorsal horn neurons.
The effects of ERK1/2 activation are less well-studied in other brain areas and in other
cell types. Recently, the role of glial cells in pain has become an area of intense interest (Milligan
and Watkins, 2009). As mentioned above, peripheral nerve injury induces ERK1/2 phosphorylation
in both microglia and astrocytes in the spinal cord dorsal horn (Zhuang et al., 2005; Ji et al.,
2009). Glial ERK1/2 activation may result in the release of inflammatory mediators, such as IL-
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1β, IL-6, and TNFα, which have been linked with central sensitization (Kawasaki et al., 2008;
Milligan and Watkins, 2009). Additionally, ERK1/2 activity in astrocytes has been associated with
a downregulation of glutamate transporters, which may contribute to activation of extrasynaptic
glutamate receptors and elevated activity in dorsal horn neurons (Sung et al., 2003; Milligan and
Watkins, 2009). After spinal cord injury (SCI), activated microglia in the spinal cord caudal to injury
show increased ERK1/2 phosphorylation, PGE2, and COX-2 expression (Zhao et al., 2007). MEK1/2
inhibitors prevented all of these biochemical changes, reduced SCI-induced hyperresponsiveness
of wide-dynamic range neurons, and reduced behavioral sensitization due to SCI. In other areas of
the nervous system, pain-related ERK1/2 activation has been associated with increases in synaptic
strength (Fu et al., 2008) and in CREB activation (Cao et al., 2009) with a presumed induction of
immediate early genes. The molecular details of nociception-related ERK1/2 signaling within the
brain as well as non-neuronal cells throughout the nervous system represents an area of promising
future scientific investigation. More generally, ERK1/2 activity in many different cell types and areas
of the nociceptive nervous system speaks to the widespread importance of ERK1/2 signaling.
ERK1 and ERK2 – Similarities and Differences
Although much is known about the function of MEK1/2-ERK1/2 signaling, little is known
about the specific functions of each ERK isoform. As outlined above (Fig. 1), information gleaned
from MEK1/2 inhibitors does not query potential isoform-specific functions since MEK1/2 activates
both ERK1 and ERK2 (Pearson et al., 2001) and since MEK1/2 inhibitors are not selective for
MEK1 versus MEK2 (Servant et al., 1996; Favata et al., 1998). As an alternative approach to
pharmacologic inhibition, researchers have used transgenic expression of a dominant negative
MEK1 (DN MEK) kinase (Shalin et al., 2004; Karim et al., 2006). In both pain models and fear
conditioning, DN MEK transgenic mice express phenotypes that nicely parallel those observed with
MEK1/2 inhibitors. Interestingly, when DN MEK1 is transiently transfected into sympathetic neurons
or expressed in transgenic animals, ERK1 and ERK2 phosphorylation is equally reduced (Shalin
et al., 2004; Karim et al., 2006). However, since this represents overexpression and may affect
both endogenous MEK isoforms, it is difficult to conclude about preferential signaling between
MEK and ERK isoforms. Therefore, neither DN MEK nor MEK inhibitor experiments are able to
address whether ERK1 or ERK2 may have specific functions. Experiments evaluating ERK1/2
activation (phosphorylation) are also limited, since phospho-specific ERK antibodies bind to both
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phosphorylated ERK1 and ERK2 due to high homology in their phosphorylation loop domains
(Fig. 2). This limits immunostaining experiments which might reveal differences in ERK1/2 isoform
phosphorylation in different cell types within tissues or at different subcellular locations. However,
since ERK1 and ERK2 are different sizes, the activation states of each isoform can be resolved by
Western blotting and have offered tantalizing clues about potential differences between isoforms.
Without evidence to the contrary, functional redundancy has been a working model in
the field since ERK1 and ERK2 share a 90% cDNA homology (Boulton et al., 1991) and since
the isoforms are coexpressed in many tissues throughout development (Krens et al., 2006b;
Krens et al., 2006a; Di Benedetto et al., 2007). However, there is emerging evidence that ERK1
and ERK2 are functionally distinct. Genetic elimination of ERK1 or ERK2 in mice results in
dramatically different phenotypes. ERK1 germline knockouts (ERK1-/-) are viable, fertile, and live
to adulthood (Pages et al., 1999). ERK2 germline knockouts (ERK2-/-) are embryonic lethal due
to defective mesodermal differentiation and placental development (Hatano et al., 2003; Saba-ElLeil et al., 2003; Yao et al., 2003). Further characterization of ERK1-/- mice has revealed a set of
interesting gain-of-function phenotypes. On the systems level, ERK1 deletion actually enhances
the association between morphine administration and a particular context, as observed using a
conditioned place preference task (Mazzucchelli et al., 2002). This behavioral phenotype was
correlated with enhanced LTP in nucleus accumbens as well as enhanced induction of immediate
early genes by glutamate stimulation in cultured striatal cells (Mazzucchelli et al., 2002). Activation
of ERK2 in cultured neurons was greatly enhanced by the loss of ERK1, raising the possibility that
ERK1 functionally antagonizes ERK2 activity in some way. Additional experimentation revealed
that ERK1-/- mice are also relatively hyperactive, spending significantly more time wheel running in
their home cages, exploring more in a novel environment, and resisting immobility in the forcedswim task when compared with wild-type (WT) littermates (Selcher et al., 2001; Mazzucchelli et
al., 2002; Engel et al., 2009). However, ERK1 deletion has no effect in fear conditioning or tests
of anxiety such as the amount of time spent in the center of an open field apparatus (Selcher et
al., 2001). Interestingly, no synaptic plasticity changes were observed in ERK1-/- hippocampus
(Selcher et al., 2001; Selcher et al., 2003), in accordance with a lack of an effect in behavioral tests
associated with hippocampal function.
Clearly, ERK1 plays important roles in different areas of the nervous system, but it
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is unclear whether this is due to a specific requirement for ERK1 or ERK2 is also involved. As
such, researchers have sought to examine the role of ERK2 in the same systems. However, this
has been somewhat difficult due to embryonic lethality of ERK2-/-. To circumvent these issues, a
hypomorphic allele was identified in which targeted insertion of a neo cassette into the mapk1
locus reduced ERK2 expression by ~30% (Satoh et al., 2007). This reduction was sufficient to
significantly impair fear conditioning and performance in spatial learning tasks. Interestingly, there
was no change in wheel running or open field exploration. Although ERK2 hypomorphs have not
yet been tested in morphine conditioned place preference, each isoform appears to be required
for different behavioral tasks. It is possible that a lack of a phenotype in the ERK2 hypomorph
is due to incomplete reduction in ERK2 expression. To achieve complete elimination of ERK2
while circumventing embryonic lethality, conditional gene deletion strategies have been employed
to varying success. Conditional deletion of ERK2 with a hGFAP-Cre line (Zhuo et al., 2001)
resulted in the loss of ERK2 in most cells of the central nervous system but produced mice that
survived to adulthood. Interestingly, these mice showed deficits in fear conditioning (Samuels et
al., 2008), similar to ERK2 hypomorphs. However, since Cre expression occurred relatively early
in development within multi-potent neural precursors, conditional deletion also reduced cortical
size probably due to reduced proliferation of neural precursors and not as a result of cell death.
Conditional deletion of ERK2 in neural crest progenitors with a Wnt1-Cre line led to embryonic
lethality probably resulting from cardiac malformations (Newbern et al., 2008). Another attempt at
conditional ERK2 deletion in the brain using a Nestin-Cre line resulted in unexpectedly incomplete
elimination of ERK2 from hippocampus and hypothalamus, and not surprisingly there was no effect
on several behavioral tests (Heffron et al., 2009). Another Nestin-Cre conditional knockout has
been reported, but impaired proliferation of neural progenitors also occurs (Imamura et al., 2008).
It is important to note that the effect of ERK2 deletion on the proliferation of neural progenitors is
not shared by ERK1-/- mice, since brain structure is grossly similar between ERK1-/- mice and their
WT littermates (Selcher et al., 2001). Thus, targeted deletion or disruption of ERK2 expression
has significantly different results in nervous system development. From these studies, it seems
likely that ERK1 and ERK2 also play distinct roles in learning and memory in the adult nervous
system, although developmental effects of ERK2 may confound this interpretation. An inducible
conditional deletion strategy could be employed in the future to rigorously test the role of ERK2 in
these contexts.
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Besides the different phenotypes incurred by deletion of ERK1 or ERK2, additional
evidence of isoform-specific functions has been reported in other systems on the cellular level. In the
NIH/3T3 fibroblast cell line, RNAi-mediated knockdown of ERK2 significantly reduces proliferation
(Vantaggiato et al., 2006), which is consistent with observations in neural progenitors and is similar
to the effects obtained by interfering with Raf-MEK-ERK signaling in fibroblasts (Seger and Krebs,
1995). Paradoxically, knockdown of ERK1 actually enhances proliferation. Knockdown of ERK1 is
associated with an increase in immediate early gene activation following serum stimulation, while
ERK2 knockdown is associated with the opposite effect. However, the role of ERK1 and ERK2 in
fibroblasts is controversial, since a subsequent study found no “gain-of-function” effects of ERK1
knockdown (Lefloch et al., 2008). In fact, systematically varying the relative amounts of ERK1 and
ERK2 knockdown led Lefloch, et al. to the model that ERK1 and ERK2 were functionally redundant,
but that the differences in their expression levels within different cell types gave rise to apparent
functional differences (Lefloch et al., 2008, 2009). Overall, these results suggest that ERK2, but
not ERK1 plays, a predominant role accelerating fibroblast proliferation. Whether this is due to
intrinsic functional differences or merely to relative expression levels remains to be determined.
However, additional evidence supports the existence of intrinsic functional differences, since the
rate of nuclear-cytoplasmic shuttling is different for ERK1 and ERK2 in NIH/3T3 cells (Marchi et al.,
2008). ERK1 shuttles at slower rates than ERK2 due to sequence differences in the N-terminus.
Moreover, there are other amino acid sequence differences that may impact MEK1/2 binding, ERK
dimerization, and subcellular localization (see Fig. 2, Boulton et al., 1991; Zhang et al., 1994; Cobb
and Goldsmith, 2000). These subtle differences in sequence may manifest in different proteinprotein interactions that may be functionally important, between kinases and scaffolds for example.
Indeed, ERK1 and not ERK2 interacts with the scaffold MP1 (Schaeffer et al., 1998). Therefore,
differences between ERK1 and ERK2 on the cellular and molecular level are likely to underlie the
different phenotypes observed with the deletion of ERK1 and ERK2.
What roles do ERK1 and ERK2 play in nociception and nociceptive sensitization?
Using MEK1/2 inhibitors and DN MEK mice, it has become clear that ERK1/2 activity
throughout the pain neuraxis is required for behavioral sensitization. However, little is known about
the relative importance of ERK1 and ERK2. By Western blot analysis, it appears that noxious
stimulation, inflammation, and nerve injury all increase the phosphorylation state of both ERK1 and
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ERK2 in most cases (Ji et al., 1999; Karim et al., 2001; Ji et al., 2002; Obata et al., 2003; Song
et al., 2005). The one exception to this is in the amygdala in which ERK1 phosphorylation does
not appear to change following formalin injection (Carrasquillo and Gereau, 2007). In other areas,
ERK2 is generally more phosphorylated than ERK1. However, these biochemical observations are
not a direct test of function, and represent a composite of ERK1/2 phosphorylation from tissue that
is a heterogeneous mix of cell types. Given emerging evidence in other fields that ERK1 and ERK2
may even have opposing functions, potential isoform-specific roles in nociception and nociceptive
sensitization is possible. If so, this may allow for a more specific therapeutic intervention which
would target the important isoform in nociceptive sensitization without inhibiting unrelated functions
of the less important isoform.
To test directly the role of ERK1 and ERK2 in nociception and nociceptive sensitization,
I took a genetic approach that combined targeted deletion of ERK isoforms with a thorough
behavioral and biochemical characterization of the mutant mice. Results of this study indicate that
ERK1 is dispensable for behavioral sensitization in models of acute chemical nociception, longterm inflammatory pain, and neuropathic pain. It does not appear that ERK2 masks the effects of
ERK1 deletion since ERK2 activation in pain models is unaltered by the loss of ERK1. Mice were
also generated to lack ERK2 expression in small-diameter, unmyelinated nociceptors. Nociceptor
ERK2 is required for acute chemical nociception and inflammation-induced hypersensitivity. Since
ERK1 deletion had no effect in these models, altogether the results serve as good evidence that
ERK2 and not ERK1 is required for nociceptive sensitization.
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Abstract
The extracellular signal-regulated kinase (ERK) isoforms, ERK1 and ERK2, are believed to
be key signaling molecules in nociception and nociceptive sensitization. Studies utilizing inhibitors
targeting the shared ERK1/2 upstream activator, mitogen-activated protein kinase kinase (MEK),
and transgenic mice expressing a dominant negative form of MEK have established the importance
of ERK1/2 signaling. However, these techniques do not discriminate between ERK1 and ERK2.
To dissect the function of each isoform in pain, we utilized mice with a targeted genetic deletion of
ERK1 (ERK1 KO) to test the hypothesis that ERK1 is required for behavioral sensitization in rodent
pain models. Despite activation (phosphorylation) of ERK1 following acute noxious stimulation and
in models of chronic pain, we found that ERK1 was not required for formalin-induced spontaneous
behaviors, complete Freund’s adjuvant-induced heat and mechanical hypersensitivity, and
spared nerve injury-induced mechanical hypersensitivity. However, ERK1 deletion did delay
formalin-induced long-term heat hypersensitivity, without affecting formalin-induced mechanical
hypersensitivity, suggesting that ERK1 partially shapes long-term responses to formalin. Interestingly,
ERK1 deletion resulted in elevated basal ERK2 phosphorylation. However, this did not appear to
influence nociceptive processing, since inflammation-induced ERK2 phosphorylation and pERK1/2
immunoreactivity in spinal cord were not elevated in ERK1 KO mice. Additionally, systemic MEK
inhibition with SL327 attenuated formalin-induced spontaneous behaviors similarly in WT and
ERK1 KO mice, indicating that unrelated signaling pathways do not functionally compensate for the
loss of ERK1. Taken together, these results suggest that ERK1 plays a limited role in nociceptive
sensitization and supports a predominant role for ERK2 in these processes.
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Introduction
Extracellular signal-regulated kinases (ERK), ERK1 and ERK2, are mitogen activated
protein kinases (MAPK; Pearson et al., 2001) that have been identified as critical players in
sensitization to noxious stimuli following peripheral inflammation and nerve damage (Ji et al., 1999;
Karim et al., 2001; Ji et al., 2002; Ciruela et al., 2003; Obata et al., 2003; Song et al., 2005). A variety
of acute noxious stimuli and chronic pain models result in ERK1/2 activation (phosphorylation) at
many levels of the nociceptive sensory system including dorsal root ganglion, spinal cord, and
amygdala (Ji et al., 2009). The use of inhibitors which block activation of both ERK1 and ERK2
by inhibiting their shared upstream MAP kinase kinases (MEK1/2) and transgenic expression in
neurons of a dominant negative form of MEK1, which suppresses MEK1/2-ERK1/2 signaling, have
demonstrated that ERK1/2 is necessary for nociceptive sensitization (Ji et al., 1999; Karim et al.,
2001; Ji et al., 2002; Song et al., 2005; Hu et al., 2006; Karim et al., 2006; Seino et al., 2006; Ji et
al., 2009).
Although much is known about MEK1/2-ERK1/2 signaling, little is known about the specific
functions of each ERK isoform. Functional redundancy has been a working model because the
isoforms are 90% homologous (Boulton et al., 1991) and no isoform-specific inhibitors currently
exist. However, there is emerging evidence that ERK1 and ERK2 may be functionally distinct.
ERK1 knockouts (ERK1 KO) are viable but exhibit behavioral abnormalities correlated with altered
synaptic plasticity in striatum (Pages et al., 1999; Selcher et al., 2001; Mazzucchelli et al., 2002),
whereas ERK2 knockouts are embryonic lethal at E8.5 (Krens et al., 2006). Alternative methods for
targeting ERK2, including reduced expression from a hypomorphic mutant allele and conditional
deletion in telencephalon, have revealed a requirement for ERK2 in several learning and memory
paradigms (Satoh et al., 2007; Samuels et al., 2008). In cell culture, genetic targeting or RNA
interference experiments suggest specific roles for ERK1 and ERK2 (Mazzucchelli et al., 2002;
Vantaggiato et al., 2006). Evidence to support this hypothesis includes the observations that ERK1
exclusively interacts with the MEK-ERK signaling scaffold MP1 (Schaeffer et al., 1998) and the fact
that differences in amino acid sequence between ERK1 and ERK2 occur in domains which may
affect MEK1/2 binding, ERK dimerization, and subcellular localization (Boulton et al., 1991; Zhang
et al., 1994; Cobb and Goldsmith, 2000). Indeed, ERK1 and ERK2 have different rates of shuttling
between the cytoplasm and nucleus due to sequence differences in the N-terminus (Marchi et al.,
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2008).
Currently, the importance of ERK1 in nociceptive sensitization remains unknown.
Therefore, we tested the necessity of ERK1 in acute noxious sensitization and in models of chronic
inflammatory and neuropathic pain using ERK1 KO mice. Although ERK1 is activated in these
models, genetic deletion of ERK1 had a minimal impact on these ERK-dependent behaviors.
Interestingly, ERK1 deletion increased basal ERK2 phosphorylation without affecting inflammationinduced changes in ERK2 phosphorylation. Our observations indicate that ERK1 is not required for
nociceptive sensitization and suggest that ERK2 plays a predominant role.
Methods
Animals
All experiments were performed according to the guidelines of the National Institutes of Health and
were approved by the Animal Care and Use Committee of Washington University School of Medicine.
Mice were housed with a 12 h/12 h light/dark cycle and ad libitum access to food and water. Targeted
deletion of ERK1 was achieved by homologous recombination in a process described in detail
previously (Fig. 1; Nekrasova et al., 2005). Briefly, the targeting vector deleted exons 1-6 of mapk3,
which includes the kinase active site and phosphorylation loop, and replaced them with a Neo cassette
flanked with loxP sites. Embryonic stem cells from 129 Sv mice were transfected and selected
for homologous recombination. Successfully targeted clones were injected into CD1 blastocysts,
which
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C57BL/6 mapk3 mutant heterozygotes were crossed producing mice heterozygous for the mapk3
mutant allele, homozygous for the mutant allele (ERK1 KO), and homozygous for the wild-type
mapk3 allele (WT). 7- to 9-week old ERK1 KO and WT male littermates from these crosses were
used in all experiments. The experimenter was blind to the genotype and treatment in all behavioral
experiments.
Measurement of Heat and Mechanical Thresholds
All behavioral tests were performed in rooms isolated from other activity and with white noise
present. Tests were conducted at room temperature (~25°C) during the second half of the light
cycle. Before testing, mice were allowed to acclimate to the behavioral room and apparatus for
2-3 hours. After acclimation, measurements of paw withdrawal thresholds to heat and mechanical
stimuli were performed. Measurements were consistently made when mice were calm. Modular
clear plexiglass behavior chambers (width=10 cm, length=10 cm, height=15 cm), which could be
placed on different floor surfaces, were used with one mouse per chamber. Responses to heat
were measured using a modified Hargreaves test (Hargreaves et al., 1988). Mice were placed in
behavior chambers on a 390G Plantar Test Apparatus (IITC Life Science, Woodland Hills, CA) with
a glass plate floor heated to ~30°C. Radiant heat was applied to the plantar surface of the hindpaw
using a focused beam of light with an active intensity of 14% maximal, a cutoff of 20 sec, and
idle intensity of 5% maximal. 100% beam intensity heats to ~250°C. To measure paw withdrawal
latency, a timer was automatically initiated at the onset of heat application (active intensity), and
upon paw withdrawal, the heat source was returned to idle intensity automatically stopping the timer.
Five independent measurements, separated by 15 min alternating between right and left paws,
were used to determine baseline withdrawal latency. For time points hours after paw injections, 2
independent measurements were averaged. On subsequent days, 3 independent measurements
were used. To measure responses to mechanical stimuli, mice were placed in behavioral chambers
on an elevated wire mesh floor. Calibrated von Frey filaments (North Coast Medical Inc. Morgan
Hill, CA) were then applied through the mesh to the plantar surface of the hindpaw between the
anterior and posterior foot pads, except for the spared nerve injury experiment in which filaments
were applied to the lateral surface of the hindpaw in sural nerve territory. Filaments were pressed
into the skin until the filament bent, held for approximately 1 sec, and then removed. Withdrawal of
the hindpaw from the mesh indicated a positive withdrawal response. Each filament was applied
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5 times at a frequency of approximately 0.5 Hz. The lightest filament (0.008 g) was initially used
followed by progressively heavier filaments until the filament that evoked 3 withdrawals out of 5
applications was reached. The calibrated force of the filament was recorded as the paw withdrawal
threshold. Three to five independent measurements were averaged to yield the baseline threshold
for each hindpaw. Hours after paw injections, a single measurement was used, while on subsequent
days, 3 independent measurements were averaged for each time point.
Formalin-Induced Spontaneous Behaviors
To measure spontaneous behavioral responses to formalin injection, mice were acclimated in
behavior chambers with a plexiglass floor for at least 1 h. Mice were then injected subcutaneously
with 10 μl 2% formalin (Sigma-Aldrich, St. Louis, MO) in sterile 0.9% NaCl into the plantar surface
of the hindpaw and immediately returned to the behavior chamber. Total time spent licking and
lifting the injected paw was recorded in five minute bins for one hour. In experiments with the
MEK inhibitor, SL327 (Tocris Bioscience, Ellisville, MO), mice were allowed to acclimate as above,
injected with SL327 or vehicle (DMSO), and then returned to the behavior chamber. Thirty minutes
later, mice were injected into the plantar surface of the hindpaw with 3.5% formalin, returned to the
behavior chamber, and video recorded from below with a webcam (Logitech) at a resolution of 960
x 720 for one hour without the experimenter present. Subsequently, videos were scored for time
spent licking, lifting, and flinching the injected paw.
Formalin and Complete Freund’s Adjuvant-Induced Hypersensitivity
Formalin-induced hypersensitivity to heat and mechanical stimuli was used as a model of persistent
pain. Heat hypersensitivity to formalin was assayed by measuring baseline paw withdrawal
latencies using a Hargreaves-style apparatus as described above on Day 1. On Day 2, mice
were acclimated (2-3 h) and injected with 10 µl 2% formalin (in sterile 0.9% NaCl). Threshold
measurements from the injected (ipsilateral) and uninjected (contralateral) paws were made at
1 h, 2 h, and 3 h post-injection. On subsequent post-injection days, mice were first allowed to
acclimate (2-3 h), and then paw withdrawal thresholds were obtained. To measure mechanical
hypersensitivity to formalin, a similar timecourse was performed except von Frey filaments were
used as detailed above. Intraplantar injections of 10 µl 3.5% formalin (in sterile 0.9% NaCl) were
made and subsequent threshold measurements were obtained. A higher concentration of formalin
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was used in mechanical experiments because 2% formalin did not produce robust mechanical
hypersensitivity in either WT or ERK1 KO mice (data not shown). Intraplantar injection of complete
Freund’s adjuvant (CFA, 10 µl, 1.0 mg/ml, Sigma-Aldrich) was used as a chronic inflammatory pain
model. The same experimental design used in formalin-induced hypersensitivity experiments was
used to assay mechanical and heat hypersensitivity following CFA injection.
Spared Nerve Injury Model
To measure mechanical hypersensitivity following spared nerve injury (Decosterd and Woolf, 2000),
paw withdrawal thresholds from the lateral surface of each hindpaw were obtained using von Frey
filaments with the up-down method (Chaplan et al., 1994). Baseline thresholds were measured
on Day 1 following 2-3 h of acclimation on wire mesh. On Day 2, mice were anesthetized with
pentobarbital, a small incision in the thigh was made, and the three main branches of the sciatic
nerve were exposed. The common peroneal and tibial nerves were ligated with 8-0 silk suture and
cut distal to ligation. 1 mm of distal nerve stump was removed, and the surgical wound was closed
with 7 mm surgical clips. After 3 days of recovery, clips were removed. To measure mechanical
hypersensitivity after surgery, mice were acclimated to the mesh (2-3 h), and mechanical withdrawal
thresholds were measured from the sural nerve territory (lateral surface of hindpaw).
Sample Preparation and Western Blot Analysis
Mice were placed individually in cages and allowed to acclimate for 2-3 h to approximate behavioral
testing conditions. For formalin and CFA experiments, mice were then injected subcutaneously
into the plantar surface of the hindpaw with 10 μl of 3.5% formalin or vehicle (0.9% NaCl) in
formalin experiments or 10 μl of CFA or 0.9% NaCl in CFA experiments. Mice were then sacrificed
using a guillotine and spinal cords were rapidly removed by hydraulic extrusion. In dose-finding
experiments with SL327, mice were acclimated as above, injected with SL327 or vehicle (DMSO),
returned to their cage for 30 minutes, injected with 3.5% formalin, and sacrificed 3 minutes after
paw injection. Spinal cord levels lumbar 3-6 (L3-L6) were isolated, and ipsilateral and contralateral
sides were separated. For CFA experiments, the dorsal half was isolated and flash-frozen on dry
ice. For formalin experiments, the entire dorso-ventral extent was flash-frozen. In experiments with
uninjected mice, the lumbar enlargement was isolated and flash-frozen without further dissection. In
naïve subjects, immediately following spinal cord extraction thoracic and lumbar dorsal root ganglia
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(DRG) were dissected in ice-cold phosphate-buffered solution (PBS; Mediatech Inc. Manassas,
VA), pooled into a single sample, and immediately homogenized. Frozen spinal cord and fresh
DRG samples were homogenized using a dounce homogenizer in ice-cold buffer containing 20 mM
Tris, pH 7.5, 1 mM EDTA, 1 mM Na4P2O7, 25 µg/ml aprotinin (Sigma-Aldrich), 25 µg/ml leupeptin
(Sigma-Aldrich), 100 μM PMSF (Roche Applied Science, Indianapolis, IN), 1 µg/ml microcystin LR
(Enzo Life Science, Plymouth Meeting PA), and 1 mM Na3VO4 (Sigma-Aldrich) in Milli-Q distilled
water. Protein concentrations were determined with the BCA protein assay (Pierce Biotechnology,
Rockford, IL) and SmartSpec 3000 Spectrophotometer (Bio-Rad, Hercules, CA).
Protein homogenates were size separated by SDS-PAGE. For pERK/ERK or ERK/actin
Westerns, 10 µg protein was used. For JNK and p38 Westerns, 20 µg of DRG homogenate was
used, and 20-40 µg of spinal cord homogenate was used. For formalin and CFA experiments,
precast Tris-HCl 4% stacking and 10% separating polyacrylamide midi-gels were used (Biorad).
For experiments with naïve mice, 5% stacking and 10% separating polyacrylamide mini-gels
were prepared based on the Laemmli system (Coligan et al., 2001). Gels were transferred to
nitrocellulose membranes using a wet transfer system (Biorad). Membranes were blocked for 1 h
at room temperature (RT) with Odyssey blocking buffer (LI-COR Biotechnology, Lincoln NE) and
then simultaneously probed with two primary antibodies from different host species for 1 h at RT
diluted in blocking buffer unless otherwise noted. Primary antibodies used include anti-pERK1/2
(mouse monoclonal, 1:1000; Cell Signaling, Danvers MA), anti-ERK1/2 (rabbit polyclonal, 1:1000;
Cell Signaling), anti-actin (1:2000, mouse monoclonal; Sigma-Aldrich), anti-JNK (rabbit polyclonal,
1:1000; Cell Signaling), anti-pJNK (mouse monoclonal, 1:1000; Cell Signaling), anti-p38 (rabbit
polyclonal, 1:1000; Cell Signaling), anti-p-p38 (mouse monoclonal, 1:500, primary incubation for 4
h at RT; Cell Signaling), anti-β-tubulin (mouse monoclonal, 1:20,000; Sigma). After several washes,
membranes were then incubated for 1 h at RT with fluorescently-conjugated secondary antibodies
goat anti-rabbit IRDye800 (1:20,000; LI-COR Biotechnology) and goat anti-mouse AlexaFluor680
(1:20,000; Invitrogen, Carlsbad, CA), which were detected with the Odyssey Infrared Fluorescence
Imaging System (LI-COR Biotechnology) for simultaneous detection of 700 and 800 nm wavelength
fluorescent emissions corresponding to mouse and rabbit primary antibodies, respectively.
Densitometry of bands in 700 (pERK1/2, pJNK, p-p38, β-tubulin or actin) and 800 (ERK1/2, JNK,
p38) channels was quantified using the Odyssey Infrared Fluorescence Imaging System software
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(LI-COR Biotechnology).
Immunohistochemistry
Mice were placed individually in cages and allowed to acclimate for 2-3 h to approximate behavioral
testing conditions. Three minutes after formalin injection (10 μl, 3.5% in 0.9% NaCl) mice were
overdosed with Avertin anesthesia (1.25% working solution in 0.9% NaCl diluted from a stock of
1.0 mg/ml 2,2,2 tribromoethanol in tert-amyl alcohol, both from Sigma-Aldrich) by intraperitoneal
injection. Mice were then transcardially perfused at a rate of 15-20 ml per minute with warm (~37°C)
PBS and then 150 ml ice-cold paraformaldehyde (4% in PBS). Spinal cord was isolated, rinsed in
PBS overnight at 4°C, then cryoprotected in 30% sucrose/PBS for 2 days at 4°C. Transverse 30
μm sections were obtained using a cryostat and collected in ice-cold PBS. Floating sections were
then stained for pERK1/2 using DAB secondary detection. All incubations were performed with
gentle agitation at RT, unless otherwise noted, with several washes between steps. Endogenous
peroxidase activity was suppressed by incubating in 10% methanol, 0.3% H2O2 (in PBS) for 30
minutes. Sections were blocked with 1% normal goat serum/0.02% Triton X-100 in PBS (1%
NGST) for 1 h, and then incubated in anti-pERK1/2 (1:3000 in 1% NGST, rabbit polyclonal; Cell
Signaling) overnight at 4°C. Sections were removed from 4°C and allowed to warm to RT for 1
h, after which sections were incubated with biotinylated goat anti-rabbit IgG (1:200 in 1% NGST;
Vector Laboratories, Burlingame, CA) for 1 h and then extrAvidin peroxidase (1:1000 in 1% NGST;
Sigma-Aldrich) for 1 h. Finally, sections were incubated for 6 minutes with a 3,3’-diaminobenzidine
(DAB) solution supplemented with nickel prepared from a DAB Substrate Kit (Vector Laboratories).
Sections were placed on microscope slides and dehydrated by exposing slices to ethanol/water
solutions with progressively increasing concentrations of ethanol and finally CitriSolv (Fisher
Scientific, Pittsburgh, PA). Following dehydration, slides were coverslipped with distrene plasticizer
xylene mounting media (Electron Microscopy Sciences, Hatfield, PA). Bright field and dark field
images were captured with a 10x objective using an Olympus (Center Valley, PA) compound
microscope with a Photometrics (Tucson, AZ) CoolSnap HQ monochrome camera. Bright and
dark field images from the same field were then superimposed in Photoshop (version 7.0, Adobe,
San Jose, CA) and the lamina II-III boundary was traced on the dark field image. The boundary
was then applied to the bright field image, and the resultant image was used to count positively
staining cell profiles in lamina I-II using ImageJ (version 1.42, NIH, Bethesda, MD). During imaging
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and quantification, the experimenter was blind to genotype. Color images were obtained using a
NanoZoomer automated microscope (Hamamatsu, Hamamatsu City, Japan).
Statistical Analysis
Statistical analysis was performed using Excel (Microsoft, Redmond, WA) and Prism (GraphPad
Software, La Jolla, CA). Details of specific statistical tests are included in the results sections.
Graphs showing means and standard error of the mean (S.E.M.) were graphed using Prism.
Results
Baseline sensory function remains normal in ERK1 KO mice.
Although a large body of evidence indicates that ERK1/2 is important in nociception, little is known
about the relative contribution of each individual isoform. To assess the role of ERK1 in nociceptive
sensory function, we utilized mice with a targeted deletion of mapk3 (ERK1 KO), in which part of
exon 1 and all of exons 2-6 are replaced with a pPGKneolox cassette (Nekrasova et al., 2005).
Deletion of ERK1 was confirmed by Western blots of spinal cord and dorsal root ganglion (DRG)
tissue obtained from ERK1 KO mice (Fig. 2A,B). As expected, ERK1 immunoreactivity was
undetectable in ERK1 KO mice (Fig. 2A,B; unpaired t-test, *** p<0.001). Deletion of ERK1 had
no effect on ERK2 protein expression (unpaired t-test). These data confirm previous findings that
ERK1 protein is eliminated from the central nervous system (Selcher et al., 2001; Nekrasova et
al., 2005) and extends these findings to the peripheral nervous system by demonstrating ERK1
deletion without altered ERK2 expression.
After confirming the absence of ERK1 in important nociceptive anatomic loci, we measured
the baseline sensory function of ERK1 KO mice. The latency to paw withdrawal from a radiant heat
source was comparable between ERK1 KO and WT mice (Fig. 2C). Additionally, paw withdrawal
thresholds to mechanical stimulation with von Frey filaments in ERK1 KO mice were similar to WT
littermates (Fig. 2C). In both cases, there was no statistically significant difference between WT and
ERK1 KO mice (unpaired t-test). Both sensory tests rely on reflexive withdrawal of the hind limb to
measure threshold responses. Since alterations in motor function secondary to ERK1 deletion could
confound the results of these tests, we also screened the ERK1 KO mice for motor abnormalities.
We found no difference in the performance of ERK1 KO and WT mice on the accelerating rotarod
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Figure 2: Disruption of mapk3 eliminates ERK1
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littermates using a Hargreaves-style apparatus. No
differences were observed in hindpaw mechanical
withdrawal thresholds obtained with von Frey
filaments from WT (n=14) and ERK1 KO (n=13)
littermates. Error bars indicate S.E.M. (unpaired
t-test; *** p<0.001).
task or in exploratory behaviors in an open field task (supplemental Fig. S1 at end of chapter).
Overall, these results indicate that genetic disruption of ERK1 does not affect baseline withdrawal
responses from heat or mechanical stimuli.
ERK1 is not required for 1st or 2nd phases of the formalin test.
Previous reports indicate that spinal ERK1 is activated (phosphorylated) within minutes after
intraplantar injection of the noxious chemical formalin and that inhibition of spinal ERK1/2 using
intrathecally-applied MEK inhibitors reduces the second phase of spontaneous formalin-induced
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nociceptive behaviors (Ji et al., 1999; Karim et al., 2001). Therefore, we hypothesized that ERK1
was necessary for full expression of spontaneous nociceptive behaviors following formalin injection.
Surprisingly, ERK1 KO and WT littermates have indistinguishable formalin responses (Fig. 3). Both
WT and ERK1 KO show a stereotypical biphasic response characterized by an immediate increase
in licking and lifting (1st phase) which subsides momentarily but gradually increases and persists
over the following ~30 minutes (2nd phase). There is no statistically significant difference between
genotypes when considering the complete timecourse of the formalin response (2-way RM ANOVA:
F=0.64, DFn=1, DFd=308, P value = 0.4304). Moreover, the amount of time spent in nociceptive
behaviors in the 1st phase (0-5 min) and the 2nd phase (5-40 min) is similar between the genotypes
(Fig. 3, unpaired t-test). Overall, these data indicate that even in the absence of ERK1, formalin can
induce robust spontaneous behaviors which have previously been shown to require ERK1 and/or
ERK2, suggesting a specific role for ERK2 in this process.
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Figure 4: ERK1 is not necessary for CFA-induced hypersensitivity. A. To measure CFAinduced heat hypersensitivity, WT (n=10) and ERK1 KO (n=10) littermates were injected with CFA
subcutaneously into the plantar surface of the hindpaw. Paw withdrawal latencies to a radiant heat
stimulus were then obtained from both hindpaws, ipsilateral and contralateral to CFA injection,
using a Hargreaves-style apparatus. Data were normalized to pre-injection baseline paw withdrawal
latencies within subject and plotted as percent baseline. B. To measure CFA-induced mechanical
allodynia, WT (n=6) and ERK1 KO (n=6) littermates were injected with CFA, and paw withdrawal
thresholds to light touch were measured using von Frey filaments. In all cases, there was no
statistically significant difference between genotypes. Error bars indicate S.E.M.

ERK1 KO mice develop robust hypersensitivity in long-term inflammatory and neuropathic pain
models.
ERK1 and/or ERK2 contribute to the development and maintenance of chronic inflammatory and
neuropathic pain (Ji et al., 2009). To directly assess the contribution of ERK1 from all tissues to CFAinduced hypersensitivity, ERK1 KO mice were injected with CFA into the hindpaw and examined for
hypersensitivity to radiant heat and mechanical stimuli over time. ERK1 KO mice became robustly
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hypersensitive to radiant heat applied to the paw ipsilateral to CFA injection (Fig. 4A). The degree
of hypersensitivity in ERK1 KO mice was comparable to WT littermate controls (2-way RM ANOVA:
F=1.38, DFn=1, DFd=90, P=0.2562). In the contralateral paw, there was no statistically significant
hypersensitivity over time (2-way RM ANOVA: F=1.96, DFn=5, DFd=90, P=0.0923). Moreover,
there was no statistically significant difference between the genotypes (2-way RM ANOVA: F=2.26,
DFn=1, DFd=90, P=0.1504). CFA injection also produced dramatic hypersensitivity to mechanical
stimulation that was indistinguishable between WT and ERK1 KO littermates (Fig. 4B). There was
no statistically significant difference between genotypes in withdrawal thresholds in the ipsilateral
paw (2 way RM ANOVA: F=0.86, DFn=1, DFd=70, P=0.3761) or the contralateral paw (2 way RM
ANOVA: F=4.41, DFn=1, DFd=70, P=0.062). Overall, these data indicate that ERK1 KO mice show
normal sensitization to mechanical and heat stimuli in the CFA model of long-term inflammatory
pain.
The mechanisms driving nociceptive sensitization in neuropathic pain are often distinct from
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Figure 5: ERK1 KO and WT littermates develop similar mechanical hypersensitivity
following peripheral nerve injury. One day after baseline measurements, WT (n=9) and ERK1
KO (n=10) littermates were anesthetized and the tibial and common peroneal branches of the
sciatic nerve were ligated then transected, leaving the sural branch intact. Following the spared
nerve injury surgery, paw mechanical withdrawal thresholds were measured ipsilateral (solid lines)
and contralateral (dashed lines) to nerve injury. Baseline and post-injury withdrawal thresholds
were determined by probing the lateral plantar surface of the paw, which is innervated by the sural
nerve. Data are represented as percent baseline within each subject. Error bars indicate S.E.M.
Contributions: This experiment was performed by Chengshui Zhao.
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is different between neuropathic (Obata et al., 2004; Zhuang et al., 2005) and inflammatory (Ji et
al., 2002; Obata et al., 2003) pain models. However, the relative importance of ERK1 or ERK2
in neuropathic pain remains unknown. To address this issue, we measured the responses of
ERK1 KO mice in the spared nerve injury (SNI) model, in which two branches of the sciatic nerve
are transected (tibial and common peroneal branches) leaving the third branch, the sural nerve,
intact. In skin innervated by the sural nerve ipsilateral to SNI, ERK1 KO and WT mice developed
equivalent, robust mechanical hypersensitivity (Fig. 5). In the contralateral paw, withdrawal
thresholds remained unchanged relative to baseline. There is no statistically significant difference
between ERK1 KO and WT littermates in withdrawal thresholds ipsilateral (2-way RM ANOVA:
F=0.05, DFn=1, DFd=102, P=0.8263) or contralateral (2-way RM ANOVA: F=0.89, DFn=1,
DFd=102, P=0.3591) to the nerve injury. These results indicate that ERK1KO mice are equally
susceptible to SNI-induced mechanical hypersensitivity as WT littermates, suggesting that ERK1
is not required in this model of neuropathic pain.
ERK1 KO mice show reduced heat hypersensitivity after intraplantar injection of formalin.
Intraplantar injection of formalin produces well-characterized immediate spontaneous behaviors,
which give way to hypersensitivity to heat and mechanical stimuli hours after the injection (Fu et al.,
2001; Zeitz et al., 2004; Hu et al., 2006). Inhibition of ERK1/2 activation in the amygdala has no
effect on immediate spontaneous behaviors but, instead, dramatically reduces long-term formalininduced hypersensitivity (Carrasquillo and Gereau, 2007). Therefore, we reasoned that although
there was no apparent role of ERK1 in formalin-induced spontaneous nociceptive behaviors, ERK1
may be involved in longer term formalin-induced hypersensitivity. To test this hypothesis, we injected
ERK1 KO and WT littermates with formalin and measured responses to heat and mechanical
stimuli. Interestingly, ERK1 KO mice showed attenuated heat hypersensitivity 1 and 2 hours
after 2% formalin injection in the ipsilateral paw (Fig. 6A). A two-way repeated measures ANOVA
confirmed this difference, indicating a significant main effect of genotype (F=9.69, DFn=1, DFd=56,
P=0.0076) with a Bonferroni post-test revealing a significant difference at 1 h and 2 h time points
(p<0.05). Neither WT nor ERK1 KO mice developed heat hypersensitivity in the contralateral paw.
At the same time points after 3.5% formalin injection, ERK1 KO mice developed robust mechanical
hypersensitivity ipsilateral to injection that was similar to WT littermates (Fig. 6B). Although 1 h and
3 h time points appear elevated in ERK1 KO mice, there is no statistically significant difference
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ERK1. A. Spinal cord (SC) homogenates from naïve WT (n=7) and ERK1 KO (n=8) littermates were

mogenates were used to evaluate the expression and phosphorylation of related MAPKs, JNK and
p38. The integrated intensities of JNK2/3, JNK1, and p38 bands were divided by corresponding
loading control β-tubulin bands, normalized to the mean WT intensity, and expressed as fold WT.
To evaluate phosphorylation, pJNK2/3, pJNK1, and p-p38 bands were divided by their corresponding total protein bands from the same samples, normalized, and then expressed as fold WT. No
significant difference was detected between WT and ERK1 KO mice in either spinal cord or DRG
(WT SC n=7, ERK1 KO SC n=8, WT DRG n=5, ERK1 KO DRG n=6; unpaired t-test). WT data are
represented with white bars, and ERK1 KO data are represented with grey bars.
the basal phosphorylation state of each isoform independently (Fig. 7A). Interestingly, ERK1 KO
mice have significantly elevated basal ERK2 phosphorylation compared with WT littermates in both
spinal cord and DRG. It is important to note that in these tissues, total ERK2 expression remains
unaltered (Fig. 2). To determine whether the activity of structurally related MAP kinases may be
affected by ERK1 deletion, we analyzed spinal cord and DRG homogenates from naive WT and
ERK1 KO littermates for JNK and p38 expression and phosphorylation (Fig. 7B-D). No significant
difference was detected between ERK1 KO and WT homogenates, suggesting that altered basal
p38 or JNK activity cannot account for the minimal behavioral impact of ERK1 deletion. Overall,
these data do indicate that, in spinal cord and DRG, ERK1 elimination results in enhanced basal
phosphorylation of ERK2.
Inflammation-induced elevation of pERK2 is equivalent between ERK1 KO and WT littermates.
Given that ERK2 phosphorylation is elevated in naïve ERK1 KO mice, we hypothesized that noxious
stimulation would lead to hyperphosphorylation of ERK2. To test this hypothesis, ERK1 KO and WT
mice were injected with either formalin or saline and sacrificed at the peak of formalin-induced
ERK1/2 phosphorylation in spinal cord (3 min post-injection; Fig. 8A). After normalizing to the total
ERK loading control, ipsilateral intensities were divided by contralateral intensities within each
subject, to provide a within animal control. As previously reported (Karim et al., 2001), injection
of WT mice with formalin significantly increased pERK1 and pERK2 as compared with WT salineinjected mice (Fig. 8A; for pERK1: unpaired t-test p<0.001; for pERK2: 2-way ANOVA F=55.92,
DFn=1, DFd=20, P<0.0001). ERK1 KO mice also show significant elevation of pERK2 following
formalin injection (2-way ANOVA F=55.92, DFn=1, DFd=20, P<0.0001). Interestingly, there is no
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significant difference between WT and ERK1 KO littermates in formalin-induced pERK2 increases
(2-way ANOVA F=2.11, DFn=1, DFd=20, P=0.1617). These data suggest that ERK1 deletion does
not affect the change in spinal ERK2 phosphorylation due to formalin-induced inflammation. Similar
results were obtained when using the CFA model of inflammation (Fig. 8B). WT and ERK1 KO
littermates were injected with CFA or saline and sacrificed at the peak time point of CFA-induced
ERK1/2 phosphorylation (30 min post-injection; Ji et al., 2002). Western blot analysis of the dorsal
portion of L3-L6 spinal cords indicated a significant increase in ipsilateral pERK1 for WT and pERK2
for both WT and ERK1 KO mice injected with CFA as compared with saline-injected mice (pERK1:
unpaired t-test, p<0.001; pERK2: 2-way ANOVA, F=21.02, DFn=1, DFd=17, P=0.0003). This CFAinduced increase in pERK2 was not different between WT and ERK1 KO mice (2-way ANOVA
F=0.13, DFn=1, DFd=17, P=0.7202). Similar results were obtained by normalizing pERK/ERK
values to WT saline (supplemental Fig. S2, S3 at end of chapter). Using this alternative analysis,
ERK1 KO mice have elevated pERK2 in all conditions compared to WT littermates. However, the
relative increase in pERK2 due to formalin or CFA appears similar between WT and ERK1 KO, as
is reflected in Fig. 7. Overall, these data indicate that ERK1 deletion does not affect inflammationinduced elevation of pERK2.
Formalin-induced pERK1/2 immunostaining is slightly reduced in ERK1 KO mice.
Although increases in pERK2 following noxious stimulation appear unaffected by ERK1 deletion,
it is possible that the anatomic localization of pERK2 is altered which may reflect compensatory
changes in nociceptive circuitry arising from the loss of ERK1 during development. To address this,
ERK phosphorylation was measured by immunohistochemistry with a phospho-specific ERK1/2
antibody, since current antibodies cannot discriminate between pERK1 and pERK2 due to high
sequence homology in the phosphorylation loop. ERK1 KO mice were injected with formalin and
L3-L4 spinal cord sections were stained for pERK1/2. Interestingly, formalin-injected ERK1 KO
mice had a similar pattern of pERK1/2 immunoreactivity to WT littermates (Fig. 9A). For both
genotypes, positively-staining cell profiles and more diffuse fiber staining was evident in the
superficial lamina of the dorsal horn ipsilateral to paw injection. The dorso-ventral or medio-lateral
extent of pERK1/2 immunostaining was not appreciably different between genotypes. To quantify
pERK1/2 staining, all pERK1/2-positive cell profiles found in the superficial dorsal horn (lamina I
and lamina II), as defined by dark field illumination, were counted from serial sections separated by
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at least 90 μm (Fig. 9B). In both WT and ERK1 KO littermates, significantly more pERK1/2 positive
cell profiles appear ipsilateral to formalin injection than contralateral (2-way ANOVA, F=56.68,
DFn=1, DFd=4, P=0.0017). Interestingly, the number of pERK1/2-positive cell profiles ipsilateral
to formalin injection is significantly reduced in ERK1 KO mice compared to WT littermates (2-way
ANOVA, F=9.79, DFn=1, DFd=8, P=0.0141). This likely reflects the loss of ERK1 phosphorylation
following formalin, which is normally seen in WT mice (Fig. 8). Importantly, in ERK1 KO mice
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Fig

formalin-induced pERK1/2 immunostaining is not elevated and does not occur in unexpected
laminae of the dorsal horn. Both observations would argue against the potential confounds of ERK2
hyperphosphorylation or developmental remodeling of nociceptive circuitry.
MEK inhibition attenuates formalin-induced spontaneous behaviors similarly in WT and ERK1 KO
littermates.
Although we observed no change in p38 or JNK expression or phosphorylation with ERK1 deletion,
it remains possible that other signaling pathways compensate for the loss of ERK1 in the context
of nociceptive sensitization. To address this possibility, we sought to test whether MEK inhibition
could reduce formalin-induced spontaneous nociceptive behaviors in ERK1 KO mice, as has been
reported in WT mice (Karim et al., 2001). Previous studies have utilized intrathecal delivery of
MEK inhibitors. Since ERK1 is eliminated in all tissues of the ERK1 KO and since ERK1/2 activity
is important for nociceptive sensitization in areas besides spinal cord, a more appropriate test
would involve systemic MEK inhibition. SL327 is a structural analogue of U0126 that is bloodbrain barrier permeable and has previously been used to inhibit MEK in the brain by systemic
intraperitoneal administration (Atkins et al., 1998). However, it has not yet been used in the formalin
test and has not been evaluated in spinal cord. Thus, we began our study by determining the dose
of SL327 required to maximally inhibit formalin-induced ERK1/2 phosphorylation in spinal cord
(Fig. 10A). Pretreatment with both 30 and 50 mg/kg SL327 intraperitoneally 30 minutes before
3.5% formalin injection to the hindpaw significantly reduced pERK1 and pERK2 in spinal cord
tissue ipsilateral and contralateral to the injected paw (1-way ANOVA: pERK1 ipsi F=14.9, DFn=3,
DFd=11, P=0.0012; pERK2 ipsi F=29.85, DFn=3, DFd=11, P<0.0001; pERK1 contra F=15.23,
DFn=3, DFd=11, P=0011; pERK2 contra F=36.42, DFn=3, DFd=11, P<0.0001). Therefore, we
used 50 mg/kg SL327 to evaluate the effect of systemic MEK inhibition on the formalin test in both
WT and ERK1 KO littermates (Fig. 10B). 50 mg/kg SL327 significantly attenuated formalin-induced
spontaneous nociceptive behaviors in WT mice (2-way RM ANOVA F=8.09, DFn=1, DFd=198,
P=0.0108). Importantly, no difference was detected between WT and ERK1 KO mice injected with
SL327 (2-way RM ANOVA F=0.91, DFn=1, DFd=187, P=0.3528). Vehicle injected ERK1 KO and
WT littermates also behaved similarly (2-way RM ANOVA F=0.08, DFn=1, DFd=165, P=0.7795),
recapitulating results from Fig. 3 in animals injected with DMSO. Overall, these data indicate that
systemic MEK inhibition reduces spontaneous nociceptive behavior in the formalin test regardless
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of ERK1 deletion, suggesting that compensation from MEK-independent signaling pathways in
ERK1 KO is negligible.
Discussion
Although it is clear that ERK1 and/or ERK2 drive behavioral sensitization in many pain
models, little is known about the relative contribution of each isoform and whether they are
redundant. This study is the first to address directly the role of ERK1 in rodent models of pain by
characterizing the nociceptive function of ERK1 KO mice. We found that acute sensitivity to both
noxious heat and the noxious chemical, formalin, remains intact despite the loss of ERK1 from
all tissues. ERK1 deletion does not affect hypersensitivity due to chronic inflammation or nerve
injury. Interestingly, long-term formalin-induced hypersensitivity to heat is slightly reduced by ERK1
deletion. Altogether, these data suggest ERK1 is not required for nociceptive sensitization.
Accumulating evidence from this study and elsewhere strongly suggests that spinal ERK2,
and not ERK1, is critical for CFA-induced hypersensitivity. Targeting ERK1/2 nonspecifically, either
with intrathecally applied MEK inhibitors or with transgenic neuron-specific expression of dominant
negative MEK, attenuates CFA-induced hypersensitivity (Ji et al., 2002; Obata et al., 2003; Karim et
al., 2006). Interestingly, RNAi-mediated ERK2 knockdown in spinal cord dramatically reduces CFAinduced behavioral sensitization (Xu et al., 2008). However, due to the partial reduction of ERK2
expression achieved with this method, there was a relatively small effect on ERK2 phosphorylation.
ERK2 knockdown also caused an elevation of ERK1 phosphorylation in the spinal cord. In the
physiologically normal context of isoform co-expression, spinal ERK1 is phosphorylated following
CFA injection to the paw (Ji et al., 2002; Obata et al., 2003; Adwanikar et al., 2004; Xu et al.,
2008), raising the possibility that ERK1 plays some role in behavioral sensitization. The current
study directly addresses this question and demonstrates that ERK1 deletion has no effect on CFAinduced heat or mechanical hypersensitivity. Given the combined results of targeting MEK, ERK2
and now ERK1, it is likely that spinal ERK2 specifically drives CFA-induced hypersensitivity.
In the present study, we observed that ERK1 deletion is accompanied by increased
ERK2 phosphorylation in the spinal cord and DRG of naïve mice. This could arise if ERK isoforms
normally compete for binding and phosphorylation with their shared upstream kinase MEK.
Without ERK1 expression, MEK binds and exclusively phosphorylates the remaining isoform
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ERK2. Similar observations have been made in other systems, supporting such a model of MEKERK1/2 interaction. In NIH/3T3 cells, RNAi-mediated knockdown of one isoform elevates the
phosphorylation state of the remaining isoform (Vantaggiato et al., 2006; Lefloch et al., 2008).
However, the degree of isoform competition varies with context. In vivo, ERK1 deletion only affects
ERK2 phosphorylation in certain non-neuronal tissues, such as the thymus (Nekrasova et al.,
2005), but not in hippocampus, cortex, and striatum (Mazzucchelli et al., 2002). However, primary
cultures of cortex or striatum from ERK1 KO embryos exhibit ERK2 hyperphosphorylation following
stimulation with either glutamate or KCl without altered phosphorylation in untreated cultures. It
appears that MEK-ERK1/2 interactions depend on cellular context, relative activity of MEK-ERK
signaling, and perhaps developmental context given the differences between embryonic cultures
and adult mice (Mazzucchelli et al., 2002).
In all studies utilizing isoform-specific knockout or knockdown, the functional importance
of ERK isoform hyperphosphorylation is difficult to separate from the effect of deleting the
targeted isoform. In ERK1 KO mice, ERK2 hyperphosphorylation in striatal cultures is correlated
with augmented long-term synaptic potentiation in striatum and enhanced place preference
conditioning for morphine (Mazzucchelli et al., 2002). Similar ERK2 hyperphosphorylation occurs
in hippocampal cultures from ERK1 KO embryos (Mazzucchelli et al., 2002), but there is minimal
impact of ERK1 deletion on hippocampal plasticity and, behaviorally, no effect on hippocampusdependent tasks such as contextual fear conditioning and passive avoidance (Selcher et al.,
2001). In the present study, elevated ERK2 phosphorylation is not associated with altered baseline
withdrawal responses to noxious heat or mechanical stimulation, and there is no gain-of-function
in nociceptive sensitization.

Additionally, spinal pERK2 elevation above baseline following

intraplantar formalin or CFA is similar between WT and ERK1 KO. This suggests that elevated
basal ERK2 phosphorylation is unrelated to nociceptive sensitization. Basal phosphorylation may
occur in non-nociceptive cells of the spinal cord, or it may be an artifact of tissue preparation or
homogenization. In both cases, deletion of ERK1 would lead to ERK2 hyperphosphorylation only
in this non-nociceptive-specific pool of ERK.
An alternative interpretation is that ERK2 hyperphosphorylation actually relates to
nociception and functionally compensates for the loss of ERK1, masking a physiologic role for
ERK1. We do not favor this interpretation for several reasons. First, knockdown of spinal ERK2
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also increases basal ERK1 phosphorylation without affecting baseline sensory responses but
with a profound effect on CFA-induced hypersensitivity (Xu et al., 2008). If ERK isoforms were
interchangeable in the nociceptive spinal cord, then one would expect ERK1 to compensate for the
loss of ERK2, which did not occur. Second, pERK1/2 immunohistochemistry is actually reduced
in ERK1 KO mice, indicating that elevated pERK2 cannot make up for the loss of ERK1 in total
pERK1/2 immunoreactivity. If isoforms were completely redundant, this net loss of pERK1/2 would
be expected to affect formalin-induced spontaneous behaviors. Nevertheless, it remains difficult to
exclude a role for ERK1 without directly testing ERK2 function. The converse is also true and, as
such, the current study solidifies our understanding of spinal ERK2 function in the CFA model, as
outlined above.
To our knowledge, the present study is the first to examine the role of ERK isoforms in the
formalin model of chemical nociception. Moreover, our experiments with the systemically active
MEK inhibitor, SL327, provide additional evidence that ERK1/2 activity is required for the behavioral
response to formalin. Since SL327 exerts similar effects in WT and ERK1 KO mice, it seems likely
that ERK2 is specifically required in this behavioral model, although this must be directly tested. It
is tempting to hypothesize that the underlying cellular mechanisms of the formalin test would also
rely upon ERK2 and not ERK1. These mechanisms may include sensitization processes in spinal
cord that amplify incoming nociceptive information via enhanced synaptic strength and intrinsic
excitability (Ikeda et al., 2006; Sandkuhler, 2009) both of which involve ERK1/2 (Ji et al., 2009).
Formalin also increases primary afferent activity, which likely contributes to immediate, phase 1
behavioral responses (Puig and Sorkin, 1996). Since SL327 decreases the 1st phase of the formalin
test and since ERK1 appears to be dispensable for formalin-induced spontaneous behaviors, our
results predict that ERK2 specifically contributes to elevated afferent activity, perhaps by increasing
excitability via direct phosphorylation of voltage-gated sodium channels (Stamboulian et al., 2010).
Noxious stimulation or inflammation induces hypersensitivity to heat which is largely due
to peripheral sensitization of primary afferent nociceptors (Levine and Alessandri-Haber, 2007).
Previous studies have demonstrated a role for nociceptor ERK1/2 in inflammation-induced
peripheral sensitization using MEK inhibitors (Dai et al., 2002; Obata et al., 2003; Zhuang et al.,
2004; Seino et al., 2006). ERK1/2 may contribute to heat hypersensitivity by modulating TRPV1
(Zhuang et al., 2004; Firner et al., 2006), which is a molecular sensor of noxious heat that is required
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for CFA-induced heat hypersensitivity (Caterina et al., 2000; Levine and Alessandri-Haber, 2007).
Our observation that ERK1 is not required for CFA-induced heat hypersensitivity suggests that
ERK2 may specifically modulate TRPV1, a possibility which must be directly tested. Interestingly,
our results also indicate that formalin-induced heat hypersensitivity is in part mediated by ERK1.
The discrepancy between CFA- and formalin-induced heat hypersensitivity reported here may be
the result of discrete parallel signaling pathways within nociceptive terminals that are sensitive
to either CFA or formalin. Given that ERK1 KO mice develop heat hypersensitivity at later time
points after formalin injection, it is also possible that ERK1 contributes to heat hypersensitivity but
ultimately ERK2 is sufficient to induce sensitization.
Besides spinal cord and DRG, ERK1/2 is activated in many regions of the nociceptive
system following noxious stimulation including the amygdala (Carrasquillo and Gereau, 2007). In
amygdala, microinjection of MEK inhibitors does not affect acute formalin-induced spontaneous
behaviors but does attenuate mechanical hypersensitivity. In the current study, we found that
ERK1 deletion does not affect formalin-induced mechanical hypersensitivity. This fits well with our
previous observations that formalin did not significantly induce ERK1 phosphorylation in amygdala
(Carrasquillo and Gereau, 2007). However, since amygdala MEK inhibition affected both ERK1
and ERK2 phosphorylation, it was difficult exclude a role for ERK1. The current study extends our
knowledge of the amygdala’s role in nociception by providing evidence that ERK1 is not required
for formalin-induced mechanical hypersensitivity.
Results from the present study indicate that ERK1 is not required for formalin-induced
spontaneous behavior, chronic inflammatory and neuropathic pain models, suggesting a
predominant isoform-specific role for ERK2. Isoform-specific functions may also occur in humans,
since copy number variation of each isoform yields distinct neurological deficits. ERK1 deletion
or duplication is associated with autism (Kumar et al., 2008), while reduced ERK2 expression is
associated with microcephaly, cognitive deficits, and developmental delay (Newbern et al., 2008).
The relevance to the human nervous system suggests that dissecting the roles of ERK1 and ERK2
will be important for understanding and treating chronic pain conditions.
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Abstract
After injury or inflammation, kinases within nociceptive sensory neurons coordinate multiple
extracellular signals to sensitize the cell to subsequent noxious stimulation, a process known
as peripheral sensitization. Extracellular signal-regulated kinases 1 and 2 (ERK1/2) have been
implicated in peripheral sensitization with the use of inhibitors and genetic manipulations which
cannot specifically target the two isoforms. Previous studies, using mice that lack ERK1 in all
tissues (ERK1-/-), have suggested that ERK1 is not important in rodent models of pain. However,
due to embryonic lethality in ERK2-/- mice the role of ERK2 in nociceptive sensory neurons remains
unknown, since germline ERK2 deletion is embryonic lethal. To test the importance of ERK2 in
nociceptors, we have conditionally deleted ERK2 in cells expressing NaV1.8, a highly specific
marker for small-diameter unmyelinated nociceptors. Interestingly, conditional ERK2 knockouts
(ERK2f/f;NaV1.8-Cre) spent more time at cooler temperatures on the thermal gradient thermotaxis
assay without any deficits in heat or mechanical sensation. Loss of ERK2 in nociceptors significantly
attenuated the 2nd phase of the formalin test as well as mechanical hypersensitivity in the complete
Freund’s adjuvant (CFA) model of inflammatory pain. Previous work has shown no effect of ERK1
deletion in these models, suggesting that ERK2 is specifically required. Nerve growth factor (NGF),
which is an inflammatory mediator involved in peripheral sensitization, produced dramatically less
heat hypersensitivity in ERK2f/f;NaV1.8-Cre mice. Interestingly, ERK1 deletion exacerbates NGFinduced heat hypersensitivity. Since ERK1/2 signaling has been implicated in axon outgrowth and
epidermal innervation and since we observed alterations in responses to NGF, it was important to
evaluate the effects of ERK1/2 mutations on sensory neurons and their axons. Conditional deletion
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of ERK2 partially reduced peptidergic innervation of the epidermis, while innervation was unaffected
in ERK1-/- mice. There was no effect of ERK2 conditional deletion on the proportion of peptidergic
cell bodies or the expression of the NGF receptor, TrkA. Partial loss of peptidergic innervation
may contribute to diminished behavioral sensitization in ERK2f/f;NaV1.8-Cre mice. Overall, these
data indicate that nociceptor ERK2 expression is necessary for epidermal innervation and rodent
models of inflammatory pain.
Introduction
Nociceptors transduce noxious stimuli and transmit nociceptive information from peripheral tissues
to the central nervous system (Hucho and Levine, 2007). In the context of injury or inflammation,
nociceptors can become sensitized so that they respond to innocuous stimuli and respond more
robustly to noxious stimuli. This process of peripheral sensitization involves intracellular signaling
cascades within nociceptors which integrate input from multiple extracellular inflammatory mediators
and orchestrate a variety of effector responses that include facilitation of transduction currents and
enhancement of neuronal excitability. Kinases are components within these signaling cascades,
and the mitogen activated protein (MAP) kinases, extracellular signal-regulated kinases (ERK) 1
and ERK2, are critical among them. ERK1/2 activation (phosphorylation, pERK1/2) occurs in the
soma of small-diameter sensory neurons following heat, cold, and noxious mechanical stimulation
(Dai et al., 2002; Mizushima et al., 2006). Injection of inflammatory mediators, capsaicin, formalin,
or complete Freund’s adjuvant (CFA) into peripheral tissues also increases pERK1/2 in both the
soma and in peripheral terminals of afferents (Averill et al., 2001; Dai et al., 2002; Obata et al.,
2003; Zhuang et al., 2004; Seino et al., 2006; Tsuda et al., 2007). Importantly, the use of inhibitors
which block activation of ERK1 and ERK2 by inhibiting their shared upstream MAP kinase kinases
(MEK1/2) reduces behavioral sensitization with concomitant reduction in primary afferent pERK1/2
(Dai et al., 2002; Obata et al., 2003; Zhuang et al., 2004; Seino et al., 2006). Although instructive,
these studies cannot address the relative contribution of ERK1 and ERK2, since inhibitors do not
selectively affect each isoform.
Although inhibitor studies do not address potential isoform differences, genetic strategies are
yielding provocative new results suggesting that the functions of ERK1 and ERK2 may be quite
different. Despite relatively high sequence homology (Boulton et al., 1991) and similar identified
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downstream targets (English et al., 1999), deletion of ERK1 has no impact on viability (Pages et
al., 1999; Nekrasova et al., 2005), while ERK2 deletion is embryonic lethal by E8.5 with deficits
in mesodermal differentiation and trophoblast formation (Krens et al., 2006). Reduced expression
of ERK2 due to a hypomorphic allele and conditional deletion of ERK2 in telencephalon results
in learning and memory deficits that are not phenocopied in ERK1-/- mice (Selcher et al., 2001;
Mazzucchelli et al., 2002; Satoh et al., 2007; Samuels et al., 2008). Interestingly, deletion of ERK1
actually enhances performance in conditioned place preference to morphine, which is associated
with enhanced striatal plasticity (Mazzucchelli et al., 2002). The hypothesis that ERK1 and ERK2
are functionally distinct is supported by observations that ERK1 exclusively interacts with the
scaffolding protein MP1 (Schaeffer et al., 1998) and that ERK1 and ERK2 shuttle between the
nucleus and cytoplasm at different rates (Marchi et al., 2008).
Little is known about the specific roles of ERK1 and ERK2 in pain plasticity. A recent study has
demonstrated that partial viral-mediated shRNA knockdown of ERK2 in spinal cord dramatically
reduced CFA-induced heat and mechanical hypersensitivity (Xu et al., 2008). Deletion of ERK1
has no effect in this model, suggesting that ERK2 is the predominant isoform in modulating
spinal plasticity in this model (Alter et al., 2010). However, the relative importance of ERK1 and
ERK2 in nociceptors and peripheral sensitization remains unknown. To assess the role of ERK2
in nociceptors, we utilized the Cre-loxP system to delete ERK2 in small-diameter, unmyelinated
sensory neurons expressing NaV1.8 (Agarwal et al., 2004). Conditional deletion of ERK2 attenuated
behavioral sensitization in several inflammatory pain models and partially reduced innervation
of the epidermis. In parallel experiments, ERK1 deletion had minimal effects, except following
the injection of nerve growth factor (NGF) in which case deleting ERK1 versus ERK2 produced
opposing effects. Overall, our observations support an isoform-specific role for ERK2 in peripheral
sensitization and epidermal innervation.
Methods
Animals
All experiments were approved by the Animal Care and Use Committee of Washington University
School of Medicine and were performed in accordance with guidelines of the National Institutes of
Health. Mice were housed with ad libitum access to food and water on a 12 h/12 h light/dark cycle.
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7- to 10-week old male littermates were used in all experiments. The experimenter was blind to the
genotype in all experiments.
Generation of ERK1 and ERK2 Mutant Mice
Conditional deletion of ERK2 in small-diameter, unmyelinated sensory neurons was achieved with
a Cre/loxP approach. A targeting construct including exon 2 of mapk1 flanked by loxP sites (flox)
and the neomycin (neo) selection gene was transfected into 129 embryonic stem (ES) cells as
described previously (Fig. 1A; Samuels et al., 2008). After selection for homologous recombination,
ES cells were transfected with a Cre-expressing plasmid and screened for excision of neo. ES
cells lacking Cre but containing the exon 2 flanking loxP sites (flox, f) were injected into C57BL/6
blastocysts. Germline chimeras were backcrossed two times onto the C57/BL6 background to
generate homozygous floxed ERK2 mice (ERK2f/f) mice. The generation of NaV1.8-Cre mice was
described previously (Agarwal et al., 2004). Briefly, the NaV1.8 (Scn10a) locus was isolated from
a bacterial artificial chromosome (BAC) genomic DNA library from 129 mice. A targeting construct
was assembled containing the coding sequence for Cre recombinase, a polyadenylation tail, and
an ampicillin (amp) resistance gene flanked by frt sites. Recombinogenic engineering was utilized,
and clones positive for homologous recombination were transiently transfected with flp recombinase
to remove amp. A combined restriction digest and southern blotting technique determined that Cre
had been inserted 90 kb from the 5’ end of the BAC. The engineered Cre-containing BAC was
released from its vector with a NotI digest, purified, and then injected into oocyte pronuclei of the
hybrid B6D2 mouse strain. Founder progeny were backcrossed eight times onto the C57/BL6
background. To generate ERK2f/f;NaV1.8-Cre mice used in experiments, three successive crosses
were performed: 1. ERK2f/f X NaV1.8-Cre, 2. ERK2f/+;NaV1.8-Cre X ERK2f/f, 3. ERK2f/f;NaV1.8-Cre
X ERK2f/f. ERK2f/f mice used in these crosses were backcrossed two times onto the C57/BL6 as
outlined above. All subsequent breeding pairs were progeny of established ERK2f/f;NaV1.8-Cre
X ERK2f/f breeding pairs (cross 3). Therefore, mice used in all experiments are mixed C57/BL6
(~90%), 129, and DBA2. As such, great care was taken to include littermate controls in each
experiment.
The generation of ERK1-/- mice was described in detail elsewhere (Nekrasova et al., 2005).
Briefly, exons 1-6 of mapk3, which includes the kinase active site and phosphorylation loop, were
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targeted for replacement by homologous recombination with a Neo cassette flanked with loxP sites.
Successfully targeted 129 Sv ES cells were injected into CD1 blastocysts. Chimeras with germline
transmission were obtained on the CD1 background. The mapk3 mutation was subsequently
transferred to the C57BL/6 background by backcrossing >10 times. Pure C57BL/6 heterozygotes
(ERK1+/-) were crossed to produce ERK1-/- and ERK1+/+ (WT) littermates used in all experiments.
Sample Preparation and Western Blot Analysis
Mice were sacrificed by decapitation and spinal cords were rapidly removed by hydraulic extrusion.
Spinal cord levels L3-L6 were isolated and flash frozen on crushed dry ice. Brain regions
(cerebellum, hippocampus, cortex) were dissected and flash frozen. Thoracic and lumbar DRGs
were then dissected, pooled, and immediately homogenized using a dounce homogenizer. The
homogenization buffer used for all tissues was kept on ice and consisted of 20 mM Tris, pH 7.5, 1
mM EDTA, 1 mM Na4P2O7, 25 µg/ml aprotinin (Sigma-Aldrich), 25 µg/ml leupeptin (Sigma-Aldrich),
100 μM PMSF (Roche Applied Science, Indianapolis, IN), 1 µg/ml microcystin LR (Enzo Life
Science, Plymouth Meeting PA), and 1 mM Na3VO4 (Sigma-Aldrich) in Milli-Q distilled water. Protein
concentrations were determined with the BCA protein assay (Pierce Biotechnology, Rockford, IL)
and SmartSpec 3000 Spectrophotometer (Bio-Rad, Hercules, CA). Protein homogenates (10 µg
per sample) were size separated by SDS-PAGE with 10% separating gels prepared based on
the Laemmli system (Coligan et al., 2001). Gels were transferred to nitrocellulose membranes
using a wet transfer system (Biorad) and membranes were blocked for 1 h at room temperature
(RT) with Odyssey blocking buffer (LI-COR Biotechnology, Lincoln NE). Two primary antibodies
from different host species were applied to the blots (1 h at RT diluted in blocking buffer) followed
by washes and then incubation for 1 h at RT with fluorescently conjugated secondary antibodies
goat anti-rabbit IRDye800 (1:20,000; LI-COR Biotechnology) and goat anti-mouse AlexaFluor680
(1:20,000; Invitrogen, Carlsbad, CA) diluted in blocking buffer. Membranes were then visualized
with the Odyssey Infrared Fluorescence Imaging System (LI-COR Biotechnology) for simultaneous
detection of 700 and 800 nm wavelength fluorescent emissions corresponding to mouse and
rabbit primary antibodies, respectively. Primary antibodies used include anti-actin (1:2,000, mouse
monoclonal; Sigma-Aldrich), anti-β-tubulin (mouse monoclonal, 1:1,000; Sigma-Aldrich), antipERK1/2 (mouse monoclonal, 1:1,000; Cell Signaling, Danvers MA), and anti-ERK1/2 (rabbit
polyclonal, 1:1,000; Cell Signaling). The intensity of bands in 700 nm (pERK1/2, β-tubulin, or actin)
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and 800 nm (ERK1/2) channels was quantified using the Odyssey Infrared Fluorescence Imaging
System software (LI-COR Biotechnology).
Behavioral Tests
All behavioral tests were performed during the second half of the light cycle at room temperature
(~25°C). Tests were conducted in rooms isolated from other activity and with white noise present.
Mice were allowed to acclimate to the behavior room and apparatus for 2-3 hours before testing
began unless otherwise noted. In tests measuring reflexive responses to heat or mechanical
stimuli, mice were only tested when calm in order to minimize variability.
Thermal Gradient
The thermal gradient apparatus is a continuous, rectangular metal surface with plexiglass walls and
cover. Mice were initially acclimated to the behavior room in their home cages and then individually
placed into the apparatus for a 2 hour testing session. On the first day of testing, the thermal
gradient was turned off so that mice could explore the area with a room temperature floor. On the
second day of testing, the thermal gradient was applied. On both days, webcam recordings were
made, and location of mice in the apparatus was tracked using Anymaze. The amount of time spent
in zones that are distributed evenly along the length of the rectangle was measured and plotted in
30 minute bins. Zone temperatures were measured with an infrared thermometer.
Open Field
Mice were acclimated to the behavior room in their home cages and then individually placed into a
box with a grid of infrared beams covering the horizontal space. Locomotor behavior was tracked
for one hour.
Rotarod
Mice were initially acclimated to the room. Untrained mice underwent 5 consecutive trials separated
by 15 minutes, and latency to roll or drop from the rotating rod was recorded.
Formalin-Induced Spontaneous Nociceptive Behaviors
To measure spontaneous behavioral responses to formalin injection, mice were acclimated in
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modular clear plexiglass behavior chambers (width=10 cm, length=10 cm, height=15 cm) with a
plexiglass floor for at least 1 h, injected subcutaneously with 10 μl 5% formalin (Sigma-Aldrich, St.
Louis, MO) in sterile 0.9% NaCl into the plantar surface of the hindpaw, and then returned to the
behavior chamber. Behaviors were then video recorded from below with a webcam (Logitech) at a
resolution of 960 x 720 for one hour without the experimenter present. Videos were scored for time
spent licking, lifting, and flinching the injected paw.
Measurement of Heat Thresholds
Responses to heat were measured using a modified Hargreaves test (Hargreaves et al., 1988).
Mice were placed in modular behavior chambers on a 390G Plantar Test Apparatus (IITC Life
Science, Woodland Hills, CA) with a glass plate floor heated to ~30°C, except in experiments
with CFA which were performed with a room temperature glass surface. From underneath the
glass surface, a focused beam of light was used to heat the plantar surface of the hindpaw.
At the initiation of the light beam, a timer automatically started and continued until the mouse
withdrew its paw from the stimulus or until a 20 second cutoff time was reached. At withdrawal,
the experimenter simultaneously stopped the light stimulus and the timer, recording the amount
of time to paw withdrawal (latency). Light intensity was calibrated to achieve baseline paw
withdrawal latencies between 10 and 15 seconds. After calibration with control animals (either
WT or ERK2f/f), the light intensity was kept constant within each experiment. In each experiment,
mice were initially acclimated, and then baseline paw withdrawal latencies were determined by
averaging five independent trial measurements separated by 15 min alternating between right
and left paws. The day following baseline measurements, mice were allowed to acclimate, the
right hindpaw was injected, and paw withdrawal latency measurements were collected every 15
minutes, alternating right and left hindpaws. Hour timepoint values were obtained by averaging
two of these measurements. If measured, additional timepoints over the subsequent days were
obtained by initially acclimating mice and then averaging 3 separate measurements. In all models,
post-injection measurements were divided by baseline measurements within each subject to yield
percent baseline data.
NGF-Induced Heat Hypersensitivity: After acclimation to the apparatus, baseline measurements
were obtained, and then mice were injected subcutaneously into the plantar hindpaw with 0.2
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μg NGF (2.5S purified from male mouse salivary glands; Harlan, Indianapolis, IN) in 10 μl sterile
phosphate-buffered solution (PBS; Mediatech Inc. Manassas, VA).
Formalin-Induced Heat Hypersensitivity: After obtaining baselines, mice were injected
subcutaneously into the plantar surface of the hindpaw with 5% formalin in 10 μl sterile saline
(0.9% NaCl).
Mustard oil-Induced Heat Hypersensitivity: Following baseline measurements, mustard oil (0.75%
in 10 μl light mineral oil; Sigma-Aldrich) was administered to the hindpaw by intraplantar injection.
CFA-Induced Heat Hypersensitivity: All measurements were conducted on a RT glass plate. Light
intensities were adjusted to produce 10-15 second paw withdrawal thresholds in control mice at
baseline. Using the RT glass, we found no difference between the baseline sensitivity of ERK2f/
;NaV1.8-Cre and ERK2f/f littermates (data not shown), which was consistent with experiments using
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the warmed glass plate (Fig. 2). After collecting baseline data, mice were injected subcutaneously
into the plantar surface of the hindpaw with 10 µl CFA (1.0 mg/ml, Sigma-Aldrich).
Measurment of mechanical thresholds and CFA-Induced Mechanical Hypersensitivity
To measure responses to mechanical stimuli applied to the plantar surface of the hindpaw, a set of
calibrated von Frey filaments (North Coast Medical Inc. Morgan Hill, CA) was used. To allow access
to the hindpaw, mice were placed in modular behavioral chambers on an elevated wire mesh and
allowed to acclimate. Filaments were pressed into the skin between the anterior and posterior
footpads until the filament bent, held for ~1 sec, and removed. Application of the same filament
was repeated 5 times at a frequency of ~0.5 Hz. If the mouse withdrew its paw in 3 out of the 5
applications, the calibrated weight of that filament was recorded as the paw withdrawal threshold.
For each measurement of paw withdrawal threshold, the lightest filament (0.008 g) was the first
filament applied. If the mouse did not withdrawal 3 times or more, the next heaviest filament was
applied 5 times, moving stepwise to heavier filaments until 3 out of 5 responses were obtained. To
obtain the baseline threshold, three to five independent paw withdrawal threshold measurements
were made and then averaged. On the following day, mice were allowed to acclimate, and CFA
(10 µl of 1.0 mg/ml solution) was then administered by intraplantar injection into the hindpaw. Data
points hours after injection consisted of single paw withdrawal threshold measurements, while data
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points on subsequent days represented the averaged values of three independent paw withdrawal
measurements.
Immunohistochemistry
Mice were euthanized with an overdose of Avertin anesthesia (1.25% working solution in 0.9%
NaCl diluted from a stock of 1.0 mg/ml 2,2,2 tribromoethanol in tert-amyl alcohol, both from SigmaAldrich) by intraperitoneal injection. Footpad skin from the plantar surface of the hindpaw was
collected into Zamboni’s fixative (15% picric acid and 2% paraformaldehyde in PBS) and allowed
to fix for 1-1.5 h on ice. Tissue was then washed with PBS and cryoprotected in 30% sucrose/PBS
at 4 °C for at least 48 h. Meanwhile, mice were transcardially perfused first with a warmed 0.5%
procaine/PBS solution to clear circulating blood and then with ice-cold 4% paraformaldehyde in
PBS. DRG were dissected, washed in PBS, and then cryoprotected in 30% sucrose/PBS at 4°C
for at least 48 h. 18 μm thick sections of DRG were collected. 30 μm thick sections of footpad
skin were cut perpendicular to the surface of the skin. Staining for all markers and tissues was
performed similarly using Coplin jars for blocking and washing steps. First, sections were rinsed
with Tris-buffered saline (0.9% NaCl in 100 mM Tris, pH 7.5) and then blocked with 0.2% Difco milk
(BD Biosciences), 1% bovine serum albumin (Sigma-Aldrich), 0.1% Triton-X-100 in TBS. Slides
were rinsed with TBS, covered with primary antibodies diluted in tyramide signal amplification kit
blocking reagent (Perkin-Elmer), protected with parafilm over the solution, and then placed in a
humidified chamber to incubate at 4°C overnight. Slides were then washed with 0.1% TritonX100/
TBS, rinsed with TBS, and incubated with secondary antibodies at RT for 1 h. Sections were
finally counterstained with bis-benzimide (Invitrogen), coverslipped, and imaged using either
a NanoZoomer automated microscope (Hamamatsu, Hamamatsu City, Japan) or a fluorescent
compound microscope (Nikon 80i) with a monochrome camera (CoolSnapEZ). Primary antibodies
used include anti-CGRP (goat polyclonal, 1:1,000; AbD Serotec, Raleigh NC), anti-TrkA (rabbit
polyclonal, 1:300; Millipore, Billerica, MA), anti-βIII tubulin (rabbit polyclonal, 1:2,000, skin; Covance,
Princeton, NJ), anti-βIII tubulin (mouse monoclonal, 1:1000, DRG; Millipore). Fluorescently
conjugated secondary antibodies (all from Invitrogen) used were donkey anti-mouse Alexa488
(1:200, for βIII tubulin in DRG), donkey anti-rabbit Alexa555 (1:200, for TrkA), donkey anti-goat
Alexa555 (1:200, for CGRP in DRG), donkey anti-goat Alexa488 (1:350, for CGRP in skin), and
donkey anti-rabbit Alexa555 (1:200, for βIII tubulin in skin). For quantification, the experimenter was
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blind to genotype. In DRG, sections were counted for total number of neurons (βIII tubulin-positive)
and total number of neurons expressing the marker of interest. For each section, the percentage
of total neurons expressing the marker (marker/βIII tubulin) was calculated. 2-5 sections were
counted for each animal. In footpad skin, sections of thick skin with rete ridges were selected while
viewing bis-benzimide counterstaining. The epidermal-dermal border was identified, traced on a
live image in Metamorph (Molecular Devices), and its length measured. Fibers were then counted
using the appropriate filter cube in live images, allowing the experimenter to follow fibers through
multiple focal planes. The number of fibers was then divided by the length of the epidermal-dermal
border and multiplied by 100 to yield fiber number per 100 μm length of epidermal-dermal border.
3-5 sections were analyzed per animal.
Statistical Analysis
Data analysis and graphing was performed using Excel (Microsoft, Redmond, WA) and Prism
(GraphPad Software, La Jolla, CA). Details of specific statistical tests are included in the results
sections.
Results
Conditional ERK2 deletion is tissue-specific.
To test the hypothesis that nociceptor ERK2 is required for peripheral sensitization, we generated
conditional ERK2 knockouts with the Cre-loxP system (Fig. 1A). In one line, exon 2 of mapk1 was
flanked by loxP sites, as previously described (see Methods and Samuels et al., 2008). This was
crossed with a Cre recombinase (Cre) expressing BAC transgenic line with the promoter elements
from NaV1.8 controlling Cre expression (see Methods and Agarwal et al., 2004). Since NaV1.8
is expressed primarily in small-diameter, unmyelinated sensory neurons that respond to noxious
stimuli (nociceptors), we expected progeny with the Cre transgene (ERK2f/f;NaV1.8-Cre) to lack
ERK2 only in nociceptors. Compared to control littermates that lacked the Cre transgene (ERK2f/f),
ERK2f/f;NaV1.8-Cre mice had a significant reduction in ERK2 protein in dorsal root ganglion (DRG,
Fig. 1B, t-test). Since NaV1.8-expressing nociceptors comprise a subset of sensory neurons found
within the DRG, ERK2 expression in DRG homogenates is not completely abolished. The remaining
signal in the ERK2 band is likely due to large- and medium-diameter sensory neurons which do
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Figure 1: ERK2 expression is specifically reduced in dorsal root ganglia of Erk2f/f;NaV1.8Cre mice. A. Schematic for the generation of conditional ERK2 deletion in nociceptors. Erk2f/f mice
with loxP sites flanking exon 2 were crossed with transgenic NaV1.8-Cre mice. In mice homozygous
for the flox allele that also have the transgene (Erk2f/f;NaV1.8-Cre), this results in a null allele
specifically in nociceptors with the flox allele present in all other cells. On the protein level, deletion
of exon 2 eliminates L4 and αC kinase domains that include a lysine required for catalytic activity
(amino acids 52-103 using ERK1 numbering from Introduction Fig. 2). Thus, the coding sequence
would either be inactive or not produce protein as has been observed by Western blot in other
studies (Samuels et al. 2008). B. Tissue from Erk2f/f;NaV1.8-Cre (CKO) and Erk2f/f (flox) littermates
(n=7 each group) was obtained and analyzed for total ERK1/2 expression by Western blot analysis.
The loading control was β-tubulin for DRG samples. The normalized integrated intensity of ERK2
was significantly reduced in Erk2f/f;NaV1.8-Cre mice (*** p<0.001) compared with littermate Erk2f/f
controls. No change was observed in the ERK1 band. C. Homogenates of tissue from other areas
of the nervous system (SC = spinal cord; CB = cerebellum; Cx = cortex; Hip = hippocampus)
were analyzed for ERK1/2 expression. There was no difference in ERK1 or ERK2 band intensities
between Erk2f/f and Erk2f/f;NaV1.8-Cre littermates, confirming tissue-specific deletion of ERK2 in
sensory neurons.
not express NaV1.8 as well as non-neuronal cells present in the DRG. This is consistent with and
supported by previous studies utilizing this transgenic NaV1.8-Cre line to delete several different
targeted genes exclusively in small-diameter, unmyelinated sensory neurons (Agarwal et al., 2004;
Agarwal et al., 2007; Gangadharan et al., 2009; Stosser et al., 2010). Importantly, there is no effect
of ERK2 conditional deletion on the expression of ERK1 (Fig. 1B). To confirm that ERK2 was not
deleted in other areas of the nervous system, brain and spinal cord were analyzed by Western blot
for ERK2 expression (Fig. 1C). No significant difference was observed between ERK2f/f;NaV1.8Cre and ERK2f/f littermate controls in any of the regions tested, including spinal cord, cerebellum,
cortex, and hippocampus (t-test). As an important control experiment, we also compared ERK2f/f
with WT littermates and found that the presence of loxP sites in mapk1 had no effect on protein
expression in the DRG (data not shown). Overall these data indicate that ERK2f/f;NaV1.8-Cre mice
lack ERK2 expression in small-diameter, unmyelinated nociceptors.
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Figure 2: Conditional deletion of ERK2 impairs thermotaxis without affecting withdrawal
from radiant heat or von Frey filaments. A.&B. Erk2f/f;NaV1.8-Cre (n=7) and Erk2f/f (n=8)
littermates were allowed to explore a thermal gradiant apparatus, consisting of a continuous metal
surface with temperatures ranging from 47.2°C to 11.5°C. Locomotor activity was tracked for two
hours. To analyze thermotaxis, 20 zones were created to subdivide the thermal gradient, and the
presence time of each subject within each zone was determined. The temperature of each zone
was measured using an infrared thermometer. Red and blue colored bars graphically represent the
temperature gradient. At the beginning of the thermotaxis assay (0-30 minutes), presence time for
both genotypes is distributed over many temperatures. Over time, Erk2f/f mice spend an increasing
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amount of time in the 34.0°C zone while Erk2f/f;NaV1.8-Cre mice prefer the cooler 31.7°C zone.
In B., presence time from the entire 2-hour experiment is summed and plotted as in A. C.-D. The
same mice were allowed to explore the same appartus set to room temperature one day before
the thermotaxis assay. Under these conditions, minimal differences were detected between Erk2f/
f

;NaV1.8-Cre and Erk2f/f littermates, suggesting that differences in presence time in the thermotaxis

assay (A.-B.) are related to temperature sensation and not simply exploratory behavior. For A.-D.,
* p<0.05, ** p<0.01, *** p<0.001 (2-way ANOVA repeated measures, Bonferroni post-test). E. In
the open field task, there was no difference between Erk2f/f;NaV1.8-Cre and Erk2f/f (n=7) littermates
(2-way ANOVA repeated measures), confirming that exploratory behavior is not altered in Erk2f/
f

;NaV1.8-Cre animals. F. Erk2f/f;NaV1.8-Cre (CKO; n=14) and Erk2f/f (flox; n=14) mice have similar

baseline responses to radiant heat in a Hargreaves assay. Mechanical withdrawal thresholds
measured with von Frey filaments were also similar between Erk2f/f;NaV1.8-Cre (CKO; n=9) and
Erk2f/f (flox; n=9) littermates. G. Erk2f/f;NaV1.8-Cre and Erk2f/f littermates (n=7) perform similarly on
the accelerating rotarod, indicating that gross motor function is unimpaired due to deletion of ERK2.
amount of time in the 34.0°C zone while Erk2f/f;NaV1.8-Cre mice prefer the cooler 31.7°C zone.
In B., presence time from the entire 2-hour experiment is summed and plotted as in A. C.-D. The
same mice were allowed to explore the same appartus set to room temperature one day before
the thermotaxis assay. Under these conditions, minimal differences were detected between Erk2f/
f

;NaV1.8-Cre and Erk2f/f littermates, suggesting that differences in presence time in the thermotaxis

assay (A.-B.) are related to temperature sensation and not simply exploratory behavior. For A.-D.,
* p<0.05, ** p<0.01, *** p<0.001 (2-way ANOVA repeated measures, Bonferroni post-test). E. In
the open field task, there was no difference between Erk2f/f;NaV1.8-Cre and Erk2f/f (n=7) littermates
(2-way ANOVA repeated measures), confirming that exploratory behavior is not altered in Erk2f/
f

;NaV1.8-Cre animals. F. Erk2f/f;NaV1.8-Cre (CKO; n=14) and Erk2f/f (flox; n=14) mice have similar

baseline responses to radiant heat in a Hargreaves assay. Mechanical withdrawal thresholds
measured with von Frey filaments were also similar between Erk2f/f;NaV1.8-Cre (CKO; n=9) and
Erk2f/f (flox; n=9) littermates. G. Erk2f/f;NaV1.8-Cre and Erk2f/f littermates (n=7) perform similarly on
the accelerating rotarod, indicating that gross motor function is unimpaired due to deletion of ERK2.
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Conditional deletion of ERK2 affects thermotaxis without altering withdrawal responses to heat or
mechanical stimuli.
To begin to evaluate the role of ERK2 in nociceptors, we sought to test baseline sensory function
in ERK2f/f;NaV1.8-Cre mice. As an initial test of responses to thermal stimuli, we utilized the thermal
gradient apparatus, which consists of an enclosed, rectangular area with a metal floor that is cooled
on one end of the rectangle (11.6°C), heated (47.2°C) on the other end, and with a continuous range
of temperatures between the two ends (Fig. 2A-B). ERK2f/f and ERK2f/f;NaV1.8-Cre littermates were
allowed to explore the area with the temperature gradient for two hours. ERK2f/f mice initially (0-30
min) explore the length of the rectangle, resulting in an evenly distributed presence time across the
zones. Over the next 90 minutes, ERK2f/f mice spend more time in zones ranging in temperatures
from 31°C to 36°C than in other zones. Interestingly, the presence time of ERK2f/f;NaV1.8-Cre
littermates is shifted towards cooler temperatures. The presence time of ERK2f/f;NaV1.8-Cre mice
is more distributed, with less time spent in any one zone, than ERK2f/f littermate controls. Within
each 30 minute bin, a 2-way ANOVA indicates a significant main effect of zone and a significant
interaction between zone and genotype (P<0.01) with the exception of the 0-30 min bin during which
there is no significant interaction. Bonferroni post-tests indicate significant differences in presence
time in the 34.0°C and 31.7°C zones. If presence time for the entire 2-hour test is summed (Fig.
2B), ERK2f/f;NaV1.8-Cre spend more time in the 31.7°C zone and less time in the 34.0°C zone
than ERK2f/f littermates (2-way ANOVA; significant interaction between zone and genotype, F=4.42
DFn=19 DFd=260 P<0.0001; significant main effect of zone, F=42.60 DFn=19 DFn=260 P<0.0001;
Bonferroni post-test). Importantly, we observed only minimal differences between genotypes in
presence time when there was no temperature gradient (Fig. 2C-D). These data were obtained
using the same mice in Fig. 2A-B, which were allowed to explore the same apparatus without
heating or cooling on the day before the thermotaxis assay. In both groups, significantly more
presence time was observed at the ends of the apparatus, reflecting the tendency of mice to avoid
open areas. Comparing ERK2f/f and ERK2f/f;NaV1.8-Cre mice, a statistically significant difference
was detected in the amount of time spent at the end of the apparatus (zone 20) in the 60-90 min
block (Fig. 1C) and in the summed data (Fig. 2D; 2-way ANOVA, Bonferroni post-test). This slight
difference in exploratory behavior is not likely to explain the results in Fig. 2A-B. It is conceivable
that a more distributed presence time over the temperature gradient, as seen with ERK2f/f;NaV1.8-
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Cre mice (Fig. 2A-B), may be due to hyperactivity during exploration. However, as observed in Fig.
1C-D, ERK2f/f;NaV1.8-Cre mice actually spend more time than ERK2f/f littermates in zone 20 less
time in other zones, suggesting that ERK2f/f;NaV1.8-Cre mice are not hyperactive. To directly test
this possibility, we assessed the open field behavior of ERK2f/f;NaV1.8-Cre and ERK2f/f littermates
(Fig. 2E). Mice were placed into the center of a large, enclosed, square-shaped area with a grid of
infrared beams, and exploratory behavior was tracked for one hour. ERK2f/f;NaV1.8-Cre and ERK2f/f
showed no differences in activity (beam brakes) within the open field (2-way RM ANOVA). This
suggests that hyperactivity or other alterations in exploratory behavior do not account for the effects
observed on the thermal gradient apparatus. Overall, these data indicate that thermotaxis behavior
in ERK2f/f;NaV1.8-Cre mice is altered, resulting in more presence time at cooler temperatures than
ERK2f/f littermates.
Given a cool shift in thermotaxis behavior, we next tested the response to noxious heat using
a Hargreaves apparatus. Despite alterations in an innocuous temperature range (32-34°C), we
observed no difference between ERK2f/f;NaV1.8-Cre and ERK2f/f littermates in their responses to
radiant heat (Fig. 2F, t-test). We then used von Frey filaments to assess mechanical sensitivity
and found no effect of ERK2 conditional deletion (t-test). Since locomotor deficits may confound
the interpretation of these and other behavioral models, we measured motor performance with an
accelerating Rotarod (Fig. 2G). No significant difference was observed between ERK2f/f;NaV1.8Cre and ERK2f/f littermates (2-way RM ANOVA), indicating that conditional ERK2 deletion did not
alter gross motor function. This indicates that conditional deletion of ERK2 in nociceptors does not
confound reflexive tests, such as the measurement of heat and mechanical sensitivity (Fig. 2F),
which require the ability to withdrawal the hindpaw to a given stimulus. Since there is no motor
deficit, the above data indicate that deletion of nociceptor ERK2 does not affect baseline sensitivity
to heat or mechanical stimuli.
ERK2 is necessary for peripheral sensitization.
Formalin injection produces spontaneous nociceptive behavior which responds to local anesthesia
and is associated with elevated C-fiber afferent activity (Tjolsen et al., 1992; Puig and Sorkin,
1996), implicating peripheral sensitization in this model. Since ERK1/2 activity in nociceptive
afferents has been implicated in peripheral sensitization in this and other models (Aley et al., 2001;
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Dai et al., 2002; Obata et al., 2003; Zhuang et al., 2004; Seino et al., 2006; Tsuda et al., 2007), we
sought to test the hypothesis that nociceptor ERK2 was required for formalin-induced spontaneous
nociceptive responses. ERK2f/f;NaV1.8-Cre and ERK2f/f littermates were injected with 5% formalin
and nociceptive spontaneous behaviors were video recorded for one hour and subsequently
scored for time spent licking, lifting, and flinching the injected paw. Control ERK2f/f mice exhibited
the stereotypical biphasic response to formalin injection (Fig. 3A) with an immediate behavioral
response (phase 1, 0-10 minutes) which subsides and is followed by a longer lasting delayed
response (phase 2, 10-60 minutes). Interestingly, the first phase of ERK2f/f;NaV1.8-Cre mice was
significantly higher than control ERK2f/f littermates. In contrast, the second phase is significantly
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Figure 3: ERK2 is required for peripheral sensitization. A. Erk2f/f;NaV1.8-Cre (n=8) and Erk2f/f
(n=5) littermates were injected subcutaneously into the hindpaw with 5% formalin. The amount
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of time exhibiting stereotypical nociceptive behavioral responses (licking, lifting, and flinching the
injected paw) was recorded in five minute bins for an hour following injection. During early timepoints
(0-10 min, phase 1), Erk2f/f;NaV1.8-Cre mice exhibit more spontaneous nociceptive behaviors than
controls. Later in the test (10-60 min, phase 2), nociceptive behaviors are reduced in Erk2f/f;NaV1.8Cre mice compared to Erk2f/f littermates (2-way repeated measures ANOVA, * p<0.05 Bonferroni
post-test). B. Dividing formalin-induced nociceptive behavior into first and second phases revealed
a significantly increased response of Erk2f/f;NaV1.8-Cre mice (CKO) over Erk2f/f (flox) littermates
in the first phase. Paradoxically, Erk2f/f;NaV1.8-Cre mice had a significantly attenuated response
in the second phase compared to controls (* p<0.05, t-test), suggesting that ERK2 is required
for peripheral sensitization despite elevated first phase responses. C. Following intraplantar
injection of the inflammatory mediator NGF (0.2 μg in 10 μl) paw withdrawal latency to radiant
heat decreases in Erk2f/f littermate controls, representing heat hypersensitivity (n=9, 1-way RM
ANOVA with Dunnett post-test comparing to Erk2f/f baseline; * p<0.05, *** p<0.001). Erk2f/f;NaV1.8Cre mice do not develop significant hypersensitivity to NGF (n=11, 1-way RM ANOVA with Dunnett
post-test comparing to Erk2f/f;NaV1.8-Cre baseline). There is also a significant difference when
comparing the two groups (2-way RM ANOVA main effect of genotype). D. Acute NGF-induced
heat hypersensitivity was calculated by averaging ipsilateral paw withdrawal latencies from 1 to 3
hours following injection. Erk2f/f;NaV1.8-Cre (CKO) mice had significantly less NGF-induced heat
hypersensitivity than Erk2f/f (flox) littermates (n=14 both groups; t-test, ** p<0.01).
attenuated in ERK2f/f;NaV1.8-Cre mice compared to ERK2f/f littermates. A 2-way repeated
measures (RM) ANOVA confirmed this complicated result, indicating a significant interaction
between genotype and time after formalin injection (F=2.80, DFn=11, DFd=121, P=0.0028). When
dividing the behavioral response into separate phases (Fig. 3B), ERK2f/f;NaV1.8-Cre mice exhibit a
statistically significant increase in their initial response to formalin (phase 1) compared with ERK2f/f
littermate controls (t-test) and a statistically significant decrease in the duration of nociceptive
behavior in the second phase compared to controls (t-test). The effect of ERK2 conditional deletion
on the first phase likely suggests alterations in acute nociception, such as the initial detection
of formalin and the afferent barrage that follows. The effect on the second phase suggests that
ERK2 deletion impairs peripheral nociceptor sensitization. It is interesting that ERK2f/f;NaV1.8-Cre
mice exhibit reduced second phase behaviors despite elevated first phase behaviors and perhaps
suggests multiple independent effects of ERK2 deletion within nociceptors.
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To address the role of ERK2 in peripheral sensitization more directly, we turned to a model of
heat hypersensitivity following injection of the inflammatory mediator NGF. NGF-induced heat
hypersensitivity requires peripheral sensitization, involving the potentiation of heat transduction
via modulation of TRPV1 (Huang et al., 2006). To test the requirement of nociceptor ERK2 for
NGF-induced heat hypersensitivity, ERK2f/f;NaV1.8-Cre and ERK2f/f littermates were injected
with NGF, and changes in their responses to radiant heat were tracked over several days (Fig.
3C). Interestingly, ERK2f/f;NaV1.8-Cre mice had significantly elevated paw withdrawal latencies
compared with ERK2f/f littermates (2-way RM ANOVA, F=5.11, DFn=1, DFd=72, P=0.0364),
indicating reduced sensitization in ERK2f/f;NaV1.8-Cre mice. Indeed, ERK2f/f;NaV1.8-Cre mice
failed to develop statistically significant hypersensitivity relative to normalized baseline withdrawal
thresholds, while control ERK2f/f littermates did (1-way ANOVA, Dunnett post-test comparing to
baseline within each group). In the contralateral paw, no significant difference between genotypes
was noted (2-way RM ANOVA; data not shown). To directly evaluate sensitization processes on
an intermediate timescale (hours), paw withdrawal latencies from the first three hours following
NGF injection were averaged and plotted in Fig. 3D. ERK2f/f;NaV1.8-Cre mice develop dramatically
less heat hypersensitivity following NGF injection than ERK2f/f littermates (t-test). Both analyses
indicate that ERK2 is required for NGF-induced heat hypersensitivity over the complete timecourse
of hypersensitivity and during the first few hours following injection. Taken with results from the
formalin test, these data indicate that nociceptor ERK2 is required for peripheral sensitization.
Nociceptor ERK2 contributes to long-term inflammatory mechanical hypersensitivity.
Previous work has suggested that ERK1/2 sensitizes nociceptors in the CFA model of inflammatory
pain (Obata et al., 2003). Given our findings that nociceptor ERK2 contributed to peripheral
sensitization in the formalin and NGF models, we hypothesized that conditional deletion of ERK2
in nociceptors would attenuate behavioral sensitization following hindpaw injection of CFA. Control
ERK2f/f mice exhibited a dramatic reduction in paw withdrawal threshold to mechanical stimulation
with von Frey filaments (Fig. 4A) that persisted for one week after CFA injection. One hour after
injection, the paw withdrawal thresholds of ERK2f/f;NaV1.8-Cre mice were lower than baseline and
were similar to ERK2f/f thresholds. However, at all timepoints afterwards, ERK2f/f;NaV1.8-Cre mice
had higher thresholds than ERK2f/f littermates, indicating attenuated mechanical hypersensitivity (2way RM ANOVA; significant main effect of genotype F=9.43, DFn=1, DFd=105, P=0.0078). In the
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paw contralateral to CFA injection, we did not observe significant mechanical hypersensitivity, and
there was no difference between ERK2f/f;NaV1.8-Cre and ERK2f/f littermates (2-way RM ANOVA;
data not shown). These results indicate that ERK2 in nociceptors contributes to mechanical
hypersensitivity following inflammation.
Since CFA-induced mechanical hypersensitivity and NGF-induced heat hypersensitivity were
attenuated in ERK2f/f;NaV1.8-Cre mice, we hypothesized that CFA-induced heat hypersensitivity
would be attenuated by conditional ERK2 deletion. Surprisingly, ERK2f/f;NaV1.8-Cre mice
developed robust hypersensitivity to heat following CFA injection that was not different from that
observed in control ERK2f/f littermates (Fig. 4B, 2 way RM ANOVA). No significant hypersensitivity
was observed in the paw contralateral to CFA injection, and there was no difference between
genotypes (2 way RM ANOVA; data not shown). These data indicate that ERK2 is not required for
heat hypersensitivity following CFA. Given the discrepancy between CFA and NGF models, we
sought to define the role of nociceptor ERK2 in processes underlying heat hypersensitivity using
additional, mechanistically distinct behavioral models. Hindpaw injection of formalin and mustard
oil both produce robust heat hypersensitivity (Zeitz et al., 2004; Bautista et al., 2006), probably
through activation of TRPA1 and subsequent peripheral sensitization (Bautista et al., 2006;
McNamara et al., 2007). Interestingly, ERK2f/f;NaV1.8-Cre mice develop heat hypersensitivity after
hindpaw injection of either formalin (Fig. 4C) or mustard oil (Fig. 4D) that is equivalent to ERK2f/f
littermate controls (t-test). Overall, these data suggest that nociceptor ERK2 is specifically required
in NGF-induced heat hypersensitivity but is not required in other models of heat hypersensitivity.
Conditional deletion of ERK2 elevates phosphorylation of ERK1.
Since conditional deletion of ERK2 had no effect in some models of heat hypersensitivity but
profound effects in NGF-induced heat hypersensitivity, it seemed possible that ERK1 and ERK2
may have redundant functions and that ERK1 may compensate for the loss of ERK2 in some
situations. To address this, we analyzed the expression and activation state (phosphorylation) of
ERK1 in ERK2f/f;NaV1.8-Cre mice. As noted above (Fig. 1B), ERK1 expression in DRG homogenates
is not affected by conditional deletion of ERK2. Using the same homogenates to measure ERK1
phosphorylation (pERK1) by Western blot, we found that ERK2f/f;NaV1.8-Cre mice had significantly
greater pERK1 in DRG than ERK2f/f control littermates (Fig. 5A, t-test). There was no effect of
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experiments displayed in B.&C. resulted from a collaboration between Dan O’Brien and Ben Alter.
The experiment displayed in D. was a collaboration between Ben Alter and Maiko Satomoto.
ERK2 conditional deletion on pERK1 levels in spinal cord (Fig. 5B), which is consistent with our
observations that manipulation of ERK2 expression in DRG did not affect ERK2 expression in spinal
cord (Fig. 1C). It is worthwhile to note that in the quantification histograms ERK2 phosphorylation
appears unchanged by conditional ERK2 deletion. This is actually due to the analysis method, in
which the pERK2 band is normalized to the ERK2 band. Since total ERK2 expression is reduced
in ERK2f/f;NaV1.8-Cre DRG, the total amount of pERK2 present is also reduced, which can be
appreciated in the example image. The lack of an effect on pERK2/ERK2 also indicates that the
proportion of phosphorylated ERK2 remaining in the DRG is not affected by the targeted deletion
of ERK2 in nociceptors and suggests that ERK2 phosphorylation remains normal in cells that do
not express NaV1.8. However, within the NaV1.8-expressing population, it seems likely that ERK1
is hyperphosphorylated and raises the possibility that ERK1 may functionally compensate for the
loss of ERK2.
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ERK1 deletion exacerbates NGF-induced heat hypersensitivity.
If ERK1 could functionally compensate for the loss of ERK2 and if ERK1 and ERK2 were completely
redundant, then it seems reasonable that deletion of ERK1 would produce similar effects as
deletion of ERK2. Indeed, we previously observed that deletion of ERK1 from all tissues (ERK1-/-)
led to elevated ERK2 phosphorylation (pERK2) in DRG and spinal cord (Alter et al., 2010), which
is analogous to the effects seen in ERK2f/f;NaV1.8-Cre DRG. However, on the behavioral level,
ERK1 deletion had no effect on sensitization to formalin or CFA injection, suggesting that ERK1
cannot compensate for the loss of ERK2 in these models. Given these and our current results, it
seems that basal ERK1 hyperphosphorylation is not behaviorally relevant. However, we had not
previously tested the role of ERK1 in other models of heat hypersensitivity. To our surprise, ERK1
deletion had the opposite effect of ERK2 conditional deletion on NGF-induced heat hypersensitivity
(Fig. 6A-C). Following intraplantar injection of NGF, ERK1-/- mice have significantly shorter paw
withdrawal latencies than control WT littermates (Fig. 6A, 2-way RM ANOVA significant main effect
of genotype F=4.52, DFn=1, DFd=88, P=0.045), indicating that ERK1-/- mice have exaggerated
heat hypersensitivity. No significant difference between ERK1-/- and WT littermates was detected in
the paw contralateral to NGF injection (2-way RM ANOVA; data not shown). After averaging the first
three hours following NGF-injection (Fig. 6B), we observed a significant difference between ERK1/-

and WT littermates (t-test). For comparison, results from ERK2f/f;NaV1.8-Cre and ERK2f/f mice in

the same test are presented again in Fig. 6C. Although performing statistical tests across these two
experiments would be inappropriate given background strain differences, it is interesting to note
the similarity between control groups in the magnitude of NGF-induced heat hypersensitivity. We
also measured the effect of ERK1 deletion in mustard oil-induced heat hypersensitivity and found
no difference between ERK1-/- and WT littermates (t-test). This is similar to the effect seen with
conditional ERK2 deletion (Fig. 4D). Interestingly, from our previous study, we found that ERK1/-

mice had diminished formalin-induced heat hypersensitivity (Alter et al., 2010), which is different

than the effect of conditional ERK2 deletion (Fig. 4C) in which ERK2f/f;NaV1.8-Cre and ERK2f/f
littermates developed a similar degree of heat hypersensitivity. Therefore, in different models of
heat hypersensitivity, manipulation of ERK1 or ERK2 produces distinct results. Following injection
of NGF, conditional deletion of ERK2 attenuates heat hypersensitivity, while deletion of ERK1
exacerbates heat hypersensitivity. Overall, these results argue against functional redundancy and
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mineral oil) is not different between ERK1-/- and WT littermates (n=5, t-test). Contributions: The
experiments displayed in A.-C. were performed by Ben Alter. The experiment shown in D. resulted
from a collaboration between Ben Alter and Dan O’Brien.
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Figure 7: Survival of peptidergic sensory neurons is unaffected by ERK2 deletion. A.
Representative images indicate the presence of CGRP-positive cells within dorsal root ganglia of
Erk2f/f;NaV1.8-Cre and Erk2f/f littermates. B. TrkA immunoreactiivity is similar between Erk2f/f and
Erk2f/f;NaV1.8-Cre dorsal root ganglia. C. CGRP- and TrkA-positive cell profiles were counted from
L4 dorsal root ganglia (n=5-6 animals). Counts were divided by number of cells immunoreactive for
βIII-tubulin, a general neuronal marker. No significant difference was detected between Erk2f/f and
Erk2f/f;NaV1.8-Cre dorsal root ganglia (t-test), indicating that deletion of ERK2 does not affect DRG
neuronal survival. Scale bar = 100 μm. Contributions: The experiments in this figure culminated
from a collaboration between Maiko Satomoto and Ben Alter.
prompted us to further investigate the effects of ERK isoform deletion on NGF-induced heat
hypersensitivity.
Peptidergic nociceptors are present and express TrkA normally despite conditional ERK2 deletion.
Nociceptors can be divided into subgroups based on the expression of neuropeptides, growth
factor receptors, and sensory transduction channels (Hucho and Levine, 2007). Peptidergic
nociceptors express calcitonin gene related peptide (CGRP) and the growth factor receptor TrkA.
In vivo, TRPV1 expression is highly enriched within peptidergic neurons. Moreover, a growing
body of data supports a model of inflammatory heat hypersensitivity involving NGF binding to TrkA
with subsequent potentiation of TRPV1 function, although the precise intracellular signaling events
downstream of TrkA remain controversial (Huang et al., 2006). Given the importance of peptidergic
neurons to inflammatory heat hypersensitivity, it was important to determine whether these
neurons were present and expressing the TrkA receptor. Therefore, L4 DRG from ERK2f/f;NaV1.8Cre and ERK2f/f littermates were stained for the peptidergic marker, CGRP, and for TrkA (Fig. 7).
CGRP-positive cells were observed in ERK2f/f;NaV1.8-Cre DRG and there was no difference in the
percentage of CGRP-positive neurons compared to ERK2f/f littermates (Fig. 7A, 7C, t-test). This
indicates that the proportion of peptidergic neurons is not altered by conditional deletion of ERK2.
We also observed TrkA-positive cell profiles in the DRG of ERK2f/f;NaV1.8-Cre mice (Fig. 7B).
The proportion of TrkA-positive cells relative to the total number of neurons was also no different
between genotypes (Fig. 7C, t-test). These results indicate that peptidergic cells are present and
express the receptor for NGF in ERK2f/f;NaV1.8-Cre mice, suggesting that behavioral phenotypes
are not due to a loss of peptidergic nociceptor
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ERK2 and not ERK1 is required for peptidergic epidermal innervation.
Previous work has implicated ERK1/2 signaling in axon outgrowth in vitro (Markus et al., 2002a).
In vivo knockout studies have shown that upstream molecules in the MAPK cascade and potential
downstream targets for ERK1/2 are important in epidermal innervation, e.g. Raf isoforms and the
transcription factor SRF (Zhong et al., 2007; Wickramasinghe et al., 2008). Given a reduction in
behavioral sensitization in several pain models and a blunted response to NGF, it seemed possible
that peripheral innervation required ERK2 signaling. To test this hypothesis, footpad skin from ERK2f/
f

;NaV1.8-Cre and ERK2f/f littermates was stained for βIII-tubulin, which specifically labels axons. In

ERK2f/f thick skin (Fig. 8A), fine nerve endings could be observed extending from dermis into the
epidermis. The vast majority of these free nerve endings are nociceptive, since they do not stain
positive for tyrosine hydroxylase and are therefore not sympathetic (Rice et al., 1998). Fibers could
also be seen in ERK2f/f;NaV1.8-Cre thick skin (Fig. 8B), without any gross structural differences.
To quantify the density of epidermal innervation, random fields of thick skin were examined, the
length of the dermal-epidermal border was measured, and the number of fibers crossing this border
was counted (Fig. 8C). Interestingly, we observed a small but significant decrease in the number
of βIII-tubulin-positive fibers in ERK2f/f;NaV1.8-Cre thick skin as compared with thick skin from
ERK2f/f littermates (t-test). This suggests that ERK2 partially contributes to nociceptor epidermal
innervation. To determine whether a subset of fibers is affected, adjacent sections of skin were
stained for the peptidergic marker, CGRP (Fig. 8A-B). Although CGRP-positive fibers were present
in thick skin from ERK2f/f;NaV1.8-Cre mice, a significant reduction in the density of fibers compared
with control ERK2f/f skin was observed (Fig 8C). Together, these results suggest that the decrease
in innervation is restricted to peptidergic fibers, since the absolute number of fibers lost per unit
length of dermal-epidermal border is the same for both CGRP- and βIII-tubulin-positive fibers.
Given the loss of peptidergic fibers following conditional deletion of ERK2, we sought to characterize
epidermal innervation in ERK1-/- mice. Footpads from ERK1-/- and WT littermates were processed
and stained for CGRP and βIII-tubulin (Fig. 9). Despite the loss of ERK1 in all tissues, fibers positive
for both CGRP and βIII-tubulin were present in ERK1-/- skin and were without obvious structural
abnormalities. Quantification of the fiber density revealed that there was no difference between
ERK1-/- and WT skin in either total (Fig. 9C) or peptidergic (Fig. 9F) innervation, indicating that
ERK1 is not required for innervation of the epidermis. Overall, these results indicate that ERK2
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is similar to the number of βIII-tubulin-positive fibers lost, consistent with a reduction in peptidergic
innervation and not simply a loss of CGRP expression.
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is partially required for peptidergic innervation of the epidermis. Importantly, ERK1 deletion has
no effect on innervation density, indicating that ERK2 plays an isoform specific role in epidermal
innervation.
Discussion
Accumulating evidence suggests that ERK1 and ERK2 play distinct roles. The present study is
the first to address the role of ERK2 in nociceptors. Conditional deletion of ERK2 in nociceptors
attenuated behavioral sensitization in several models, including the formalin test, NGF-induced
heat hypersensitivity, and CFA-induced mechanical hypersensitivity. Attenuated behavioral
sensitization was accompanied by a partial loss of peptidergic innervation of the epidermis, which
likely contributes to the behavioral phenotypes. Additionally, we observed a significant increase in
ERK1 phosphorylation due to the conditional deletion of ERK2. However, global ERK1 deletion had
no effect on peripheral innervation and actually exacerbated NGF-induced heat hypersensitivity.
Our previous study of ERK1 deletion indicated that ERK1 was not required for formalin-induced
spontaneous behavior or CFA-induced mechanical hypersensitivity (Alter et al., 2010). Taken
together, these results suggest that ERK2 and not ERK1 is required for epidermal innervation and
peripheral sensitization.
Although we set out to test the role of ERK2 in acute sensitization of the nociceptor, it became
clear that ERK2 was required for a more fundamental process of epidermal innervation. Previous
studies have implicated ERK1/2 signaling in axon outgrowth in vitro using either MEK inhibitors
or a constitutively active MEK1-ERK2 fusion protein (Robinson et al., 1998; Markus et al., 2002a;
Markus et al., 2002b; Wickramasinghe et al., 2008). Conditional deletion of upstream MAP kinases
Raf-1 and B-Raf using a neuronal nestin-Cre line reduced axonal branching in embryos (Zhong
et al., 2007). However, direct in vivo evaluation of the importance of ERK2 in axon outgrowth of
sensory neurons has been difficult since germline deletion of ERK2 is lethal early in development
(Krens et al., 2006) and conditional deletion of ERK2 with Wnt1-Cre leads to late embryonic lethality
(Newbern et al., 2008). To our knowledge, the present study provides the first in vivo evidence
that ERK2 is required for epidermal innervation. Moreover, ERK1 is dispensible for epidermal
innervation, suggesting that signaling pathways underlying axonal outgrowth rely exclusively
upon ERK2. It is possible that ERK2 affects other functions associated with trophic support, such
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as cell survival. However, the percentage of peptidergic neurons is unaltered in ERK2f/f;NaV1.8Cre mice, suggesting that peptidergic neurons are not lost. It is possible that a total reduction in
all DRG neurons might yield a similar percentage of CGRP neurons when in fact there is some
neuronal loss. This is unlikely since the change in DRG CGRP and βIII-tubulin counts must be
proportionately equivalent and, if so, one would expect a more significant reduction in βIII-tubulin
fiber counts in the skin than we observed. Although our data suggest the requirement of ERK2 for
peptidergic epidermal innervation we do not directly address the timeframe of this requirement.
Since Cre activity begins at P0 in the BAC transgenic NaV1.8-Cre line (Agarwal et al., 2004) and at
that time epidermal innervation of the footpad has occured (Coggeshall et al., 1994; Jackman and
Fitzgerald, 2000; Baccei and Fitzgerald, 2010), it is likely that peptidergic fibers are initially present
in developing ERK2f/f;NaV1.8-Cre mice but then die back. This would suggest that ERK2 is required
for peptidergic fiber maintanence, which is certainly possible given that continued trophic support
is required to maintain epidermal innervation in adult animals (Bennett et al., 1998). Overall, it
seems likely that the loss of peptidergic fibers in ERK2f/f;NaV1.8-Cre skin is not due to cell loss but
is instead due to failed maintanence of nociceptor axons, although a more detailed analysis over
perinatal development may be warranted.
The partial loss of peptidergic innervation in ERK2f/f;NaV1.8-Cre mice may underlie some of the
behavioral phenotypes we observed. Ablation of all NaV1.8-expressing cells results in a dramatic
reduction in the 2nd phase of the formalin test and significantly attenuates CFA-induced mechanical
hypersensitivity (Abrahamsen et al., 2008), both of which are phenocopied with conditional deletion
of ERK2 in the same cells. Additionally, ablation of TRPV1-expressing terminals with neurotoxic
capsaicin treatments diminishes formalin-induced spontaneous nociceptive behaviors (Peterson
et al., 1997; Chen et al., 2007), suggesting that the presence of peptidergic fibers is required for
formalin-induced behavioral responses. Peptidergic fibers also express the receptor for NGF, TrkA.
Loss of these fibers and the resulting loss of TrkA may explain the attenuated NGF-induced heat
hypersensitivity we observed in ERK2f/f;NaV1.8-Cre mice. Peptidergic fiber loss may also account
for alterations in thermotaxis behavior, in which conditional deletion of ERK2 increased presence
time in 30-32°C zones and decreased presence time in 34-36°C zones relative to controls. Several
TRP channels, which are activated in this innocuous temperature range, contribute to thermotaxis
behaviors (Dhaka et al., 2006), including TRPM8, TRPV3, and TRPV4. Although the temperature
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sensitivity for TRPV4 fits best with the temperature range affected in ERK2f/f;NaV1.8-Cre mice,
deletion of TRPV4 actually shifts presence time towards warmer temperatures (Lee et al., 2005).
Therefore, it seems more likely that conditional deletion of ERK2 in nociceptors affects TRPM8 or
TRPV3 function, since deletion of either channel shifts thermotaxis towards cooler temperatures
(Moqrich et al., 2005; Dhaka et al., 2007). Although controversial (Dhaka et al., 2008), TRPM8
expression has been reported in peptidergic neurons (Okazawa et al., 2004; Kobayashi et al.,
2005; Takashima et al., 2007). Therefore, loss of peptidergic fibers may result in the absence of
TRPM8 expression in the skin, compromising temperature sensation in the innocuous range. It
is also possible that TRPV3 signaling is altered by loss of peptidergic fibers. Although TRPV3 is
expressed in keratinocytes and not sensory neurons (Dhaka et al., 2006), loss of peptidergic fibers
may prevent signaling downstream of TRPV3 and alter thermotaxis. Overall, our data indicate that
the presence of ERK2-dependent peptidergic fibers seems to be critical in the formalin test, in
NGF-induced heat hypersensitivity, and in thermotaxis.
Our analysis of epidermal innervation indicates that nonpeptidergic fiber density remains normal
in ERK2f/f;NaV1.8-Cre mice, since the change in density of all fibers matches the change in CGRPpositive fibers. Given the continued presence of peptidergic fibers, it seems likely that ERK2
plays an important role in sensitizing this subpopulation of nociceptors. The deficit we observed in
CFA-induced mechanical hypersensitivity supports this hypothesis. A recent study has found that
nonpeptidergic, MrgD-expressing cells are required for CFA-induced mechanical hypersensitivity
(Cavanaugh et al., 2009). Interestingly, ablation of these cells has no effect on CFA-induced heat
hypersensitivity. Conditional deletion of ERK2 produces similar results. Loss of peptidergic neurons
using neurotoxic capsaicin or resiniferotoxin treatments produces the converse effect -- inflammatory
heat hypersensitivity is abolished while there is no effect on mechanical hypersensitivity (Chen et al.,
2007; Cavanaugh et al., 2009; Mishra and Hoon, 2010). This suggests that the loss of peptidergic
fibers in ERK2f/f;NaV1.8-Cre mice cannot explain the behavioral phenotype we observed in the CFA
model. Taken together, these data support a model in which different subsets of nociceptors utilize
ERK2 in different contexts. Nonpeptidergic neurons do not require ERK2 for epidermal innervation
but do require ERK2 for inflammatory mechanical sensitization. Some peptidergic fibers clearly
require ERK2 for epidermal innervation. Other peptidergic fibers do not require ERK2 for epidermal
innervation and also do not require ERK2 in peripheral sensitization. The existence of this third
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group is supported by our observations that, despite the loss of ERK2, CFA, formalin, and mustard
oil can all induce robust heat hypersensitivity in ERK2f/f;NaV1.8-Cre mice. It is interesting to note
that formalin-induced heat hypersensitivity is attenuated in mice lacking ERK1 (Alter et al., 2010).
This fits well with the above model and implies that functional differences observed between ERK1
and ERK2 may be due to cell type specific expression of each isoform. Immunohistochemical
experiments with careful controls for antibody specificity will be required to test this hypothesis. It
is also possible that ERK1 and ERK2 are expressed in the same cell, but functional coupling or
signaling microdomains restrict the involvement of one isoform or another.
The effect of conditional ERK2 deletion on peptidergic innervation raises interesting questions about
the maintanence of innervation within the unaffected subgroups of nociceptors. Nonpeptidergic
neurons lose their requirement for NGF and upregulate the trophic factor receptor Ret around
birth and during postnatal development (Molliver et al., 1997). Previous studies have implicated
Ret signaling in nonpeptidergic epidermal innervation, since conditional deletion of Ret with Wnt1Cre reduced MrgD-postive fiber density in the epidermis (Luo et al., 2007) and deletion of the Ret
co-receptor GDNF family receptor α 2 (GFRα2) decreased overall fiber density without affecting
peptidergic innervation (Lindfors et al., 2006). Since deletion of either ERK isoform had no effect on
nonpeptidergic epidermal innervation, it seems likely that Ret signaling does not utilize the MAPK
pathway in vivo, although this should be directly tested. However, it is also possible that ERK1 and
ERK2 may be redundant downstream of Ret, which could be evaluated in double knockout animals.
In addition to nonpeptidergic fibers, many peptidergic fibers remained despite the loss of ERK2. This
differential effect of ERK2 deletion on peptidergic fibers could be explained if different intracellular
signaling cascades were required downstream of NGF-TrkA signaling. Another possibility would be
that these fibers are maintained by other trophic factors. GFRα3 receptors have been observed
in peptidergic fibers expressing TRPV1 (Malin et al., 2006), which might explain the survival of a
subset of peptidergic fibers that could contribute to the preserved inflammatory heat hyperalgesia
observed in ERK2f/f;NaV1.8-Cre mice.
The behavioral response to formalin includes spontaneous nociceptive behaviors that manifest in
distinct early and late phases (Tjolsen et al., 1992). Conditional deletion of ERK2 in nociceptors
paradoxically increases the first phase and decreases the second phase. As mentioned above,
the decrease in the second phase may be attributed to reduced peptidergic terminals. However,
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it is unclear how ERK2 deletion might increase the first phase response. Both phases require the
expression of TRPA1, and in vitro data suggests that formalin chemically modifies and activates
TRPA1 (McNamara et al., 2007). It is possible that the peptidergic fibers that remain in ERK2f/
;NaV1.8-Cre mice express TRPA1. In the conditional knockout, these fibers may have relatively
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greater afferent input than in normal mice, and therefore initial transduction of the noxious stimulus
is actually elevated. However, since peptidergic fibers are diminished, nociceptor sensitization due
to neurogenic inflammation is also diminished, resulting in a reduced second phase. At odds with
this hypothesis is our observation that mustard oil-induced heat hypersensitivity is not affected
by loss of ERK2. However, it is possible that the competing processes of elevated acute sensory
transduction and diminished peptidergic sensitization preclude the observation of a phenotype
following mustard oil injection.
One plausible mechanism for reduced NGF-induced heat hypersensitivity in ERK2f/f;NaV1.8Cre mice is the partial loss of TrkA-expressing fibers. However, exaggerated NGF-induced heat
hypersensitivity observed in ERK1-/- mice cannot be explained by changes in innervation, since
we observed no differences in CGRP- or βIII-tubulin-positive fiber density. Taken together, it is
possible that the behavioral effects of ERK2 deletion may be due to acute functional changes, as
well as structural differences. Assuming that behavioral phenotypes relate to acute sensitization
processes, it is tempting to speculate about the apparently opposing functions of ERK1 and ERK2.
It is possible that ERK1 competes with ERK2 for MEK activity and thereby partially inhibits NGFinduced sensitization, tuning the behavioral response to NGF. This hypothesis is supported by the
observation that deletion of ERK1 increases the phosphorylation status of ERK2 in DRG (Alter et al.,
2010). Similar gain-of-function effects of ERK1 deletion have been observed in cultured fibroblasts
and cell lines (Vantaggiato et al., 2006) as well as in a morphine conditioned place preference
paradigm (Mazzucchelli et al., 2002) and, in both cases, have been associated with hyperactivity
of ERK2. Further experimentation investigating the activity of ERK1 and ERK2 downstream of NGF
should elucidate these questions. Other explanations for the exaggerated response of ERK1-/- mice
to NGF could include the possibility that ERK1 acts through independent anti-nociceptive pathways
or that global deletion of ERK1 affects other systems outside the nociceptor which enhance NGFinduced hypersensitivity indirectly. Inducible tissue-specific manipulation of ERK1 and ERK2
expression would help to address these provocative questions.
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The current study indentifies an isoform-specific role for ERK2 in epidermal innervation within
a subset of peptidergic fibers. Moreover, the loss of nociceptor ERK2 attenuates peripheral
sensitization in the formalin test and in inflammatory mechanical hypersensitivity. Given the results
of this study, it is possible that therapeutic inhibition of ERK2 may actually result in a peripheral
neuropathy, although the importance of ERK2 in myelinated sensory axons remains to be
determined. Further characterization of the role of ERK2 in pain will be important in understanding
the pathophysiological mechanisms in chronic pain conditions and developing new therapeutic
options to treat them.
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Chapter 4: Conclusions and Future Directions
A large body of evidence implicates ERK1/2 in nociception and nociceptive sensitization.
Since ERK1 and ERK2 play distinct functional roles in other systems, I hypothesized that the
ERK1/2 isoforms differentially contribute to sensitization of the nociceptive system. To test directly
the requirement for ERK1 in all tissues, ERK1-\- mice were compared with WT littermates in rodent
behavioral models of pain. Despite the activation of ERK1 following noxious stimulation, it appeared
that ERK1 was dispensable for formalin-induced spontaneous nociceptive behaviors, inflammationinduced mechanical and heat hypersensitivity, and nerve injury-induced mechanical hypersensitivity.
In contrast, conditional deletion of ERK2 in nociceptors (ERK2f/f;NaV1.8-Cre) attenuated formalininduced spontaneous nociceptive behaviors and reduced inflammation-induced mechanical
hypersensitivity. This suggests that ERK2 is required for behavioral sensitization in these models
and that ERK1 cannot compensate for the loss of ERK2. Interestingly, injection of the inflammatory
mediator NGF had the opposite effects in ERK2f/f;NaV1.8-Cre and ERK1-\- mice. NGF-induced heat
hypersensitivity was diminished by conditional deletion of ERK2, while sensitization was actually
exaggerated by the loss of ERK1. To better understand potential mechanisms underlying these
behavioral effects, nociceptor microanatomy was evaluated by immunohistochemistry. Conditional
deletion of ERK2 partially reduces nociceptor innervation of the skin. The partial loss is restricted
to peptidergic nociceptors and is not associated with loss of peptidergic neurons. Deletion of ERK1
has no effect on nociceptor innervation.
Altogether, these results identify ERK2 specific roles on the behavioral level in several
models of nociception and nociceptive sensitization. Additionally, characterization of mice lacking
ERK2 in nociceptors revealed a role for ERK2 in epidermal innervation, providing in vivo evidence
that ERK signaling contributes to axon growth and/or maintenance. These behavioral and structural
functions appear to be specific to ERK2 since ERK1 is not able to compensate for the loss of
ERK2. During this study, another group reported that partial knockdown of ERK2 in the spinal
cord significantly attenuated inflammation-induced heat and mechanical hypersensitivity (Xu et al.,
2008). Results from the current study support and extend these findings, indicating that ERK2 is
the predominant isoform in nociceptors and spinal cord.
ERK2 is necessary for epidermal innervation in a subset of peptidergic fibers
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Although the initial purpose for conditionally deleting ERK2 in nociceptors was
to test the importance of ERK2 in peripheral sensitization, characterization of ERK2f/f;NaV1.8-Cre
mice revealed a partial loss of peptidergic fibers in the epidermis (see Chapter 3). Previous studies
have implicated ERK1/2 signaling in axon growth assays in vitro (Markus et al., 2002). Although
there have not yet been reports directly assessing the role of ERK1/2 in vivo, molecules upstream
and downstream have been implicated. For example, the upstream kinases Raf-1 and B-Raf are
required for cutaneous arborization (Zhong et al., 2007). A downstream transcription factor, SRF,
is required for footpad epidermal innervation in NaV1.8-expressing neurons (Wickramasinghe et
al., 2008). The current study is consistent with the previous studies implicating Raf-MEK-ERKSRF signaling in promoting epidermal innervation and provides in vivo evidence that ERK2 is
specifically required.
Diminished peptidergic innervation may be due to a deficit in the initial elaboration of
fibers into the epidermis, an exaggerated loss of fibers during axon pruning, or a deficit in the
continued maintenance of innervation in mature skin. When considering these possibilities, it
is helpful to compare the timeline of nociceptor development with the predicted onset of ERK2
deletion. By crossing the transgenic NaV1.8-Cre line with a ROSA26 reporter line (Soriano, 1999),
Cre-mediated excision at the ROSA26 locus was initially detected at P0 without any excision
detected at E17 (Agarwal et al., 2004). Sensory neurons which develop into nociceptors are born
in several waves of neurogenesis between E9 and E11 (Marmigere and Ernfors, 2007) well before
the anticipated onset of Cre expression. Importantly, fiber loss due to the deletion of ERK2 was
not associated with cell loss suggesting that the process of neuronal birth and naturally occurring
cell death are unaffected in ERK2f/f;NaV1.8-Cre mice. Axon growth towards target tissues proceeds
shortly thereafter in a proximodistal manner so that innervation of the footpad is well established
before birth (Coggeshall et al., 1994; Jackman and Fitzgerald, 2000; Baccei and Fitzgerald, 2005).
Since epidermal innervation occurs before birth, it is likely that peptidergic fibers are present in
the epidermis of ERK2f/f;NaV1.8-Cre mice before the onset of Cre expression. During this late
embryonic period, the epidermis of the hindpaw is initially hyperinnervated with nerve endings
reaching through the developing epidermis to the surface of the skin (Jackman and Fitzgerald,
2000). However, by E20 fibers have retracted towards the dermis and form a more mature
configuration with a subepidermal plexus of nerve fibers from which fine nerve endings extend
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into the epidermis. Although it is possible that ERK2 deletion affects this process of retraction, it is
unlikely since there is probably a delay between Cre-mediated excision of ERK2 coding regions
and a decrease in ERK2 protein levels due to the continued presence of previously transcribed
ERK2. Additionally, upon gross examination, the subepidermal plexus found in ERK2f/f;NaV1.8-Cre
mice appeared similar to that of control littermates. There is also evidence that trophic support in
mature animals is required to maintain epidermal innervation, since infusion of NGF-sequestering
antibodies into the skin results in ~40% reduction in innervation density (Bennett et al., 1998). From
the current study, it is difficult to determine whether the loss of innervation results from a defect
in initial fiber growth, pruning, or maintenance since all of these processes occur at time points
near the expected onset of Cre expression. Analysis of epidermal innervation over the perinatal
development will help to address this question.
Although the specific cellular mechanism underlying the fiber loss is not yet
identified, it is reasonable to hypothesize it is related to a defect in NGF-TrkA signaling. NGF and
TrkA are required for epidermal innervation during embryonic development (Patel et al., 2000). In
mature animals, exogenous application of NGF into the skin induces ERK1/2 activation in the DRG
(Averill et al., 2001). Additionally, the fibers that are lost in ERK2f/f;NaV1.8-Cre mice are peptidergic,
CGRP-positive fibers. Since CGRP expression almost completely overlaps with TrkA expression in
DRG (Averill et al., 1995), the lost fibers are likely to express TrkA. As mentioned above, interfering
with NGF-TrkA signaling decreases epidermal innervation (Bennett et al., 1998). The magnitude of
this decrease approximates the relative amount peptidergic fibers in the skin (Zylka et al., 2005).
All of this data suggests that reduced peptidergic epidermal innervation is likely to due to impaired
NGF-TrkA signaling. Results from the current study strongly suggest that ERK2 is downstream of
TrkA activation and is important for peptidergic innervation. One way to test this hypothesis would
be to determine whether ERK2 activation by NGF could increase epidermal innervation. Indeed,
NGF overexpression in epidermal keratinocytes or elevations in NGF due to skin wounding result
in hyperinnervation of the epidermis (Albers et al., 1994; Constantinou et al., 1994; Reynolds and
Fitzgerald, 1995). Crossing ERK2f/f;NaV1.8-Cre mice to the NGF overexpressing transgenic line or
manipulating NGF content in the skin of ERK2f/f;NaV1.8-Cre mice by injury or exogenous application
would determine whether ERK2 was required for NGF-induced increases in epidermal innervation.
The initial observation that ERK2 is partially required for peptidergic epidermal innervation raises
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many interesting developmental questions which will be the topic of subsequent investigation.
The loss of one-third of peptidergic fibers in ERK2f/f;NaV1.8-Cre mice but the
presence of other peptidergic fibers and all nonpeptidergic fibers suggests the existence of three
distinct populations of nociceptors. One set of peptidergic fibers requires ERK2 for epidermal
innervation. The remaining peptidergic fibers and nonpeptidergic fibers do not require ERK2 for
epidermal innervation. It is likely that in the ERK2-dependent peptidergic fibers that ERK2 signals
downstream of the TrkA receptor (see above). In ERK2-independent peptidergic fibers, it is also
likely that NGF-TrkA signaling promotes their continued innervation of the epidermis. However,
these fibers are not affected by the deletion of ERK2, which could be due to at least two reasons.
The first is that ERK1 and ERK2 are redundant in this subset of neurons and that ERK1 is able to
compensate for the loss of ERK2. This may explain the hyperphosphorylation of ERK1 in ERK2f/
;NaV1.8-Cre DRG homogenates (see below for discussion). A second possibility is that ERK1/2
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signaling is not required for epidermal innervation in these neurons, but that other pathways
emanating from TrkA are actually required. These may include PI3K-Akt or ERK5 signaling
(Markus et al., 2002). Additional experiments using ERK1-/-;ERK2f/f;NaV1.8-Cre double knockout
mice might distinguish these two possibilities. The third set of nociceptors is the nonpeptidergic
nociceptors. These fibers also do not require ERK2 for innervation of the epidermis. Previous
studies have demonstrated that developing nonpeptidergic fibers require NGF-TrkA signaling for
epidermal innervation since all fibers initially express TrkA (Patel et al., 2000). After downregulating
TrkA and upregulating Ret (Molliver et al., 1997), maintenance of epidermal innervation may also
switch from TrkA to Ret signaling. This has been supported with experiments showing diminished
nonpeptidergic innervation in mice with conditional Ret deletion, although confounds such as cell
loss and gastrointestinal defects makes these conclusions relatively tentative (Luo et al., 2007;
Golden et al., 2010). Whether nonpeptidergic neurons require Ret or TrkA for epidermal innervation,
the lack of an effect of ERK2 deletion indicates that either ERK1 and ERK2 are redundant in
these fibers or neither isoform is required and that other cascades are important instead. It will be
particularly interesting to determine the developmental timecourse of fiber loss in ERK2f/f;NaV1.8Cre mice in relation to the nonpeptidergic fibers. If ERK2 contributes to the initial innervation of
the epidermis, as is a possibility mentioned above, then it could be that the requirement for ERK2
signaling delineates small-diameter nociceptors before the switch in expression of TrkA to Ret in
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developing nonpeptidergic fibers.
It is also possible that separate ERK2-dependent and ERK2-independent
populations represent an artifact of conditional ERK2 deletion and that ERK2 is actually required
for peripheral innervation of all fiber types. For example, “ERK2-independent” fibers may innervate
the epidermis at an earlier developmental time point than “ERK2-dependent” fibers. Cre-dependent
excision of ERK2 might then occur immediately before innervation by “ERK2-dependent” fibers.
This would cause the loss of innervation in only a subset of fibers and appear as if the remaining
fibers did not require ERK2. A way to test this possibility would be to use alternative Cre lines,
such as the knock-in NaV1.8-Cre line in which Cre expression occurs earlier at E13/14 (Stirling
et al., 2005). This may be the ideal way to determine whether ERK2 is required for initial fiber
innervation since this developmental time point roughly coincides with the beginning of trophic
dependence (Mendell et al., 1999). However, it is also possible that ERK2 modulates naturally
occurring cell death in addition to its functions in epidermal innervation, which could confound
the interpretation of this experiment (Coggeshall et al., 1994; Mendell et al., 1999). Manipulations
on a Bax-/- background in which apoptotic cell death is diminished may provide a way around this
potential confound, as has been successfully performed to analyze the function of NGF, TrkA, and
Ret after developmental periods of naturally occurring cell death (Patel et al., 2000; Honma et al.,
2010).
It will also be interesting to determine the molecular mechanisms associated with
fiber loss in ERK2f/f;NaV1.8-Cre mice. In vitro experiments that analyze the mechanisms underlying
axon growth may provide some insights. Axon growth depends on signaling events that occur both
locally at the nerve terminal and distantly in the soma (Markus et al., 2002). MEK1/2 inhibitors
applied only to axons and not cell bodies induce growth cone collapse in sympathetic neurons
(Atwal et al., 2003), suggesting that ERK1/2 activity maintains growth cone structure. This may
occur by phosphorylation of microtubule associate proteins either directly or via GSK3β (Markus et
al., 2002; Goold and Gordon-Weeks, 2005). Modulation of microtubule assembly might then allow
for regulation of growth cone structure. Transcriptional alterations also play a role in axon growth,
and ERK1/2 signaling may be involved (Markus et al., 2002; Wickramasinghe et al., 2008). Indeed,
retrograde ERK1/2 signaling has been reported in the sciatic nerve (Johanson et al., 1995), and it
is thought that NGF-TrkA signaling endosomes may be transported to the soma where ERK may
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initiate transcriptional changes via transcription factors such CREB, SRF, or NFAT (Markus et al.,
2002; Wickramasinghe et al., 2008). However, a recent study with a two-compartment culture
system found that NGF-TrkA signaling endosomes activate ERK5 instead of ERK1/2 (Watson et
al., 2001). Moreover, NGF-mediated cell survival required ERK5 activity when NGF was applied
only to the axons. In other studies implicating retrograde TrkA-ERK1/2 signaling, NGF was applied
in single chamber cultures to both soma and axons (Wickramasinghe et al., 2008). In agreement
with these findings, Watson et al. also found NGF-induced ERK1/2 phosphorylation, but this
was only observed when NGF was applied to cell bodies. This suggests that ERK1/2 may not
be involved in retrograde signaling to the soma. In support of this model, a nerve ligation study
revealed that NGF injection to the paw actually decreased the amount of retrogradely transported
pERK1/2 compared to baseline (Averill et al., 2001). Since conditional deletion of ERK2 resulted
in a reduction in epidermal innervation without affecting cell survival, it will be very interesting to
determine whether transcriptional changes occur in ERK2f/f;NaV1.8-Cre mice that might account for
fiber loss. If transcriptional programs are unaltered in ERK2f/f;NaV1.8-Cre mice, it is likely that ERK2
promotes epidermal innervation locally by modulating cytoskeletal stability.
The results of this study indicate that ERK2 deletion results in a partial loss of peptidergic
fibers in the epidermis. ERK1 deletion throughout development has no effect on epidermal
innervation. This suggests that ERK2 plays an isoform-specific role in this process. Additional
studies using double knockout animals must be performed to determine whether ERK1/2 activity
is important for epidermal innervation in ERK2-independent fibers. In conjunction with this line of
investigation, it will be interesting to interrogate other intracellular signaling cascades downstream
of growth factor receptors in the fibers that are not affected by ERK2 deletion.
ERK1 and ERK2 do not modulate baseline responses to radiant heat or mechanical stimuli
Previous studies with MEK1/2 inhibitors have indicated that basal ERK1/2 activity
does not appear to control responses to acute noxious heat or mechanical stimulation in naïve
animals. Application of inhibitors by intraplantar injection or by intrathecal administration has no
effect on baseline withdrawal responses to radiant heat or mechanical stimulation (Ji et al., 1999;
Obata et al., 2003; Hao et al., 2008). Additionally, transgenic mice expressing a dominant negative
MEK1 have normal baseline sensitivity to radiant heat (Karim et al., 2006). These findings fit well
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with findings from the ERK mutants. Deletion of ERK1 in all tissues or ERK2 in nociceptors has
no impact on baseline sensitivity to radiant heat or mechanical stimulation with von Frey hairs
(see Chapters 2 and 3). This observation has important ramifications. First, it means that the
loss of peptidergic fibers in ERK2f/f;NaV1.8-Cre mice does not affect baseline responses. Second,
this frames the interpretation of changes in basal ERK1/2 phosphorylation seen in the isoformspecific mutant mice. In ERK1-/- mice, ERK2 is hyperphosphorylated in the spinal cord and DRG
of naïve animals (Chapter 2). In ERK2f/f;NaV1.8-Cre mice, the converse occurs such that ERK1
is hyperphosphorylated in DRG (Chapter 3). Although interesting in considering the relationship
between the isoforms (see below for discussion), it appears that these changes in phosphorylation
in naïve animals have no affect on baseline withdrawal to heat or mechanical stimuli. The behavioral
relevance of baseline hyperphosphorylation could be queried with MEK inhibitors in naïve animals.
However, since there is no effect of MEK inhibitors on baseline withdrawal responses in WT
animals with both ERK1 and ERK2, the relevance of this question to physiological nociception
seems limited.
One behavioral finding that may be related to baseline hyperphosphorylation is
the thermotaxis deficit observed in ERK2f/f;NaV1.8-Cre mice (see Chapter 3). This could occur by
several mechanisms. Hyperphosphorylation of ERK1 could play some role in epidermal innervation,
actively inhibiting the growth or maintenance of peptidergic fibers. However, this does not appear
to be the case since ERK1 deletion in DRGs has no effect on peptidergic innervation. Another
possible mechanism may be that ERK1 hyperphosphorylation in existent fibers within the epidermis
sensitizes those fibers to warm stimuli. This may prompt ERK2f/f;NaV1.8-Cre mice to spent more
time at cooler temperatures. This seems less likely given that ERK2f/f;NaV1.8-Cre mice do not have
reduced withdrawal latencies to radiant heat, although there may be changes in relatively narrow
temperature ranges which would allow for this potential mechanism. Alternatively, ERK2-dependent
peptidergic fibers may contribute to thermotaxis behavior, perhaps by expressing TRPM8 which is
activated in the innocuous cool range of temperatures. Loss of these fibers may result in increased
time spent at cooler temperatures. Future experiments using the systemic MEK1/2 inhibitor, SL327
(Chapter 2), may address this problem. If hyperphosphorylation of ERK1 drives the thermotaxis
behavior, MEK1/2 inhibition should normalize the behavior of ERK2f/f;NaV1.8-Cre mice. If the cause
of the altered behavior is due to structural changes, then the MEK1/2 inhibitor will have no effect on
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the thermotaxis behavior.
Nociceptor ERK2 is required for inflammation-induced mechanical hypersensitivity
The combined analysis of ERK1-/- and ERK2f/f;NaV1.8-Cre mice indicated that
ERK2 specifically drives peripheral sensitization in inflammation. ERK1-/- mice developed robust
hypersensitivity to mechanical stimuli following CFA-induced inflammation (see Chapter 2). On the
other hand, CFA-induced mechanical hypersensitivity was significantly attenuated in ERK2f/f;NaV1.8Cre mice (see Chapter 3). Since ERK2 deletion is restricted to small-diameter, unmyelinated DRG
neurons, the reduced mechanical hypersensitivity observed in ERK2f/f;NaV1.8-Cre mice is due to
diminished peripheral sensitization. This behavioral phenotype is probably not due to the partial
loss of peptidergic fibers, because ablation experiments suggest that peptidergic fibers are not
involved in inflammation-induced mechanical hypersensitivity (Chen et al., 2007; Cavanaugh
et al., 2009). Moreover, ablation of nonpeptidergic fibers specifically attenuates mechanical
hypersensitivity without affecting thermal hypersensitivity (Cavanaugh et al., 2009), which is similar
to the ERK2f/f;NaV1.8-Cre phenotype. This might suggest that ERK2 drives hypersensitivity to
mechanical stimuli within nonpeptidergic neurons exclusively. Direct evaluation of this model could
be achieved by deleting ERK2 specifically in nonpeptidergic cells, although such a Cre line does not
yet exist. However, it seems unlikely that peptidergic neurons play no role in inflammation-induced
mechanical hypersensitivity. Channels that are candidates for the mammalian mechanotransducer,
such as ASICs or TRPA1 (Hu et al., 2006; Kerstein et al., 2009; Kwan et al., 2009; Smith and
Lewin, 2009), are expressed more frequently in peptidergic neurons (Story et al., 2003; Kobayashi
et al., 2005; Poirot et al., 2006). Moreover, facilitation of mechano-sensitive currents has been
observed in peptidergic neurons in culture (Lechner and Lewin, 2009). Therefore, it seems very
likely that peptidergic fibers contribute to CFA-induced mechanical hypersensitivity in addition
to nonpeptidergic fibers. One potential molecular mechanism involves TRPA1. Considering that
responses to mustard oil and the first phase response to formalin are not absent in ERK2f/f;NaV1.8Cre mice, it is likely that TRPA1-expressing fibers are present in the epidermis despite the loss of
ERK2. Additionally, both genetic deletion and pharmacological inhibition of TRPA1 has implicated
it in mechanotransduction in the skin-nerve preparation and on the behavioral level in CFA-induced
mechanical hypersensitivity (Eid et al., 2008; Kerstein et al., 2009; Kwan et al., 2009; da Costa et
al., 2010). Since ERK1/2 has previously been shown to modulate TRPV1 (Zhuang et al., 2004),
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a precedent has been set for acute modulation of other TRP channels by ERK1/2 in nociceptors.
Therefore, it is quite possible that ERK2 modulates TRPA1 function and, thereby, contributes to
mechanical hypersensitivity following inflammation. Although the partial loss of peptidergic fibers in
ERK2f/f;NaV1.8-Cre mice precludes definitive answers, it seems likely that ERK2 drives sensitization
of the remaining nociceptors, peptidergic and nonpeptidergic alike.
Nociceptor ERK2 and inflammatory heat hypersensitivity
Inflammatory heat hypersensitivity is thought to involve sensitization of peptidergic
nociceptors, given the results of ablation studies (Chen et al., 2007; Cavanaugh et al., 2009;
Mishra and Hoon, 2010) and the observation that TRPV1 is expressed predominantly in peptidergic
neurons in mice (Zwick et al., 2002; Woodbury et al., 2004; Breese et al., 2005). However, there
is likely to be a role for nonpeptidergic neurons in inflammatory states, since TRPV1 expression
and function is upregulated in nonpeptidergic cells after several days of CFA-induced inflammation
(Breese et al., 2005). This would argue for the importance of nonpeptidergic cells in longer term
heat hypersensitivity, in processes involving altered protein expression. Acute hypersensitivity,
developing within minutes to hours, is probably mediated by fast post-translation mechanisms,
which to date have all involved TRPV1 (Huang et al., 2006). Although inflammatory heat
hypersensitivity is attenuated by MEK inhibitors applied both intrathecally and peripherally (Ji et al.,
2002; Obata et al., 2003; Zhuang et al., 2004), deletion of ERK1 in all tissues or deletion of ERK2 in
nociceptors had no effect on CFA-induced heat hypersensitivity (see Chapters 2 and 3). There are
several possible reasons for this. One would be that ERK1 and ERK2 serve redundant functions
in the subset of nociceptors underlying CFA-induced heat hypersensitivity. Another possibility is
that CFA-induced heat hypersensitivity does not actually involve ERK1/2 activity in the nociceptor,
since the study that implicated peripheral ERK1/2 activity in the CFA model did so by intrathecally
applying MEK1/2 inhibitors (Obata et al., 2003). This method of drug delivery certainly affects
spinal cord dorsal horn since intrathecal administration of MEK1/2 inhibitors decreases spinal
ERK1/2 activation following noxious stimulation (Ji et al., 1999; Karim et al., 2001; Ji et al., 2002).
Therefore, intrathecal MEK inhibition may only be functionally relevant in spinal cord dorsal horn,
in which case somatic ERK1/2 activation may not be important for behavioral hypersensitivity.
Finally, it is also possible that other non-ERK1/2 dependent pathways are sufficient to produce
inflammatory heat hypersensitivity. Deletion of both ERK1 and ERK2 from nociceptors may be a
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way to address these different possibilities.
In contrast to CFA-induced heat hypersensitivity, NGF-induced heat hypersensitivity
is attenuated in ERK2f/f;NaV1.8-Cre mice. This is somewhat surprising since CFA-induced heat
hypersensitivity requires NGF-TrkA signaling (Pezet and McMahon, 2006). This discrepancy could
be explained by the reduction in peptidergic innervation. With a normal complement of fibers, CFAinduced heat hypersensitivity requires NGF, but without some fibers, other inflammatory signaling
molecules and pathways compensate. This could be tested by assessing the NGF-dependence
of CFA-induced heat hypersensitivity in ERK2f/f;NaV1.8-Cre mice. Although the reason that NGFinduced heat is attenuated in ERK2f/f;NaV1.8-Cre mice remains unclear, evaluation of ERK1-/- mice
may shed some light on mechanism since there are no changes in epidermal innervation that
make interpretation difficult. Interestingly, deletion of ERK1 actually exaggerates NGF-induced
heat hypersensitivity. This suggests that the phenotypes observed following NGF injection may not
be due to structural changes but instead may result from altered intracellular signaling in existent
fibers. Although speculative, this leads to a model in which ERK1 and ERK2 are both downstream
of TrkA activation, but that ERK1 antagonizes ERK2 function (see below for discussion). Assuming
nociceptor ERK1/2 signaling is behaviorally relevant in CFA-induced heat hypersensitivity, there
must also be distinct signaling pathways involving ERK1 and ERK2 that drive heat hypersensitivity.
This separate “isoform-redundant” pathway may involve upstream G-protein coupled receptors
such as adrenergic or bradykinin receptors. This could be directly tested by determining whether
epinephrine- or bradykinin-induced heat hypersensitivity require ERK1, nociceptor ERK2, or either
isoform by using the ERK mutants described in this study and double knockouts.
Finally, ERK1 deletion delays formalin-induced heat hypersensitivity (see Chapter 2).
Interestingly, formalin-induced heat hypersensitivity is not altered by conditional deletion of ERK2
in nociceptors. This indicates that ERK1 may be preferentially activated downstream of TRPA1.
However, mustard oil-induced heat hypersensitivity is unaffected by the loss of ERK1, which is
at odds with the formalin result since both chemicals activate TRPA1. This apparent discrepancy
may relate to the concentration of agonist, such that more concentrated formalin solutions would
equivalently activate ERK1 and ERK2. In this case, the isoforms may then appear to be redundant.
Overall, these studies indicate that ERK1 and nociceptor ERK2 are dispensable for CFA-induced
heat hypersensitivity. However, testing the effects of double knockouts and evaluating the
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responses of ERK mutants to additional inflammatory mediators will help to clarify whether either
isoform can drive hypersensitivity or neither isoform is required. From these experiments, it seems
likely that multiple isolated signaling pathways can lead to heat hypersensitivity. ERK isoforms
probably participate in some of these pathways with a requirement for specific isoforms in some
cases (e.g. NGF-induced heat hypersensitivity) and no requirement in others. Understanding the
cellular and molecular basis for these seemingly insulated cascades represents an exciting area
of future research
Nociceptor ERK2 is required for formalin-induced sensitization
Conditional deletion of ERK2 in nociceptors produced an unusual phenotype in the
formalin test (see Chapter 3). The first phase was elevated while the second phase was reduced.
Deletion of ERK1 in all tissues has no effect on either phase of the formalin test. The first phase is
thought to represent the initial detection of formalin and formalin-evoked nociceptor activity (Tjolsen
et al., 1992). The second phase results from peripheral and central sensitization. Interestingly,
inhibiting or genetically targeting TRPA1 reduces both phases of the formalin test (McNamara et
al., 2007). Moreover, systemic inhibition with the blood-brain barrier penetrant MEK1/2 inhibitor
SL327 also reduces both the first and second phase of the formalin test (see Chapter 2). Therefore
ERK1/2 activity on the whole increases 1st and 2nd phase responses, which would not explain the
elevated 1st phase in ERK2f/f;NaV1.8-Cre mice. One potential explanation for the elevated 1st phase
response of ERK2f/f;NaV1.8-Cre mice is that structural changes not directly related to nociceptive
plasticity cause elevated initial responses. This may occur if the partial loss of peptidergic fibers
observed is also associated with an increase in the input from remaining fibers. Since mustard
oil responses are normal in ERK2f/f;NaV1.8-Cre mice, it is likely that TRPA1 is present. Therefore,
elevated input from TRPA1-expressing fibers may account for increased 1st phase behaviors. This
could be tested by applying TRPA1 antagonists before formalin injection in ERK2f/f;NaV1.8-Cre
mice.
Despite an elevated 1st phase, ERK2f/f;NaV1.8-Cre mice have reduced 2nd phase responses.
This could be due to reduced peptidergic innervation, since ablation of TRPV1 expressing fibers
prior to formalin injection reduces the 2nd phase of the formalin test (Peterson et al., 1997; Chen et
al., 2007). Formalin induces inflammation and the release of inflammatory mediators like substance
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P, bradykinin, and many others (Damas and Liegeois, 1999). The loss of peptidergic fibers may
reduce nociceptor activity downstream of these other inflammatory mediators. Moreover, the fibers
themselves probably contribute to some amount of formalin-induced inflammation since nociceptor
terminals release peptides into the skin as part of a neurogenic inflammatory response (Reeh et al.,
1986). However, if TRPA1-positive fiber input is elevated, as proposed above, it seems likely that
nociceptor input would be robust despite the reduction in neurogenic inflammation. In this case,
it is likely that although TRPA1-expressing fibers are present, sensitization within these fibers is
attenuated due to the loss of ERK2. This could be due to reduced sensitization of TRPA1 itself or
by diminished excitability. Inducible deletion strategies may circumvent alterations in epidermal
innervation and allow a direct test of this hypothesis.
Spinal ERK1 is not required for inflammation-induced hypersensitivity
As mentioned above, it is difficult to determine the exact cellular site of ERK1/2
action based on inhibitor experiments alone. However, during the course of the present study, a
targeted knockdown of ERK2 in spinal cord was reported (Xu et al., 2008). In this study, viral vectors
containing short-hairpin RNA sequences that targeted ERK2 were injected intraparenchymally into
the dorsal horn of the lumbar spinal cord. This resulted in partial knockdown of ERK2 expression
and a profound attenuation of CFA-induced mechanical and thermal thresholds. The results of
the current study compliment and extend these findings. Although Xu et al. identified a role for
ERK2 in the spinal cord, they did not directly address a potential role for ERK1 and, therefore, did
not determine whether isoform specific functions existed in the nociceptive spinal cord. Since the
current study found that ERK1 was not required for CFA-induced hypersensitivity, it seems very
likely that ERK2, but not ERK1, is specifically required in the spinal cord. An important caveat
is that the methods of deletion are very different, so comparisons are not without some degree
of uncertainty. The ideal experimental tools would include RNAi-mediated knockdown of both
isoforms or the development of a conditional ERK1 allele that could be compared more directly with
ERK2f/f mice. Results from the current study suggesting the importance of ERK2 should motivate
additional experimentation using identical methods to manipulate ERK isoform expression.
Competition Model
In other systems, isoform specific roles have been identified for ERK1 and ERK2
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(see Chapter 1). In fibroblasts, reduction in ERK2 expression diminishes proliferation (Vantaggiato
et al., 2006; Lefloch et al., 2008). The effect of targeting ERK1 is controversial. In some reports,
reducing ERK1 expression paradoxically increases proliferation rates (Vantaggiato et al., 2006).
Other studies have found either no effect of ERK1 targeting or similar but less pronounced effects
and only in the context of ERK2 deletion (Lefloch et al., 2008; Voisin et al., 2010). Associated
with these experiments, deletion of one ERK isoform resulted in the hyperphosphorylation of
the remaining isoform. This led to the proposal of a competition model. In this model, ERK1 and
ERK2 coexist within the same signaling microdomain. Each isoform can be phosphorylated by
MEK1/2. However, ERK1 is less able to transmit the signal than ERK2. This is probably not due
to differences in the catalytic domains of ERK1/2, since the phosphorylation loop and active site
are highly homologous (see Chapter 1). Instead, domains regulating protein-protein interactions
probably underlie this difference. For example, cytoplasmic-nuclear shuttling of ERK1 is slower
than ERK2 due to amino acid differences in the N-terminus (Marchi et al., 2008). Binding to protein
substrates may also be different, since a study comparing the crystal structures of ERK1 and ERK2
found subtle but potentially important structural differences in D-motif binding site and the Backside
motif binding site (Kinoshita et al., 2008).
The competition model would explain several results observed both in the literature and in
the current study. In the current study, deletion of one ERK isoform increased the phosphorylation
state of the remaining isoform. This is predicted by the competition model and has also been
observed in other systems (see Chapter 2). The model may also explain the behavioral effects of
ERK deletion on NGF-induced heat hypersensitivity. Deletion of ERK2 attenuates NGF-induced
heat hypersensitivity, suggesting that ERK2 is predominant. ERK1 is not able to compensate for
the loss of ERK2, supporting the idea that ERK1 is not able to effectively transmit signals from
TrkA. On the other hand, deletion of ERK1 relieves competition for MEK binding, increasing ERK2
phosphorylation and exaggerating heat hypersensitivity. It is important to note that this model is
speculative. Genetic manipulations are not equivalent, and fiber loss in ERK2f/f;NaV1.8-Cre mice
precludes definitive conclusions. However, the model could be tested by assessing NGF-induced
ERK phosphorylation in the ERK mutant lines. It would also be interesting to determine whether
the opposing effects of ERK isoform deletion observed on the behavioral level also occur on the
cellular level, which is a fundamental assumption of the model. Ongoing experiments assessing
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NGF-induced TRPV1 potentiation in the ERK mutants will address this issue. Additionally, isoformspecific antibody staining, with rigorous controls, will also help determine whether ERK1 and ERK2
are coexpressed in the same cell which would also be required for this model. The model also
predicts that deleting both ERK1 and ERK2 might exacerbate deficits observed with only ERK2
deletion. This could be evaluated by characterizing mice that lack ERK1 and ERK2 in nociceptors.
Targeted ERK2 inhibition to treat chronic pain?
The results of the current study suggest that ERK2 is the predominant isoform
driving peripheral sensitization. Since ERK1 has no effect in a variety of rodent models of pain, it
seems logical to target ERK2 specifically to treat chronic pain conditions. There is some evidence
to suggest that this may help to circumvent potential side effects of ERK1/2 inhibition. ERK1 is
involved in regulating hepatocyte survival (Fremin et al., 2007; Fremin et al., 2009), directing
erythropoetic development (Guihard et al., 2010), tuning adaptive immunity by modulating thymocyte
development (Pages et al., 1999), and initiating adipogenesis (Bost et al., 2005). These metabolic
and immune system functions may be negatively affected by nonselective inhibition of ERK1 and
ERK2, suggesting that selective inhibition of ERK2 activity may be preferred. However, results
from this study also indicate that nociceptor ERK2 is partially required for epidermal innervation.
It will be important to determine whether ERK2 deletion affected innervation during development
or whether continued ERK2 activity was required to maintain innervation. If ERK2 is required for
fiber maintenance, systemic ERK2 inhibition may lead to denervation. This may be analgesic but
may also create a neuropathic pain state. It is also hard to predict the effect of ERK2 inhibition
in other fiber types in the peripheral nervous system. Further study will resolve some of these
questions. It is important to note that not all nociceptor fibers are lost from the epidermis. As such,
the results of the current study are fairly promising. On the behavioral level, targeted deletion of
ERK2 attenuates inflammation-induced hypersensitivity. Moreover, ERK1 is not required in these
models, suggesting that focused inhibition of ERK2 may be a novel approach to treating chronic
pain.

135

Bibliography
Agarwal N, Offermanns S, Kuner R (2004) Conditional gene deletion in primary nociceptive neurons
of trigeminal ganglia and dorsal root ganglia. Genesis 38:122-129.
Albers KM, Wright DE, Davis BM (1994) Overexpression of nerve growth factor in epidermis of
transgenic mice causes hypertrophy of the peripheral nervous system. J Neurosci 14:14221432.
Atwal JK, Singh KK, Tessier-Lavigne M, Miller FD, Kaplan DR (2003) Semaphorin 3F antagonizes
neurotrophin-induced phosphatidylinositol 3-kinase and mitogen-activated protein kinase
kinase signaling: a mechanism for growth cone collapse. J Neurosci 23:7602-7609.
Averill S, McMahon SB, Clary DO, Reichardt LF, Priestley JV (1995) Immunocytochemical
localization of trkA receptors in chemically identified subgroups of adult rat sensory
neurons. Eur J Neurosci 7:1484-1494.
Averill S, Delcroix JD, Michael GJ, Tomlinson DR, Fernyhough P, Priestley JV (2001) Nerve
growth factor modulates the activation status and fast axonal transport of ERK 1/2 in adult
nociceptive neurones. Mol Cell Neurosci 18:183-196.
Baccei M, Fitzgerald M (2005) Development of pain pathways and mechanisms. In: Wall and
Melzack’s Textbook of Pain, 5th Edition (McMahon SB, Koltzenburg M, eds), pp 145-147:
Elsevier.
Bennett DL, Koltzenburg M, Priestley JV, Shelton DL, McMahon SB (1998) Endogenous nerve
growth factor regulates the sensitivity of nociceptors in the adult rat. Eur J Neurosci
10:1282-1291.
Bost F, Aouadi M, Caron L, Even P, Belmonte N, Prot M, Dani C, Hofman P, Pages G, Pouyssegur J,
Le Marchand-Brustel Y, Binetruy B (2005) The extracellular signal-regulated kinase isoform
ERK1 is specifically required for in vitro and in vivo adipogenesis. Diabetes 54:402-411.
Breese NM, George AC, Pauers LE, Stucky CL (2005) Peripheral inflammation selectively increases
TRPV1 function in IB4-positive sensory neurons from adult mouse. Pain 115:37-49.
Cavanaugh DJ, Lee H, Lo L, Shields SD, Zylka MJ, Basbaum AI, Anderson DJ (2009) Distinct
subsets of unmyelinated primary sensory fibers mediate behavioral responses to noxious
thermal and mechanical stimuli. Proc Natl Acad Sci U S A 106:9075-9080.
Chen HS, He X, Wang Y, Wen WW, You HJ, Arendt-Nielsen L (2007) Roles of capsaicin-sensitive

136

primary afferents in differential rat models of inflammatory pain: a systematic comparative
study in conscious rats. Exp Neurol 204:244-251.
Coggeshall RE, Pover CM, Fitzgerald M (1994) Dorsal root ganglion cell death and surviving cell
numbers in relation to the development of sensory innervation in the rat hindlimb. Brain
Res Dev Brain Res 82:193-212.
Constantinou J, Reynolds ML, Woolf CJ, Safieh-Garabedian B, Fitzgerald M (1994) Nerve growth
factor levels in developing rat skin: upregulation following skin wounding. Neuroreport
5:2281-2284.
da Costa DS, Meotti FC, Andrade EL, Leal PC, Motta EM, Calixto JB (2010) The involvement of
the transient receptor potential A1 (TRPA1) in the maintenance of mechanical and cold
hyperalgesia in persistent inflammation. Pain 148:431-437.
Damas J, Liegeois JF (1999) The inflammatory reaction induced by formalin in the rat paw. Naunyn
Schmiedebergs Arch Pharmacol 359:220-227.
Eid SR, Crown ED, Moore EL, Liang HA, Choong KC, Dima S, Henze DA, Kane SA, Urban
MO (2008) HC-030031, a TRPA1 selective antagonist, attenuates inflammatory- and
neuropathy-induced mechanical hypersensitivity. Mol Pain 4:48.
Fremin C, Ezan F, Boisselier P, Bessard A, Pages G, Pouyssegur J, Baffet G (2007) ERK2 but
not ERK1 plays a key role in hepatocyte replication: an RNAi-mediated ERK2 knockdown
approach in wild-type and ERK1 null hepatocytes. Hepatology 45:1035-1045.
Fremin C, Bessard A, Ezan F, Gailhouste L, Regeard M, Le Seyec J, Gilot D, Pages G, Pouyssegur
J, Langouet S, Baffet G (2009) Multiple division cycles and long-term survival of
hepatocytes are distinctly regulated by extracellular signal-regulated kinases ERK1 and
ERK2. Hepatology 49:930-939.
Golden JP, Hoshi M, Nassar MA, Enomoto H, Wood JN, Milbrandt J, Gereau RW, Johnson EM, Jr.,
Jain S (2010) RET signaling is required for survival and normal function of nonpeptidergic
nociceptors. J Neurosci 30:3983-3994.
Goold RG, Gordon-Weeks PR (2005) The MAP kinase pathway is upstream of the activation of
GSK3beta that enables it to phosphorylate MAP1B and contributes to the stimulation of
axon growth. Mol Cell Neurosci 28:524-534.
Guihard S, Clay D, Cocault L, Saulnier N, Opolon P, Souyri M, Pages G, Pouyssegur J, Porteu F,
Gaudry M (2010) The MAPK ERK1 is a negative regulator of the adult steady-state splenic

137

erythropoiesis. Blood 115:3686-3694.
Hao J, Liu MG, Yu YQ, Cao FL, Li Z, Lu ZM, Chen J (2008) Roles of peripheral mitogen-activated
protein kinases in melittin-induced nociception and hyperalgesia. Neuroscience 152:10671075.
Honma Y, Kawano M, Kohsaka S, Ogawa M (2010) Axonal projections of mechanoreceptive dorsal
root ganglion neurons depend on Ret. Development 137:2319-2328.
Hu J, Milenkovic N, Lewin GR (2006) The high threshold mechanotransducer: a status report. Pain
120:3-7.
Huang J, Zhang X, McNaughton PA (2006) Inflammatory pain: the cellular basis of heat hyperalgesia.
Curr Neuropharmacol 4:197-206.
Jackman A, Fitzgerald M (2000) Development of peripheral hindlimb and central spinal cord
innervation by subpopulations of dorsal root ganglion cells in the embryonic rat. J Comp
Neurol 418:281-298.
Ji RR, Baba H, Brenner GJ, Woolf CJ (1999) Nociceptive-specific activation of ERK in spinal
neurons contributes to pain hypersensitivity. Nat Neurosci 2:1114-1119.
Ji RR, Befort K, Brenner GJ, Woolf CJ (2002) ERK MAP kinase activation in superficial spinal
cord neurons induces prodynorphin and NK-1 upregulation and contributes to persistent
inflammatory pain hypersensitivity. J Neurosci 22:478-485.
Johanson SO, Crouch MF, Hendry IA (1995) Retrograde axonal transport of signal transduction
proteins in rat sciatic nerve. Brain Res 690:55-63.
Karim F, Wang CC, Gereau RW (2001) Metabotropic glutamate receptor subtypes 1 and 5 are
activators of extracellular signal-regulated kinase signaling required for inflammatory pain
in mice. J Neurosci 21:3771-3779.
Karim F, Hu HJ, Adwanikar H, Kaplan DR, Gereau RW (2006) Impaired Inflammatory Pain and
Thermal Hyperalgesia in Mice Expressing Neuron-Specific Dominant Negative Mitogen
Activated Protein Kinase Kinase (MEK). Mol Pain 2:2.
Kerstein PC, del Camino D, Moran MM, Stucky CL (2009) Pharmacological blockade of TRPA1
inhibits mechanical firing in nociceptors. Mol Pain 5:19.
Kinoshita T, Yoshida I, Nakae S, Okita K, Gouda M, Matsubara M, Yokota K, Ishiguro H, Tada
T (2008) Crystal structure of human mono-phosphorylated ERK1 at Tyr204. Biochem
Biophys Res Commun 377:1123-1127.

138

Kobayashi K, Fukuoka T, Obata K, Yamanaka H, Dai Y, Tokunaga A, Noguchi K (2005) Distinct
expression of TRPM8, TRPA1, and TRPV1 mRNAs in rat primary afferent neurons with
adelta/c-fibers and colocalization with trk receptors. J Comp Neurol 493:596-606.
Kwan KY, Glazer JM, Corey DP, Rice FL, Stucky CL (2009) TRPA1 modulates mechanotransduction
in cutaneous sensory neurons. J Neurosci 29:4808-4819.
Lechner SG, Lewin GR (2009) Peripheral sensitisation of nociceptors via G-protein-dependent
potentiation of mechanotransduction currents. J Physiol 587:3493-3503.
Lefloch R, Pouyssegur J, Lenormand P (2008) Single and combined silencing of ERK1 and ERK2
reveals their positive contribution to growth signaling depending on their expression levels.
Mol Cell Biol 28:511-527.
Luo W, Wickramasinghe SR, Savitt JM, Griffin JW, Dawson TM, Ginty DD (2007) A hierarchical
NGF signaling cascade controls Ret-dependent and Ret-independent events during
development of nonpeptidergic DRG neurons. Neuron 54:739-754.
Marchi M, D’Antoni A, Formentini I, Parra R, Brambilla R, Ratto GM, Costa M (2008) The N-terminal
domain of ERK1 accounts for the functional differences with ERK2. PLoS One 3:e3873.
Markus A, Patel TD, Snider WD (2002) Neurotrophic factors and axonal growth. Curr Opin Neurobiol
12:523-531.
Marmigere F, Ernfors P (2007) Specification and connectivity of neuronal subtypes in the sensory
lineage. Nat Rev Neurosci 8:114-127.
McNamara CR, Mandel-Brehm J, Bautista DM, Siemens J, Deranian KL, Zhao M, Hayward NJ,
Chong JA, Julius D, Moran MM, Fanger CM (2007) TRPA1 mediates formalin-induced
pain. Proc Natl Acad Sci U S A 104:13525-13530.
Mendell LM, Albers KM, Davis BM (1999) Neurotrophins, nociceptors, and pain. Microsc Res Tech
45:252-261.
Mishra SK, Hoon MA (2010) Ablation of TrpV1 neurons reveals their selective role in thermal pain
sensation. Mol Cell Neurosci 43:157-163.
Molliver DC, Wright DE, Leitner ML, Parsadanian AS, Doster K, Wen D, Yan Q, Snider WD (1997)
IB4-binding DRG neurons switch from NGF to GDNF dependence in early postnatal life.
Neuron 19:849-861.
Obata K, Yamanaka H, Dai Y, Tachibana T, Fukuoka T, Tokunaga A, Yoshikawa H, Noguchi K
(2003) Differential activation of extracellular signal-regulated protein kinase in primary

139

afferent neurons regulates brain-derived neurotrophic factor expression after peripheral
inflammation and nerve injury. J Neurosci 23:4117-4126.
Pages G, Guerin S, Grall D, Bonino F, Smith A, Anjuere F, Auberger P, Pouyssegur J (1999) Defective
thymocyte maturation in p44 MAP kinase (Erk 1) knockout mice. Science 286:1374-1377.
Patel TD, Jackman A, Rice FL, Kucera J, Snider WD (2000) Development of sensory neurons in
the absence of NGF/TrkA signaling in vivo. Neuron 25:345-357.
Peterson MA, Basbaum AI, Abbadie C, Rohde DS, McKay WR, Taylor BK (1997) The differential
contribution of capsaicin-sensitive afferents to behavioral and cardiovascular measures
of brief and persistent nociception and to Fos expression in the formalin test. Brain Res
755:9-16.
Pezet S, McMahon SB (2006) Neurotrophins: mediators and modulators of pain. Annu Rev Neurosci
29:507-538.
Poirot O, Berta T, Decosterd I, Kellenberger S (2006) Distinct ASIC currents are expressed in rat
putative nociceptors and are modulated by nerve injury. J Physiol 576:215-234.
Reeh PW, Kocher L, Jung S (1986) Does neurogenic inflammation alter the sensitivity of
unmyelinated nociceptors in the rat? Brain Res 384:42-50.
Reynolds ML, Fitzgerald M (1995) Long-term sensory hyperinnervation following neonatal skin
wounds. J Comp Neurol 358:487-498.
Smith ES, Lewin GR (2009) Nociceptors: a phylogenetic view. J Comp Physiol A Neuroethol Sens
Neural Behav Physiol 195:1089-1106.
Soriano P (1999) Generalized lacZ expression with the ROSA26 Cre reporter strain. Nat Genet
21:70-71.
Stirling LC, Forlani G, Baker MD, Wood JN, Matthews EA, Dickenson AH, Nassar MA (2005)
Nociceptor-specific gene deletion using heterozygous NaV1.8-Cre recombinase mice.
Pain 113:27-36.
Story GM, Peier AM, Reeve AJ, Eid SR, Mosbacher J, Hricik TR, Earley TJ, Hergarden AC,
Andersson DA, Hwang SW, McIntyre P, Jegla T, Bevan S, Patapoutian A (2003) ANKTM1,
a TRP-like channel expressed in nociceptive neurons, is activated by cold temperatures.
Cell 112:819-829.
Tjolsen A, Berge OG, Hunskaar S, Rosland JH, Hole K (1992) The formalin test: an evaluation of
the method. Pain 51:5-17.

140

Vantaggiato C, Formentini I, Bondanza A, Bonini C, Naldini L, Brambilla R (2006) ERK1 and ERK2
mitogen-activated protein kinases affect Ras-dependent cell signaling differentially. J Biol
5:14.
Voisin L, Saba-El-Leil MK, Julien C, Fremin C, Meloche S (2010) Genetic demonstration of a
redundant role of extracellular signal-regulated kinase 1 (ERK1) and ERK2 mitogenactivated protein kinases in promoting fibroblast proliferation. Mol Cell Biol 30:2918-2932.
Watson FL, Heerssen HM, Bhattacharyya A, Klesse L, Lin MZ, Segal RA (2001) Neurotrophins
use the Erk5 pathway to mediate a retrograde survival response. Nat Neurosci 4:981-988.
Wickramasinghe SR, Alvania RS, Ramanan N, Wood JN, Mandai K, Ginty DD (2008) Serum
response factor mediates NGF-dependent target innervation by embryonic DRG sensory
neurons. Neuron 58:532-545.
Woodbury CJ, Zwick M, Wang S, Lawson JJ, Caterina MJ, Koltzenburg M, Albers KM, Koerber HR,
Davis BM (2004) Nociceptors lacking TRPV1 and TRPV2 have normal heat responses. J
Neurosci 24:6410-6415.
Xu Q, Garraway SM, Weyerbacher AR, Shin SJ, Inturrisi CE (2008) Activation of the neuronal
extracellular signal-regulated kinase 2 in the spinal cord dorsal horn is required for complete
Freund’s adjuvant-induced pain hypersensitivity. J Neurosci 28:14087-14096.
Zhong J, Li X, McNamee C, Chen AP, Baccarini M, Snider WD (2007) Raf kinase signaling functions
in sensory neuron differentiation and axon growth in vivo. Nat Neurosci 10:598-607.
Zhuang ZY, Xu H, Clapham DE, Ji RR (2004) Phosphatidylinositol 3-kinase activates ERK in
primary sensory neurons and mediates inflammatory heat hyperalgesia through TRPV1
sensitization. J Neurosci 24:8300-8309.
Zwick M, Davis BM, Woodbury CJ, Burkett JN, Koerber HR, Simpson JF, Albers KM (2002) Glial
cell line-derived neurotrophic factor is a survival factor for isolectin B4-positive, but not
vanilloid receptor 1-positive, neurons in the mouse. J Neurosci 22:4057-4065.
Zylka MJ, Rice FL, Anderson DJ (2005) Topographically distinct epidermal nociceptive circuits
revealed by axonal tracers targeted to Mrgprd. Neuron 45:17-25.

141

